
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Clinical applications of circulating tumor cells in metastasis and therapy - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="AE5329B88AF195C30529B800723F7FD4.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="jhemonc">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374358/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Journal of Hematology &amp; Oncology">
<meta name="citation_title" content="Clinical applications of circulating tumor cells in metastasis and therapy">
<meta name="citation_author" content="Chuan Yang">
<meta name="citation_author_institution" content="State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Sun Yat-sen University Cancer Center, Guangzhou, 510060 China">
<meta name="citation_author" content="Can Liu">
<meta name="citation_author_institution" content="The Affiliated Foshan Women and Children Hospital, Guangdong Medical University, Foshan, Guangdong China">
<meta name="citation_author" content="Chenglai Xia">
<meta name="citation_author_institution" content="The Affiliated Foshan Women and Children Hospital, Guangdong Medical University, Foshan, Guangdong China">
<meta name="citation_author" content="Liwu Fu">
<meta name="citation_author_institution" content="State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Sun Yat-sen University Cancer Center, Guangzhou, 510060 China">
<meta name="citation_publication_date" content="2025 Aug 22">
<meta name="citation_volume" content="18">
<meta name="citation_firstpage" content="80">
<meta name="citation_doi" content="10.1186/s13045-025-01733-y">
<meta name="citation_pmid" content="40846962">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374358/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374358/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374358/pdf/13045_2025_Article_1733.pdf">
<meta name="description" content="Circulating tumor cells (CTCs), which serve as an early indicator of tumors in peripheral blood, are closely associated with unfavorable prognoses in individuals with cancer. Gaining a thorough understanding of the heterogeneity and specific ...">
<meta name="og:title" content="Clinical applications of circulating tumor cells in metastasis and therapy">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Circulating tumor cells (CTCs), which serve as an early indicator of tumors in peripheral blood, are closely associated with unfavorable prognoses in individuals with cancer. Gaining a thorough understanding of the heterogeneity and specific ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374358/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12374358">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1186/s13045-025-01733-y"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/13045_2025_Article_1733.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12374358%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12374358/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12374358/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374358/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-jhemonc.png" alt="Journal of Hematology &amp; Oncology logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Journal of Hematology &amp; Oncology" title="Link to Journal of Hematology &amp; Oncology" shape="default" href="https://jhoonline.biomedcentral.com/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">J Hematol Oncol</button></div>. 2025 Aug 22;18:80. doi: <a href="https://doi.org/10.1186/s13045-025-01733-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1186/s13045-025-01733-y</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22J%20Hematol%20Oncol%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22J%20Hematol%20Oncol%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22J%20Hematol%20Oncol%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22J%20Hematol%20Oncol%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Clinical applications of circulating tumor cells in metastasis and therapy</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yang%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Chuan Yang</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Chuan Yang</span></h3>
<div class="p">
<sup>1</sup>State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Sun Yat-sen University Cancer Center, Guangzhou, 510060 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yang%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Chuan Yang</span></a>
</div>
</div>
<sup>1,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Can Liu</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Can Liu</span></h3>
<div class="p">
<sup>2</sup>The Affiliated Foshan Women and Children Hospital, Guangdong Medical University, Foshan, Guangdong China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Can Liu</span></a>
</div>
</div>
<sup>2,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Xia%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Chenglai Xia</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Chenglai Xia</span></h3>
<div class="p">
<sup>2</sup>The Affiliated Foshan Women and Children Hospital, Guangdong Medical University, Foshan, Guangdong China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Xia%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Chenglai Xia</span></a>
</div>
</div>
<sup>2,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fu%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Liwu Fu</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Liwu Fu</span></h3>
<div class="p">
<sup>1</sup>State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Sun Yat-sen University Cancer Center, Guangzhou, 510060 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fu%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Liwu Fu</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="Aff1">
<sup>1</sup>State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Sun Yat-sen University Cancer Center, Guangzhou, 510060 China </div>
<div id="Aff2">
<sup>2</sup>The Affiliated Foshan Women and Children Hospital, Guangdong Medical University, Foshan, Guangdong China </div>
<div class="author-notes p">
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
<div class="fn" id="_eqcntrb93pmc__">
<sup>#</sup><p class="display-inline">Contributed equally.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 May 13; Accepted 2025 Aug 13; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s) 2025</div>
<p><strong>Open Access</strong> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc-nd/4.0/</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12374358  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40846962/" class="usa-link">40846962</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="Abs1"><h2>Abstract</h2>
<p id="Par1">Circulating tumor cells (CTCs), which serve as an early indicator of tumors in peripheral blood, are closely associated with unfavorable prognoses in individuals with cancer. Gaining a thorough understanding of the heterogeneity and specific trajectory of CTCs during metastasis can yield valuable insights for the development of effective cancer treatment strategies. This review critically examines the contemporary knowledge of the in vivo process of CTCs, with a focus on the four key stages: dissemination, homing, colonization, and macro-metastasis. Each stage is discussed in terms of its associated characteristics, including epithelial-mesenchymal transition (EMT), dormancy, organotropism, and awakening. We also discuss recent advancements in CTC isolation, detection, cultivation and its potential applications. Additionally, it provides a comprehensive elucidation of the intricate mechanisms of immune evasion and drug resistance in CTCs, aiming to identify novel targets for cancer therapy. Finally, an overview of CTC interventions is presented, which may facilitate the development of personalized therapeutic approaches for patients and improve their metastasis-free prognostic outcomes.</p>
<section id="kwd-group1" lang="en" class="kwd-group"><p><strong>Keywords:</strong> Circulating tumor cells, Metastasis, Immune evasion, Drug resistance, Personalized therapy</p></section></section><section id="Sec1"><h2 class="pmc_sec_title">Background</h2>
<p id="Par2">The issue of metastasis has persisted since the inception of cancer treatment. However, it remains unresolved and accounts for over 90% of cancer-related fatalities [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>]. Growing evidence highlights the crucial role of circulating tumor cells (CTCs) in driving cancer metastasis. CTCs are neoplastic cells that evade the primary tumor or metastatic sites and enter the bloodstream during tumor progression. The notion of CTCs was first introduced by Ashworth, while Paget later employed the metaphor of CTCs as seeds and specific organs/tissues as fertile ground, vividly illustrating the migratory processes of CTCs within the human body [<a href="#CR2" class="usa-link" aria-describedby="CR2">2</a>]. Since then, an increasing number of investigations have documented a significant correlation between CTCs and the progression of malignancies.</p>
<p id="Par3">During the progression of tumor metastasis, CTCs encounter numerous adverse circumstances. However, these resilient tumor cells exhibit adaptability by acquiring the phenotypic traits of other stromal cells in the circulatory system, allowing them to evade the harsh living environment and migrate to distant organs, where they form remote metastases.</p>
<p id="Par4">In this in vivo process, employing distinct markers to delineate various states and subtypes of CTCs can unveil significant phenomena, such as immune evasion and resistance to pharmaceutical interventions. This approach may provide a foundation for identifying innovative therapeutic approaches and targets for cancer treatment. This review examines recent research on CTCs/ disseminated tumor cells (DTCs), summarizing their key characteristics during metastasis in vivo, including epithelial-mesenchymal transition (EMT), tumor dormancy, organotropism and awakening. These findings undoubtedly enhance our understanding of the substantial metastatic potential of CTCs.</p>
<p id="Par5">Currently, CTCs have gained significant attention in cancer prediction, diagnosis, treatment and prognosis assessment, with liquid biopsy emerging as a prominent application. Nonetheless, a paradox arises due to the limited availability of CTCs and the imperative need for comprehensive investigation. Understanding the in vivo mechanisms of CTCs presents an essential challenge, particularly in accurately characterizing isolated CTCs to determine their stages and subtypes. Achieving a flawless technological system that ensures 100% separation purity, identification accuracy and culture reliability is of utmost importance. In addition, addressing the scarcity of CTCs requires the development of highly efficient methods for in vitro expansion.</p>
<p id="Par6">In this review, we aim to comprehensively investigate the pathways and mechanisms underlying these events in the circulatory system of CTCs. Potential treatment strategies targeting CTCs are also summarized. By doing so, we aspire to generate insights that can guide the development of precision-targeted therapies, aligning with the existing clinical treatment strategy.</p></section><section id="Sec2"><h2 class="pmc_sec_title">The metastatic cascade and biological characteristics of CTCs/DTCs</h2>
<p id="Par7">CTCs undergo several critical stages, beginning with their detachment from the primary tumor site (Fig. <a href="#Fig1" class="usa-link">1</a>). The whole process of metastasis has been well-reviewed by Gerstberger et al. and Ring et al. [<a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>, <a href="#CR4" class="usa-link" aria-describedby="CR4">4</a>]. Specifically, the metastatic cascade involves four key stages: dissemination, homing, colonization, and macro-metastasis. Most CTCs acquire EMT characteristics to better adapt and survive in the dissemination journey. Despite quite a few primary tumor cells entering the bloodstream, the harsh pressures of circulation can eliminate a large number of these cells. However, some resilient CTCs withstand these pressures by entering a dormant state, particularly homing into the bone marrow, where they are known as DTCs. Once in the bone marrow, DTCs may undergo epigenetic changes and phenotypic remodeling, enhancing their stemness and metastatic potential. They then reenter the circulation and colonize distant organs, exhibiting organotropism, where they can remain dormant for extended periods. When appropriate stimuli disrupt this dormant state, these awakening cells regain vitality and contribute to macro-metastasis.</p>
<figure class="fig xbox font-sm" id="Fig1"><h3 class="obj_head">Fig. 1.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374358_13045_2025_1733_Fig1_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc14/12374358/58384eb9c675/13045_2025_1733_Fig1_HTML.jpg" loading="lazy" id="d33e233" height="843" width="669" alt="Fig. 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>The metastatic cascade of circulating tumor cells. Following detachment from the primary site, tumor cells undergo EMT and engage in intravasation to enter the bloodstream to become CTCs. CTCs with mesenchymal or epithelial-mesenchymal hybrid characteristics show enhanced survival and metastatic potential (termed EMT-CTCs). These cells are capable of homing to the bone marrow, where they enter a dormant state that promotes stemness and epigenetic remodeling. Subsequently, they can reenter the bloodstream, extravasate and colonize distant organs. When exposed to appropriate stimuli, they can reactivate, ultimately contributing to macro-metastasis. CTCs: circulating tumor cells, DTCs: disseminated tumor cells, EMT: epithelial-mesenchymal transition, ECM: extracellular matrix, HSCs: hematopoietic stem cells, TME: tumor microenvironment</p></figcaption></figure><section id="Sec3"><h3 class="pmc_sec_title">EMT: the sword of CTC dissemination</h3>
<p id="Par9">EMT involves several key changes: reorganization of the epithelial cell cytoskeleton, loss of cell polarity, detachment from the basement membrane, and the acquisition of mesenchymal cell function. This progress is crucial for enabling cells to evade shear stress, apoptosis, anoikis, cell senescence and immune surveillance. Additionally, EMT can contribute to the resistance of tumor cells against chemotherapy, radiotherapy, and other treatments. Consequently, EMT makes a remarkable contribution to the survival and metastasis of CTCs. However, there is limited knowledge regarding the biological alterations that transpire in CTCs following EMT. Despite this, certain indications exist that offer insights for further investigation into these alterations.</p>
<p id="Par10">Presently, most methods for detecting CTCs rely on the cell surface marker EpCAM, with the CellSearch platform being a notable example. However, during EMT, tumor cells undergo biological alterations that can reduce EpCAM expression. As a result, CTCs with low or absent EpCAM expression are often undetectable, leading to limited research on these CTCs. Investigating the biological changes in CTCs following EMT could provide valuable insights. For instance, blood samples from 72 colorectal cancer patients showed a significant reduction in epithelial markers (EpCAM, CK19, and CEA) in CTCs compared to tumor tissue, indicating that most CTCs lose their epithelial phenotype in the bloodstream. Similarly, DTCs in the bone marrow of esophageal cancer patients also often displayed low EpCAM levels [<a href="#CR5" class="usa-link" aria-describedby="CR5">5</a>]. Studies found that EpCAM-low CTCs had reduced proliferation but increased migration, suggesting these cells have a higher potential for metastasis [<a href="#CR6" class="usa-link" aria-describedby="CR6">6</a>]. G.Roa and colleagues noted that elevated EpCAM expression in primary and metastatic tumors is influenced by the local microenvironment, with EpCAM levels in CTCs or DTCs dropping approximately tenfold upon entering circulation [<a href="#CR7" class="usa-link" aria-describedby="CR7">7</a>]. Additionally, metastatic xenotransplantation mouse models and cell-based experiments demonstrated decreased EpCAM expression and upregulation of EMT-related genes, reinforcing the link between EMT and reduced EpCAM expression [<a href="#CR8" class="usa-link" aria-describedby="CR8">8</a>].</p>
<p id="Par11">Conversely, EMT progress shows upregulated mesenchymal characteristics. This shift significantly enhances the aggressiveness of CTC clusters, as shown by Yu et al.. in 2013. Kallergi et al.. observed the expression of TWIST and Vimentin in CTCs among patients with metastatic or early breast cancer, indicating that breast cancer CTCs acquired mesenchymal characteristics. The higher prevalence of TWIST<sup>+</sup> and Vimentin<sup>+</sup> cells in patients with metastatic breast cancer (mBC) supports the role of EMT-positive CTCs in metastasis [<a href="#CR9" class="usa-link" aria-describedby="CR9">9</a>]. Additionally, CTCs undergoing EMT regulate integrin β1 and the transcription factor SLUG through elevated fibronectin expression, boosting their metastatic potential [<a href="#CR10" class="usa-link" aria-describedby="CR10">10</a>]. The upregulation of N-cadherin and stem cell marker ABCB5 also contributes to EMT [<a href="#CR11" class="usa-link" aria-describedby="CR11">11</a>]. In a cohort of 149 primary breast cancer patients, CTCs were detected in about 25% of cases, with 13.4% showing EMT markers [<a href="#CR12" class="usa-link" aria-describedby="CR12">12</a>]. Elevated levels of matrix metalloproteinase 1 (MMP1) in these patients suggest a potential link between MMP1 and EMT-positive CTCs. These findings align with other researches indicating that EMT-positive CTCs are associated with poorer prognosis in primary breast cancer cases [<a href="#CR13" class="usa-link" aria-describedby="CR13">13</a>].</p>
<p id="Par12">However, hybrid epithelial–mesenchymal (E/M) states can be enriched in CTCs from breast cancer patients [<a href="#CR14" class="usa-link" aria-describedby="CR14">14</a>]. These CTCs exhibit reversible E/M shifts that are associated with dynamic therapeutic responses and disease progression. Epithelial–mesenchymal plasticity (EMP) refers to the ability of cells to adopt mixed E/M characteristics and interconvert between intermediate E/M phenotypic states [<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>]. This plasticity may confer a survival advantage to CTCs during the various stages of the metastatic cascade. Since EMP leads to the downregulation or loss of epithelial markers, it complicates the isolation and detection of all CTC subpopulations using EpCAM antibodies.</p>
<p id="Par13">Controversies persist regarding whether EMT is the sole mechanism of CTC generation or the primary driver of metastasis. Padmanaban et al.. reported that the epithelial marker E-cadherin promotes metastasis in various models of breast cancer by limiting reactive oxygen-mediated apoptosis [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>]. Using an EMT lineage-tracing system, another group identified that non-EMT tumor cells are the dominant population in lung metastases, while EMT cells play a significant role in chemoresistance and the recurrence of lung metastasis [<a href="#CR17" class="usa-link" aria-describedby="CR17">17</a>]. Furthermore, a subsequent study revealed that epithelial CTCs, with limited mesenchymal transition, exhibited a higher lung metastatic potential compared to mesenchymal CTCs in breast cancer models [<a href="#CR18" class="usa-link" aria-describedby="CR18">18</a>]. However, these studies did not address the hybrid states of CTCs during tumor dissemination. It is plausible that CTCs adopt a hybrid E/M state while disseminating to distant organs and later undergo mesenchymal-epithelial transition (MET) to recover the epithelial phenotype. Additionally, it remains unclear which CTC subpopulation predominates in metastasis across different cancer types. Further research is needed to determine the extent to which EMT contributes to CTC formation and metastasis.</p>
<p id="Par14">The mechanisms that regulate EMT progression in CTCs are not yet fully understood. However, key signaling pathways, such as TGF-β, NOTCH, WNT/β-catenin and Hippo appear to play significant roles. Additionally, circulation pressures such as shear stress and anoikis also contribute to EMT. TGF-β, secreted by platelets or other circulation cells, activates the TGF-β/SMAD pathway in CTCs to promote and sustain the EMT phenotype and thus enhance their metastatic potential [<a href="#CR14" class="usa-link" aria-describedby="CR14">14</a>, <a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>]. Sprouse et al.. reported that polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) can interact with CTCs by forming CTC/PMN-MDSC clusters. This heterotypic clustering increases NOTCH activation in CTCs through the engagement of Jagged1 expressed by PMN-MDSCs to NOTCH1 receptor [<a href="#CR20" class="usa-link" aria-describedby="CR20">20</a>]. To depict the spatial heterogeneity of CTCs in epithelial and mesenchymal composition, blood samples from 73 localized hepatocellular carcinoma patients were collected from different veins before tumor resection. The results showed that CTCs were predominantly epithelial at the point of release, but transitioned to an EMT phenotype during circulating, mediated by SMAD2 and β-catenin signaling pathways [<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>].</p>
<p id="Par15">Tumor cells undergoing EMT are accompanied by efficient intravasation/extravasation [<a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>]. EMT boosts the invasion ability of CTCs, facilitating their movement into and out of blood vessels, thus selecting for more aggressive CTCs capable of metastasis. In essence, EMT acts as a “sword” for CTCs, facilitating their journey from primary tumors to distant organs.</p></section><section id="Sec4"><h3 class="pmc_sec_title">Dormancy: the reward of CTC homing</h3>
<p id="Par16">Tumor cells encounter numerous adverse circumstances during metastasis, including chemotherapy, shear stress from blood flow, and immune surveillance. Dormancy can serve as a protective mechanism, providing a refuge for resilient tumor cells [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>]. Typically, dormancy involves tumor cells exiting the cell cycle and entering the G0 phase, characterized by a quiescent state or very slow cell division, often associated with de-repressed p38 and suppressed ERK1/2 [<a href="#CR23" class="usa-link" aria-describedby="CR23">23</a>]. CTCs are capable of homing to the bone marrow, becoming DTCs that remain quiescent in the bone marrow for extended periods. These dormant DTCs are believed to be potential sources of CTCs, capable of migrating to other organs and initiating metastasis under appropriate conditions. Several pieces of evidence support the notion that the bone marrow serves as a critical niche for dormant CTCs/DTCs.</p>
<p id="Par17">1) DTCs in the bone marrow are often detectable in early non-metastatic cancer patients and are associated with an increased risk of metastatic disease or locoregional relapse [<a href="#CR24" class="usa-link" aria-describedby="CR24">24</a>–<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>]. To investigate the origins of DTCs in breast cancer, Demeulemeester and colleagues performed single-cell sequencing on bone marrow epithelial-like cells from six non-metastatic breast cancer patients. They found that approximately half of these single cells were classified as DTCs originating from primary tumors and/or lymph node metastases, while the remaining CNA-positive cells were present in the bone marrow of non-metastatic patients. This suggests that the bone marrow acts as an early metastatic niche for DTCs and supports the notion that DTCs can evolve independently from the primary tumor [<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>].</p>
<p id="Par18">2) The number of DTCs in the bone marrow is significantly higher than the number of CTCs in the peripheral blood collected from the same patient. For instance, in a study enrolling 40 neuroblastoma patients, matched blood and bone marrow samples were collected to detect GD2<sup>+</sup>/CD45<sup>−</sup> CTCs or DTCs using Imagestream flow cytometer. CTCs were detected in 26 of 42 patient blood samples (with the CTC number of mean 40/mL, range 1–264/mL at diagnosis; mean 6/mL, range, 1–39/mL at relapse), while DTCs were detected in 25 of 35 bone marrow samples (with the DTC number of mean 30,342/mL, range 57–291, 635/mL at diagnosis; mean 2,124/mL, range 112–15,688/mL at relapse) [<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>]. Other studies on breast cancer, prostate cancer, and squamous cell carcinoma of the oral cavity have reported similar findings, reinforcing this conclusion [<a href="#CR31" class="usa-link" aria-describedby="CR31">31</a>–<a href="#CR34" class="usa-link" aria-describedby="CR34">34</a>].</p>
<p id="Par19">3) The unique structure and diverse niches within the bone marrow play a crucial role in inducing and maintaining DTC dormancy. Bone marrow contains many different haematopoietic and non-haematopoietic cell types. The bone marrow’s trabecular framework, surrounded by endosteum covered with osteoblasts and osteoclasts, includes a network of sinusoidal capillaries that facilitate the movement of DTCs in and out of circulation. The low hemodynamic pressure in these sinusoids, combined with the anchoring effect mediated by CXCR4/SDF-1, supports efficient DTC entry [<a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>]. Specialized niches like the perivascular and endosteal niches help sustain DTC dormancy through direct and indirect interactions with host cells. It has been reported that the endosteal niche is the primary niche for hematopoietic stem cells (HSCs), but prostate cancer DTCs can compete with HSCs to engage the endosteal niche [<a href="#CR36" class="usa-link" aria-describedby="CR36">36</a>]. A range of cellular factors such as osteopontin, GAS6, TGF-β, and BMP contribute to DTC dormancy by affecting cellular behavior and interactions [<a href="#CR37" class="usa-link" aria-describedby="CR37">37</a>–<a href="#CR40" class="usa-link" aria-describedby="CR40">40</a>]. For instance, TGF-β2 derived from osteoblasts diminishes DTC proliferation via TGF-β receptor (TGF-βRIII), though its effect is modulated by AXL expression in DTCs [<a href="#CR38" class="usa-link" aria-describedby="CR38">38</a>, <a href="#CR39" class="usa-link" aria-describedby="CR39">39</a>]. Similarly, NG2<sup>+</sup> and Nestin<sup>+</sup> mesenchymal stem cells (MSCs) also produce TGF-β2 and BMP7, and activate the TGF-βRIII and BMPRIII-dependent quiescent pathway to induce dormancy in breast cancer DTCs [<a href="#CR40" class="usa-link" aria-describedby="CR40">40</a>]. Additionally, DTCs can alter the bone marrow microenvironment by secreting proteins that activate dormancy-related pathways. For instance, DTCs from indolent prostate cancer secrete acidic and cysteine-rich secretory proteins to indirectly trigger the activation of MSC-derived BMP7, which in turn activates dormancy-related signaling pathways in DTCs, such as p38, MAPK and p21 [<a href="#CR41" class="usa-link" aria-describedby="CR41">41</a>]. Furthermore, it has been observed that drug-resistant DTCs have the ability to localize in perivascular niches (PVN) withing the bone marrow, and immune signals like IFN-γ may serve as mediators of dormancy [<a href="#CR42" class="usa-link" aria-describedby="CR42">42</a>, <a href="#CR43" class="usa-link" aria-describedby="CR43">43</a>]. Dormant DTCs are also intricately linked to the EMT process of tumor cells [<a href="#CR44" class="usa-link" aria-describedby="CR44">44</a>]. Nevertheless, it is imperative to further investigate the intricate interactions among DTCs, different microenvironments, and cellular transitions.</p>
<p id="Par20">4) Bone metastases can act as a source for subsequent multi-organ metastases. Some metastases are not directly from the primary tumor but from the further spread of existing metastases. Evidence suggests that the bone microenvironment significantly contributes to the development of secondary metastases in other organs [<a href="#CR45" class="usa-link" aria-describedby="CR45">45</a>–<a href="#CR47" class="usa-link" aria-describedby="CR47">47</a>]. For instance, Zhang et al.. revealed that metastasis initially targets the bone before spreading to other organs, using models such as intra-iliac artery (IIA) / vein (IIV) injection, mammary fat pad (MFP) implantation and parabiosis in breast and prostate cancer studies. Further utilizing an evolving barcode system (EBS), they uncovered that enhanced EZH2 activity mediated epigenetic reprogramming that conferred increased stemness on cancer cells disseminated from bone microenvironment [<a href="#CR47" class="usa-link" aria-describedby="CR47">47</a>]. Similarly, another group observed that the bone microenvironment induced increased metastatic ability and endocrine-resistant phenotype on bone-metastatic ER<sup>+</sup> breast cancer cells by using EBS analysis. This process was also dependent on EZH2-mediated epigenomic reprogramming that conferred hybrid EMT and increased stemness, as well as ER reduction [<a href="#CR48" class="usa-link" aria-describedby="CR48">48</a>]. Although the re-metastases of DTCs from bone marrow have been observed, the specific mechanisms remain to be fully elucidated. Future studies should focus on how different bone niches and factors induce different epigenetic changes and phenotypic heterogeneity in DTCs, which could invigorate DTCs for further multi-organ dissemination.</p></section><section id="Sec5"><h3 class="pmc_sec_title">Organotropism: the compass of DTC colonization</h3>
<p id="Par21">After surviving circulation pressures and acquiring stemness and epigenetic changes, CTCs/DTCs migrate to colonize distant organs. This process, known as colonization, is characterized by organotropism and is influenced by tumor-specific traits, organ-specific environments, and hemodynamics.</p>
<p id="Par22">Primary tumors can reprogram distant organ microenvironments by secreting soluble factors, such as cytokines, hormones, metabolites and extracellular vesicles [<a href="#CR49" class="usa-link" aria-describedby="CR49">49</a>]. For instance, different tumor-derived exosomal integrins uptaken by organ-specific cells promote the formation of different pre-metastatic niches. Lung-tropic exosomes containing integrins α6β4 and α6β1 tend to promote lung metastasis, whereas exosomal integrin αvβ5 is associated with liver metastasis [<a href="#CR50" class="usa-link" aria-describedby="CR50">50</a>]. Additionally, tumor cell-derived factors recruit immune suppressive cells such as MDSCs, TAMs, and Treg cells into distant sites, promoting pre-metastatic niche formation. Also, these factors can switch on stromal reprogramming, further remodeling the pre-metastatic niche [<a href="#CR51" class="usa-link" aria-describedby="CR51">51</a>].</p>
<p id="Par23">Organ-specific environments, including cell composition, inflammation, and angiogenesis, play a crucial role in the adaptation and dormancy of CTCs/DTCs. For example, in lung metastasis, fibroblasts can greatly facilitate metastasis. Liu et al.. identified a metastasis-associated fibroblast subtype, tryptophan 2,3-dioxygenase-positive matrix fibroblasts (TDO2<sup>+</sup> MFs), which secret kynurenine to upregulate ferritin heavy chain 1 expression in DTCs, enabling DTCs to resist ferroptosis and inducing T cell dysfunction [<a href="#CR52" class="usa-link" aria-describedby="CR52">52</a>]. Gong et al.. found that cyclooxygenase 2 (COX-2)-expressing fibroblasts can produce prostaglandin E2 (PGE2) to drive dysfunctional dendritic cells (DCs) and suppressive monocytes. Further, tumor-associated inflammation, particularly the pro-inflammatory cytokine interleukin-1β remodeled a pre-metastatic niche [<a href="#CR53" class="usa-link" aria-describedby="CR53">53</a>]. Overall, the complex interactions and regulations within distant organs create an environment that supports CTCs/DTCs.</p>
<p id="Par24">The bone marrow serves not only as an accessible homing organ for CTCs but also an organotropic niche for their settlement. Various niches within the bone marrow provide alternative survival and residency signals, and the interactions between bone marrow cells and tumor cells play a crucial role in the formation of pre-metastatic niches [<a href="#CR54" class="usa-link" aria-describedby="CR54">54</a>]. For instance, highly metastatic melanomas can secret exosomes that promote the metastatic behavior of primary tumors by reprogramming bone marrow progenitors toward a pro-vasculogenic phenotype, stimulated by exsome-derived receptor tyrosine kinase MET [<a href="#CR55" class="usa-link" aria-describedby="CR55">55</a>].</p>
<p id="Par25">The liver is the predominant first site of metastasis for colorectal carcinoma, as colorectal cancer cells hematogenously disseminating from the intestines travel through the mesenteric vein into the hepatic portal vein and subsequently encountering the hepatic sinusoids. Similar to sinusoids in the bone marrow, CTCs can readily traverse the hepatic sinusoids and settle within the liver microenvironment. Although haemodynamics influence organotropism, the extent of this effect remains unclear. Notably, about 90% of uveal melanoma cases, despite being anatomically distant from the liver, metastasize to this organ, highlighting the significant role of tumor-specific characteristics and organ-specific niches in CTCs/DTCs homing [<a href="#CR56" class="usa-link" aria-describedby="CR56">56</a>].</p>
<p id="Par26">DTCs in the host organ can remain in a dormant state for years, as proliferating DTCs are often cleared by immune cells. DTCs also continuously remodel the microenvironment to an immune suppressive niche during the residing. This ongoing interaction leads to a co-evolution between DTCs and the tumor microenvironment.</p></section><section id="Sec6"><h3 class="pmc_sec_title">Awakening: the engine of DTC macro-metastasis</h3>
<p id="Par27">The establishment of a conducive microenvironment for tumor cell proliferation is essential for the efficient outgrowth of DTCs in distant organs, as it greatly influences the survival, sustenance, and awakening of DTCs. Reactivating dormant DTCs involves disrupting their quiescent niche, with a key mechanism being the inflammation-induced activation of the stroma.</p>
<p id="Par28">Liver and lung fibrosis, resulting from stromal cell activation, are highly associated with metastatic outgrowth and serve as sources of awakening signals for dormant DTCs [<a href="#CR57" class="usa-link" aria-describedby="CR57">57</a>]. In the liver, NK cells sustain metastatic breast cancer cell dormancy through IFN-γ signaling. However, activated hepatic stellate cells secrete the chemokine CXCL12 to induce NK cell quiescence via its receptor CXCR4, acting as a master switch for DTCs awakening [<a href="#CR58" class="usa-link" aria-describedby="CR58">58</a>]. In the lungs, fibrosis induced by collagen I enables integrin β1-mediated outgrowth of dormant D2.0R cells through the phosphorylation of Src, FAK, and subsequent activation of myosin light chain [<a href="#CR59" class="usa-link" aria-describedby="CR59">59</a>]. Additionally, WNT5A maintains melanoma DTCs in a dormant state within the lung, but age-related reprogramming of lung fibroblasts increases the secretion of the soluble WNT antagonist sFRP1. This inhibition of WNT5A in melanoma DTCs enables efficient metastatic outgrowth. Tyrosine kinase receptors AXL and MER also play roles in regulating the dormancy-to-reactivation transition in melanoma DTCs [<a href="#CR60" class="usa-link" aria-describedby="CR60">60</a>]. Furthermore, neutrophil extracellular traps (NETs), observed in the tumor microenvironment of an inflammation model in mice, contribute to the activation of DTCs and promote cancer recurrence and metastasis. This is primarily attributed to the hydrolysis of laminin by neutrophil elastase and matrix metalloproteinase 9 (MMP9), as well as the activation of the integrin α3β1 signaling pathway [<a href="#CR61" class="usa-link" aria-describedby="CR61">61</a>]. NETs also protect tumor cells from interactions with neighboring CD8<sup>+</sup> T cells and NK cells, thereby impeding the activity of anti-tumor immune cells [<a href="#CR62" class="usa-link" aria-describedby="CR62">62</a>].</p>
<p id="Par29">DTCs awake from eradicating dormancy signaling such as STING, p38 signaling after adaption to their microenvironment. Tumor-intrinsic immune regulator STING typically inhibits DTC awakening, but this inhibition can be reduced by hypermethylation of STING promoters and enhancers, thus facilitating DTC reactivation and metastatic outgrowth [<a href="#CR63" class="usa-link" aria-describedby="CR63">63</a>]. In lung metastatic niches with low TGF-β2 levels, DTCs’ dormant state is more readily disrupted, leading to outgrowth. Therefore, systemic inhibition of TGF-βRI or p38α/β activities can awaken dormant DTCs, resulting in multi-organ metastases [<a href="#CR64" class="usa-link" aria-describedby="CR64">64</a>].</p>
<p id="Par30">Additionally, the activation of dormant DTCs can be influenced by non-cellular factors present in the microenvironment, such as hypoxia and acidic conditions [<a href="#CR65" class="usa-link" aria-describedby="CR65">65</a>, <a href="#CR66" class="usa-link" aria-describedby="CR66">66</a>]. Enhancing our comprehension of the attributes and processes involved in the regulation of dormancy and awakening will enable the identification of prospective targets for augmenting susceptibility to chemotherapy resistance. This, in turn, may ultimately mitigate the likelihood of cancer recurrence and metastasis.</p></section></section><section id="Sec7"><h2 class="pmc_sec_title">The marker, isolation, identification, cultivation and application of CTCs</h2>
<section id="Sec8"><h3 class="pmc_sec_title">CTC markers</h3>
<p id="Par31">Unlike other targets in liquid biopsy, CTCs retain the complete set of genes inherited from the primary tumor, making them a potentially better reflection of both primary and secondary tissues. Consequently, the detection and analysis of CTCs offer valuable insights for cancer research, contingent upon the accurate identification of CTCs. Currently, a growing number of markers and their combinations are employed to isolate CTCs from patients’ peripheral blood, focusing mainly on tumor cell surface proteins and transcription factors. The presence of EMT and stemness-related markers on CTCs can vary depending on their initiation state and trajectory.</p>
<p id="Par32">Markers associated with EMT are frequently employed for the isolation and enrichment of CTCs. A key marker is EpCAM, an epithelial transmembrane glycoprotein that is highly expressed on tumor cell surfaces, distinguishing tumor cells from normal epithelial cells in the bloodstream. The CellSearch platform, the first FDA-approved CTC isolation platform, focuses on EpCAM and another prevalent epithelial marker, cytokeratins (CKs). Research has shown that, besides EMT, the expression of EpCAM can also be influenced by TNF-α and NF-κB [<a href="#CR67" class="usa-link" aria-describedby="CR67">67</a>]. Additionally, E-cadherins and zonula occludens (ZOs) are crucial for maintaining epithelial tissue integrity [<a href="#CR68" class="usa-link" aria-describedby="CR68">68</a>].</p>
<p id="Par33">CTCs undergoing EMT can be categorized as mesenchymal or mixed epithelial-mesenchymal CTCs, depending on whether they express mesenchymal markers alongside epithelial markers. Common mesenchymal markers include Vimentin, N-Cadherin and Fibronectin [<a href="#CR69" class="usa-link" aria-describedby="CR69">69</a>–<a href="#CR71" class="usa-link" aria-describedby="CR71">71</a>]. However, Vimentin is also found in certain normal blood cells, making it crucial to use additional indicators to identify mesenchymal CTCs accurately. Evidence shows that URI and miR-515-3p play regulatory roles in metastasis driven by vimentin in cervical and esophageal cancers, respectively [<a href="#CR72" class="usa-link" aria-describedby="CR72">72</a>, <a href="#CR73" class="usa-link" aria-describedby="CR73">73</a>]. Various transcription factors, such as TWIST, are crucial for initiating EMT [<a href="#CR74" class="usa-link" aria-describedby="CR74">74</a>]. Compared to cell surface protein markers, SNAI1 and ZEB are part of a more intricate regulatory network, influenced by miR-34 (SNAIL) and miR-200 (ZEB) families [<a href="#CR75" class="usa-link" aria-describedby="CR75">75</a>–<a href="#CR77" class="usa-link" aria-describedby="CR77">77</a>]. Increased MMP9 due to SNAIL upregulation elucidates the enhanced invasiveness and metastatic potential of EMT-driven CTCs. The involvement of the PI3K/AKT pathway in cancer is well-documented, with a recent study showing it functions as an EMT inducer in colorectal cancer [<a href="#CR78" class="usa-link" aria-describedby="CR78">78</a>]. Additionally, Plastin3 has been identified as both an EMT marker and a prognostic indicator in colorectal cancer patients, based on research involving 132 Japanese patients [<a href="#CR79" class="usa-link" aria-describedby="CR79">79</a>].</p>
<p id="Par34">The persistence of CTCs in the circulatory system may be linked to the presence of cancer stem cells (CSCs). Research has shown that CSCs, originating from somatic stem cells or differentiated progenitor cells, can drive cancer recurrence and metastasis [<a href="#CR80" class="usa-link" aria-describedby="CR80">80</a>]. Therefore, identifying and targeting CSCs within CTCs could be a promising strategy to impede cancer progression. Currently, several markers such as CD44, acetaldehyde dehydrogenase 1 (ALDH1), and gangliosides have been identified for this purpose [<a href="#CR81" class="usa-link" aria-describedby="CR81">81</a>, <a href="#CR82" class="usa-link" aria-describedby="CR82">82</a>]. For example, Tian et al. discovered that ALDH1-positive cells effectively represent ALDH1<sup>+</sup> CTCs in the peripheral blood of non-small cell lung cancer (NSCLC) patients, suggesting that ALDH1 could serve as a marker for CSCs and aid in the depletion of circulating NSCLC cells [<a href="#CR82" class="usa-link" aria-describedby="CR82">82</a>]. The identification of such specific markers for CTCs remains a crucial objective in CTC research, as detailed in Table <a href="#Tab1" class="usa-link">1</a>. Additionally, other specific markers exit in unique tumor types beyond those mentioned above, such as melanin in melanoma, which has been utilized to detect CTCs in melanoma patients [<a href="#CR83" class="usa-link" aria-describedby="CR83">83</a>]. In summary, pinpointing highly specific markers for CTCs is essential for advancing our understanding of their roles in cancer initiation and progression, thereby laying the groundwork for more precise CTC research.</p>
<section class="tw xbox font-sm" id="Tab1"><h4 class="obj_head">Table 1.</h4>
<div class="caption p"><p>Molecular markers used to identify CTCs</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Classification</th>
<th align="left" colspan="1" rowspan="1">Marker</th>
<th align="left" colspan="1" rowspan="1">Tumor type</th>
<th align="left" colspan="1" rowspan="1">Characteristic</th>
</tr></thead>
<tbody>
<tr>
<td align="left" rowspan="6" colspan="1">
<strong>Epithelial markers</strong>
</td>
<td align="left" colspan="1" rowspan="1">EpCAM (CD362) [<a href="#CR67" class="usa-link" aria-describedby="CR67">67</a>]</td>
<td align="left" colspan="1" rowspan="1">Almost all epithelial tumors</td>
<td align="left" colspan="1" rowspan="1">A commenly used marker</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">E-Cadherin [<a href="#CR84" class="usa-link" aria-describedby="CR84">84</a>]</td>
<td align="left" colspan="1" rowspan="1">Breast and stomach cancer</td>
<td align="left" colspan="1" rowspan="1">Regulated by SNAIL and SLUG</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">p120 catenin [<a href="#CR85" class="usa-link" aria-describedby="CR85">85</a>]</td>
<td align="left" colspan="1" rowspan="1">Breast cancer</td>
<td align="left" colspan="1" rowspan="1">Regulating cell polarity</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CK5/7/8/18/19/20 [<a href="#CR14" class="usa-link" aria-describedby="CR14">14</a>, <a href="#CR86" class="usa-link" aria-describedby="CR86">86</a>–<a href="#CR88" class="usa-link" aria-describedby="CR88">88</a>]</td>
<td align="left" colspan="1" rowspan="1">Almost all epithelial tumors</td>
<td align="left" colspan="1" rowspan="1">Varied in different tumors</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">ZO-1/2/3 [<a href="#CR89" class="usa-link" aria-describedby="CR89">89</a>]</td>
<td align="left" colspan="1" rowspan="1">HCC</td>
<td align="left" colspan="1" rowspan="1">Correlating to tight junction</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">ESRP1 [<a href="#CR90" class="usa-link" aria-describedby="CR90">90</a>, <a href="#CR91" class="usa-link" aria-describedby="CR91">91</a>]</td>
<td align="left" colspan="1" rowspan="1">Somatotroph adenomas, NSCLC</td>
<td align="left" colspan="1" rowspan="1">Regulating epithelial splicing</td>
</tr>
<tr>
<td align="left" rowspan="12" colspan="1">
<strong>Mesenchymal markers</strong>
</td>
<td align="left" colspan="1" rowspan="1">Vimentin [<a href="#CR72" class="usa-link" aria-describedby="CR72">72</a>, <a href="#CR92" class="usa-link" aria-describedby="CR92">92</a>]</td>
<td align="left" colspan="1" rowspan="1">Almost all mesenchymal tumors</td>
<td align="left" colspan="1" rowspan="1">Low specificity</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">N-Cadherin [<a href="#CR69" class="usa-link" aria-describedby="CR69">69</a>, <a href="#CR70" class="usa-link" aria-describedby="CR70">70</a>, <a href="#CR93" class="usa-link" aria-describedby="CR93">93</a>]</td>
<td align="left" colspan="1" rowspan="1">Almost all mesenchymal tumors</td>
<td align="left" colspan="1" rowspan="1">Protecting CTCs from NK cell killing</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Fibronectin [<a href="#CR10" class="usa-link" aria-describedby="CR10">10</a>]</td>
<td align="left" colspan="1" rowspan="1">HCC, CRPC</td>
<td align="left" colspan="1" rowspan="1">Regulating the expression of integrin-β1 and SLUG</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">TWIST [<a href="#CR94" class="usa-link" aria-describedby="CR94">94</a>, <a href="#CR95" class="usa-link" aria-describedby="CR95">95</a>]</td>
<td align="left" rowspan="3" colspan="1">Almost all mesenchymal tumors</td>
<td align="left" rowspan="3" colspan="1">EMT-associated transcriptional factors</td>
</tr>
<tr><td align="left" colspan="1" rowspan="1">SNAIL [<a href="#CR96" class="usa-link" aria-describedby="CR96">96</a>]</td></tr>
<tr><td align="left" colspan="1" rowspan="1">ZEB1 [<a href="#CR76" class="usa-link" aria-describedby="CR76">76</a>, <a href="#CR96" class="usa-link" aria-describedby="CR96">96</a>]</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">β-catenin [<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>, <a href="#CR97" class="usa-link" aria-describedby="CR97">97</a>]</td>
<td align="left" colspan="1" rowspan="1">Breast cancer</td>
<td align="left" colspan="1" rowspan="1">Promoting EMT process</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Plastin3 [<a href="#CR79" class="usa-link" aria-describedby="CR79">79</a>]</td>
<td align="left" colspan="1" rowspan="1">CRC</td>
<td align="left" colspan="1" rowspan="1">Associated with CRC prognosis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">FGFR2 [<a href="#CR98" class="usa-link" aria-describedby="CR98">98</a>, <a href="#CR99" class="usa-link" aria-describedby="CR99">99</a>]</td>
<td align="left" colspan="1" rowspan="1">Gastric cancer</td>
<td align="left" colspan="1" rowspan="1">Associated with gastric cancer prognosis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">KLF8 [<a href="#CR100" class="usa-link" aria-describedby="CR100">100</a>]</td>
<td align="left" colspan="1" rowspan="1">pancreatic cancer</td>
<td align="left" colspan="1" rowspan="1">Associated with pancreatic cancer prognosis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">SERPINE1 [<a href="#CR101" class="usa-link" aria-describedby="CR101">101</a>]</td>
<td align="left" colspan="1" rowspan="1">prostate cancer</td>
<td align="left" colspan="1" rowspan="1">SERPINE1<sup>+</sup> KRT<sup>+</sup> CTCs are in an epithelial-mesenchymal hybrid state</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Hexokinase 2 [<a href="#CR102" class="usa-link" aria-describedby="CR102">102</a>]</td>
<td align="left" colspan="1" rowspan="1">NSCLC</td>
<td align="left" colspan="1" rowspan="1">Associated with NSCLC prognosis</td>
</tr>
<tr>
<td align="left" rowspan="7" colspan="1">
<strong>Stemness-related markers</strong>
</td>
<td align="left" colspan="1" rowspan="1">CD44 [<a href="#CR82" class="usa-link" aria-describedby="CR82">82</a>, <a href="#CR103" class="usa-link" aria-describedby="CR103">103</a>, <a href="#CR104" class="usa-link" aria-describedby="CR104">104</a>]</td>
<td align="left" colspan="1" rowspan="1">Multiple tumors</td>
<td align="left" colspan="1" rowspan="1">Promoting cluster formation</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">ALDH1 [<a href="#CR82" class="usa-link" aria-describedby="CR82">82</a>, <a href="#CR105" class="usa-link" aria-describedby="CR105">105</a>, <a href="#CR106" class="usa-link" aria-describedby="CR106">106</a>]</td>
<td align="left" colspan="1" rowspan="1">NSCLC, CRC, breast cancer</td>
<td align="left" colspan="1" rowspan="1">Driving CTC stemness</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">ABCG2 [<a href="#CR107" class="usa-link" aria-describedby="CR107">107</a>, <a href="#CR108" class="usa-link" aria-describedby="CR108">108</a>]</td>
<td align="left" colspan="1" rowspan="1">NSCLC, PDAC, HCC, retinoblastoma</td>
<td align="left" colspan="1" rowspan="1">Expressed in stem-like CTCs</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CD133 [<a href="#CR109" class="usa-link" aria-describedby="CR109">109</a>, <a href="#CR110" class="usa-link" aria-describedby="CR110">110</a>]</td>
<td align="left" colspan="1" rowspan="1">PDAC, HCC</td>
<td align="left" colspan="1" rowspan="1">Expressed in stem-like CTCs</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Nestin [<a href="#CR111" class="usa-link" aria-describedby="CR111">111</a>]</td>
<td align="left" colspan="1" rowspan="1">Melanoma</td>
<td align="left" colspan="1" rowspan="1">A marker for melanoma CTCs</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">ICAM1 [<a href="#CR112" class="usa-link" aria-describedby="CR112">112</a>, <a href="#CR113" class="usa-link" aria-describedby="CR113">113</a>]</td>
<td align="left" colspan="1" rowspan="1">HCC, breast cancer</td>
<td align="left" colspan="1" rowspan="1">Promoting cluster formation</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Gangliosides 2/3/1a [<a href="#CR114" class="usa-link" aria-describedby="CR114">114</a>, <a href="#CR115" class="usa-link" aria-describedby="CR115">115</a>]</td>
<td align="left" colspan="1" rowspan="1">Breast cancer</td>
<td align="left" colspan="1" rowspan="1">Expressed in stem-like CTCs</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">
<strong>Other markers</strong>
</td>
<td align="left" colspan="1" rowspan="1">Melanin [<a href="#CR83" class="usa-link" aria-describedby="CR83">83</a>]</td>
<td align="left" colspan="1" rowspan="1">Melanoma</td>
<td align="left" rowspan="2" colspan="1">Specifically expressed in a unique tumor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PSMA, AR-V7 [<a href="#CR116" class="usa-link" aria-describedby="CR116">116</a>, <a href="#CR117" class="usa-link" aria-describedby="CR117">117</a>]</td>
<td align="left" colspan="1" rowspan="1">CRPC</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p38"><p>Note: CRC: colorectal cancer, CRPC: castration-resistant prostate cancer, HCC: hepatocellular carcinoma, NSCLC: non-small cell lung cancer, PDAC: pancreatic ductal adenocarcinoma</p></div></div></section></section><section id="Sec9"><h3 class="pmc_sec_title">CTC isolation</h3>
<p id="Par36">Currently, methods for isolating CTCs from peripheral blood primarily fall into three categories: direct separation methods based on cellular physical characteristics, immunomagnetic bead approaches that leverage biochemical characteristics and microfluidic chip technology (Fig. <a href="#Fig2" class="usa-link">2</a>).</p>
<figure class="fig xbox font-sm" id="Fig2"><h4 class="obj_head">Fig. 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374358_13045_2025_1733_Fig2_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc14/12374358/ddd05b6c00f2/13045_2025_1733_Fig2_HTML.jpg" loading="lazy" id="d33e985" height="1182" width="744" alt="Fig. 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Schematic diagram of various CTC separation techniques. The categorization of CTC separation techniques primarily involves the following methods: <strong>(A)</strong> Physical separation: A crude separation method based on physical properties. <strong>(B)</strong> Biochemical separation: A more accurate separation method based on antigen-antibody affinity. <strong>(C)</strong> Magnetic microfluidic separation: Recent separation methods that integrate physical and biochemical properties, microfluidic separation. <strong>(D)</strong> Acoustic microfluidic separation: This label-free separation utilizes different acoustic characteristics of WBCs and CTCs because of their different physical properties (i.e., size, density, and compressibility). CTCs usually experience a larger acoustic radiation force (Fac) than WBCs (Faw), resulting in a larger vertical displacement (normal to the flow direction) of CTCs than WBCs</p></figcaption></figure><p id="Par38">Physical isolation methods exploit the differences in cell size, density, dielectric properties, or acoustic characteristics between CTCs and other blood cells. However, a limitation of these methods is their low specificity, which can hinder the isolation of pure CTCs.</p>
<p id="Par39">The immunomagnetic bead technique employs tumor surface antigens to selectively bind to monoclonal antibodies conjugated with magnetic beads for CTC isolation. In the presence of an external magnetic field, cells coated with these magnetic beads are captured or directed to a designated region for isolation. This method allows for positive and negative sorting of CTCs and white blood cells (WBCs), separately. Epithelial markers, such as EpCAM and CK, are often used to distinguish CTCs from other blood cells. The CellSearch platform developed by Veridex utilizes nanoscale magnetic beads to enhance CTC capture efficiency while minimizing mechanical strain. However, this method may overlook CTCs that have undergone EMT, as these cells typically express lower levels of EpCAM [<a href="#CR118" class="usa-link" aria-describedby="CR118">118</a>, <a href="#CR119" class="usa-link" aria-describedby="CR119">119</a>]. Negative sorting employs antibodies such as CD45 or CD41 to identify and eliminate non-tumor cells, particularly WBCs, thereby enriching the CTC population and addressing challenges related to negative EpCAM expression [<a href="#CR120" class="usa-link" aria-describedby="CR120">120</a>].</p>
<p id="Par40">Microfluidics involves the precise control of fluids at the micro-scale, focusing on fluid management within micro-nano spaces, with the microfluidic chip as its core component. Recently, professor Lei and his team developed an innovative separation method called integrated ferrohydrodynamic cell separation (iFCS), which uses surface markers on leukocytes (CD45, CD15, CD66b) to selectively bind magnetic beads to WBCs, leaving CTCs unlabeled. The iFCS process consists of three stages: the first stage removes debris larger than 50 μm; the second stage enriches CTCs while removing the magnetic bead-WBC complexes; and the third stage adsorbs additional magnetic beads and WBCs, facilitating the movement of CTCs to the sides of the channel for recovery. This method does not depend on specific antigens on tumor cells and effectively isolates CTCs with minimal leukocyte contamination, achieving a separation efficiency of up to 99%. Captured CTCs with epithelial and/or mesenchymal features maintain their integrity and can survive and proliferate for a short period. Recently, microfluidics technologies, such as acoustic microfluidics that rely solely on physical properties, have emerged as efficient methods for isolating CTCs [<a href="#CR121" class="usa-link" aria-describedby="CR121">121</a>]. Other methodologies such as metabolism labeling and click chemistry, are emerging as effective and non-destructive approaches for capturing CTCs [<a href="#CR122" class="usa-link" aria-describedby="CR122">122</a>]. As innovative isolation technologies continue to emerge and advance, the enrichment of CTCs will provide a solid foundation for further research in the CTC field.</p></section><section id="Sec10"><h3 class="pmc_sec_title">CTC identification</h3>
<p id="Par41">Identifying collected CTCs is crucial for accurate counts and understanding cancer progression. Various methods for CTC identification include:</p>
<ol class="list" style="list-style-type:decimal">
<li><p id="Par43">Flow cytometry (FCM): Provides rapid, quantitative analysis and multi-channel detection. However, creating single-cell suspensions may affect cell integrity and morphology.</p></li>
<li><p id="Par44">Immunofluorescence (IF): Uses fluorescence microscopy to visualize tumor markers like CK or EpCAM. It’s susceptible to observer bias and false negatives from CTCs with an EMT phenotype.</p></li>
<li><p id="Par45">Fluorescent in situ hybridization (FISH): Detects specific gene sequences using fluorescent probes. It can be costly and complex but can be combined with IF for improved detection, as demonstrated by combining DAPI<sup>+</sup> and CD45<sup>+</sup> staining with a CEP8 probe, and utilizing convolutional neural networks (CNNs) for analysis [<a href="#CR123" class="usa-link" aria-describedby="CR123">123</a>].</p></li>
<li><p id="Par46">Quantitative real-time polymerase chain reaction (qRT-PCR): Amplifies tumor-specific mRNA sequences to profile gene expression, allowing for precise tumor cell detection [<a href="#CR124" class="usa-link" aria-describedby="CR124">124</a>].</p></li>
<li><p id="Par47">Electrochemical sensors: Identifies CTCs and quantifies tumor markers using enzymes, antibodies, or aptamers. This method is rapid, cost-effective, and easily automated, with examples including MUC1/EpCAM aptamers for detecting various cancer-derived CTCs [<a href="#CR125" class="usa-link" aria-describedby="CR125">125</a>]. Compared with the above methods, this method is easy to operate, more rapid, lower cost, and easier to automate.</p></li>
<li><p id="Par48">Photoacoustic flow cytometry: Detects melanin-bearing CTCs in vivo in melanoma patients using a high pulse rate laser and focused ultrasound transducers [<a href="#CR83" class="usa-link" aria-describedby="CR83">83</a>]. It’s label free, enabling real-time CTC counting and long-term monitoring. However, its application is limited to melanoma detection, and other tumor types require the integration of additional physical or chemical characteristics for detection by this system.</p></li>
</ol>
<p id="Par49">Each method offers unique advantages and limitations, making the choice of technique dependent on specific research or clinical needs.</p></section><section id="Sec11"><h3 class="pmc_sec_title">CTC expansion in vitro</h3>
<p id="Par50">Currently, most research on CTCs focuses on quantifying their numbers to facilitate cancer diagnosis, adjuvant therapy, and prognosis prediction. However, existing capture and detection methods often fail to distinguish between viable and non-viable tumor cells. Therefore, relying solely on CTC counts for clinical decision-making is suboptimal. Besides enumeration, gene expression profile analysis of CTCs can reveal cellular changes during tumor development and provide insights into various phenotypes. While the scarcity of CTCs limits the number of available research samples, potentially hindering significant studies, the potential for in vitro cultivation of CTCs offers a promising solution. Although the literature is still limited, valuable insights can be gained from the existing resources.</p>
<p id="Par51">The cultivation of CTCs in vitro encounters two primary challenges. The first is obtaining viable CTCs, which depends on efficient enrichment methods for isolating live CTCs from cancer patients. Techniques such as microfluidic chips, fluorescence-activated cell sorting (FACS), and negative enrichment have been shown to improve the preservation of cellular integrity and molecular characteristics. The second challenge is creating an optimal culture environment that supports CTC expansion in vitro. This involves carefully managing various physical, chemical, and biological conditions (Table <a href="#Tab2" class="usa-link">2</a>).</p>
<section class="tw xbox font-sm" id="Tab2"><h4 class="obj_head">Table 2.</h4>
<div class="caption p"><p>The determinants of efficient CTC culture in vitro</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Classification</th>
<th align="left" colspan="1" rowspan="1">Determinant</th>
<th align="left" colspan="1" rowspan="1">Function</th>
</tr></thead>
<tbody>
<tr>
<td align="left" rowspan="5" colspan="1">
<strong>Physical factors</strong>
</td>
<td align="left" colspan="1" rowspan="1">3D structure</td>
<td align="left" colspan="1" rowspan="1">Physical support [<a href="#CR139" class="usa-link" aria-describedby="CR139">139</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Matrigel</td>
<td align="left" colspan="1" rowspan="1">Physical support; Providing ECM [<a href="#CR140" class="usa-link" aria-describedby="CR140">140</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Cell aggregation</td>
<td align="left" colspan="1" rowspan="1">Preventing shear stress and anoikis [<a href="#CR141" class="usa-link" aria-describedby="CR141">141</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Suspension</td>
<td align="left" colspan="1" rowspan="1">Maintain Stemness [<a href="#CR127" class="usa-link" aria-describedby="CR127">127</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Hypoxic condition</td>
<td align="left" colspan="1" rowspan="1">Maintain Stemness [<a href="#CR127" class="usa-link" aria-describedby="CR127">127</a>]</td>
</tr>
<tr>
<td align="left" rowspan="11" colspan="1">
<strong>Chemical factors</strong>
</td>
<td align="left" colspan="1" rowspan="1">N2 supplement or B27</td>
<td align="left" colspan="1" rowspan="1">Basic metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Y-27632</td>
<td align="left" colspan="1" rowspan="1">ROCK inhibitor, preventing apoptosis [<a href="#CR142" class="usa-link" aria-describedby="CR142">142</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Noggin</td>
<td align="left" colspan="1" rowspan="1">BMP inhibitor, preventing differentiation [<a href="#CR143" class="usa-link" aria-describedby="CR143">143</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">SB202190</td>
<td align="left" colspan="1" rowspan="1">p38 inhibitor, preventing dormancy [<a href="#CR144" class="usa-link" aria-describedby="CR144">144</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">A83-01</td>
<td align="left" colspan="1" rowspan="1">ALK4/5/7 inhibitor, maintain Stemness [<a href="#CR145" class="usa-link" aria-describedby="CR145">145</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Wnt3a, Rspondin-1</td>
<td align="left" colspan="1" rowspan="1">Activating the WNT/β-catenin pathway to maintain Stemness [<a href="#CR133" class="usa-link" aria-describedby="CR133">133</a>, <a href="#CR146" class="usa-link" aria-describedby="CR146">146</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">SCF</td>
<td align="left" colspan="1" rowspan="1">cKit ligand, promoting stem cell self-renew [<a href="#CR147" class="usa-link" aria-describedby="CR147">147</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">EGF, bFGF, FGF7, FGF10, HGF, NRG1</td>
<td align="left" colspan="1" rowspan="1">Promoting proliferation [<a href="#CR132" class="usa-link" aria-describedby="CR132">132</a>, <a href="#CR148" class="usa-link" aria-describedby="CR148">148</a>–<a href="#CR151" class="usa-link" aria-describedby="CR151">151</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PGE2</td>
<td align="left" colspan="1" rowspan="1">Immunosuppressor; Promoting proliferation [<a href="#CR152" class="usa-link" aria-describedby="CR152">152</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Forskolin</td>
<td align="left" colspan="1" rowspan="1">cAMP agonist, inducing organoid swelling [<a href="#CR153" class="usa-link" aria-describedby="CR153">153</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">NAC</td>
<td align="left" colspan="1" rowspan="1">Antioxidant, preventing oxidative stress [<a href="#CR134" class="usa-link" aria-describedby="CR134">134</a>]</td>
</tr>
<tr>
<td align="left" rowspan="4" colspan="1">
<strong>Biological factors</strong>
</td>
<td align="left" colspan="1" rowspan="1">Irradiated 3T3 J2 cells</td>
<td align="left" colspan="1" rowspan="1">Providing growth niche and factor cocktail [<a href="#CR135" class="usa-link" aria-describedby="CR135">135</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">LWRN cells</td>
<td align="left" colspan="1" rowspan="1">Secreting Wnt3a, Rspondin-1 and Noggin [<a href="#CR138" class="usa-link" aria-describedby="CR138">138</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CAFs</td>
<td align="left" colspan="1" rowspan="1">Providing cell-cell interactions [<a href="#CR136" class="usa-link" aria-describedby="CR136">136</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Leukocytes</td>
<td align="left" colspan="1" rowspan="1">Favoring CTCs proliferation [<a href="#CR154" class="usa-link" aria-describedby="CR154">154</a>]</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p62"><p>Note: ECM: Extracellular Matrix, NAC: N-Acetylcysteine, CAFs: Cancer-associated fibroblasts</p></div></div></section><p id="Par52">Research has increasingly highlighted the importance of non-adherent culture conditions and low oxygen environments for successful in vitro cultivation of CTCs [<a href="#CR126" class="usa-link" aria-describedby="CR126">126</a>]. For instance, Yu et al.. established CTC lines from six patients with estrogen receptor-positive breast cancer using these conditions [<a href="#CR127" class="usa-link" aria-describedby="CR127">127</a>]. Additionally, three-dimension (3D) organoids have been developed to provide physical support that could enhance the proliferation and stemness of CTCs [<a href="#CR128" class="usa-link" aria-describedby="CR128">128</a>, <a href="#CR129" class="usa-link" aria-describedby="CR129">129</a>]. These 3D structures often incorporate synthetic hydrogels, matrigel, or natural extracellular matrix (ECM) materials such as collagen [<a href="#CR130" class="usa-link" aria-describedby="CR130">130</a>]. While synthetic hydrogels only offer basic physical support, matrigel and ECM provide enriched growth factors that promote CTC proliferation. However, the impact of different components and stiffness levels of 3D organoids on CTC organogenesis remains an unresolved issue.</p>
<p id="Par53">Several chemical factors are crucial for the rapid expansion of CTCs in vitro, and their roles can be broadly categorized into four aspects: awakening, proliferation, stemness, and oxidative balance. Firstly, CTCs often remain in a dormant state to evade circulation stress in the blood. Awakening these dormant CTCs is essential for their expansion. Typically, a low ERK and high p38 MAPK signaling coupling inhibits proliferation in dormant CTCs. Using a p38 inhibitor like SB202190 can disrupt this coupling, thereby promoting CTC awakening [<a href="#CR131" class="usa-link" aria-describedby="CR131">131</a>]. Secondly, growth factors are required to facilitate the proliferation of CTCs via G protein-coupled receptor signals. A recent work has revealed that long-term CTC-derived organoids can be established from mBC patients through the supplement of neuregulin 1 (NRG1) and/or FGF, which activates NRG1-HER3 and FGFR1 signaling to promote CTC survival and growth [<a href="#CR132" class="usa-link" aria-describedby="CR132">132</a>]. Importantly, the stemness properties of CTCs can be maintained with stem-cell factors such as WNT3a [<a href="#CR133" class="usa-link" aria-describedby="CR133">133</a>]. Moreover, antioxidants such as N-Acetylcysteine are used to prevent CTCs from oxidative stress [<a href="#CR134" class="usa-link" aria-describedby="CR134">134</a>]. However, it remains unclear whether other factors, beyond the aforementioned mechanisms, contribute to the successful expansion of CTCs. Moreover, the extent to which different combinations of these factors promote the expansion of CTCs from various cancer patients or multiple samples of a single patient is still unknown.</p>
<p id="Par54">One of the most successful applications of biological conditions is conditional reprogramming (CR), which involves co-culturing primary cells with irradiated mouse 3T3-J2 fibroblasts in the presence of RHO-related protein kinase (ROCK) inhibitor Y-27632 [<a href="#CR135" class="usa-link" aria-describedby="CR135">135</a>]. The 3T3-J2 cells provide a supportive growth niche and a cocktail of factors for primary cells, enabling them to acquire stem-like characteristics and enhance their proliferation ability. CR has proven highly effective for the expansion of primary cancer cells and is now used in various oncology areas including the establishment of patient-derived xenografts (PDXs) models, drug susceptibility testing, and precision medicine. Despite its success with primary tumor cells, the CR method has seen limited success in expanding CTCs, and the reasons for this remain unclear. One potential avenue for improvement is the inclusion of cancer-associated fibroblasts (CAFs) [<a href="#CR136" class="usa-link" aria-describedby="CR136">136</a>]. Research indicates that CAFs can significantly impact CTC proliferation, especially in 3D culture environments [<a href="#CR137" class="usa-link" aria-describedby="CR137">137</a>]. Additionally, LWRN cells may promote gastrointestinal CTC expansion because of their secretion of stem-cell factors [<a href="#CR138" class="usa-link" aria-describedby="CR138">138</a>]. Although the presence of these feeder cells may hinder the observation of CTCs, these specialized biological settings are crucial for facilitating the proliferation and survival of CTCs.</p>
<p id="Par55">Although the cultivation of CTCs in vitro can serve as a platform for screening metastatic intervention drugs and promoting CTC phenotypic analysis, it poses a significant challenge, as highlighted by the low efficiency of in vitro CTC culture (Table <a href="#Tab3" class="usa-link">3</a>). In conclusion, CTCs from advanced patients or those who progress rapidly on treatment with a high CTC count are more likely to culture in vitro successfully. Negative selection such as CD45 deletion can enrich heterogeneous CTCs for cultivation and seems to be the most feasible isolation method currently. Although suspension and organoid cultivation methods have shown promising paradigms in CTC cultivation, future research should focus on developing more efficient CTC expansion methods. Following this, establishing an effective in vitro screening platform for metastasis intervention drugs will be crucial for improving metastasis prevention strategies.</p>
<section class="tw xbox font-sm" id="Tab3"><h4 class="obj_head">Table 3.</h4>
<div class="caption p"><p>Applicable methods for CTC culture in vitro</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Cancer type</th>
<th align="left" colspan="1" rowspan="1">Stage</th>
<th align="left" colspan="1" rowspan="1">Isolation method</th>
<th align="left" colspan="1" rowspan="1">Culture condition</th>
<th align="left" colspan="1" rowspan="1">Key characteristic</th>
<th align="left" colspan="1" rowspan="1">No. of CTC lines/ successful cases / Total cultured cases</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Breast cancer</td>
<td align="left" colspan="1" rowspan="1">Advanced</td>
<td align="left" colspan="1" rowspan="1">FACS</td>
<td align="left" colspan="1" rowspan="1">Stem cell culture medium &amp; EpiCult-C medium</td>
<td align="left" colspan="1" rowspan="1">\</td>
<td align="left" colspan="1" rowspan="1">3/3/8 [<a href="#CR6" class="usa-link" aria-describedby="CR6">6</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Breast cancer</td>
<td align="left" colspan="1" rowspan="1">Advanced</td>
<td align="left" colspan="1" rowspan="1">CTC-iChip</td>
<td align="left" colspan="1" rowspan="1">Stem cell culture medium in 4% O<sub>2</sub>, suspension condition *</td>
<td align="left" colspan="1" rowspan="1">CTCs are from patients progressing on treatment</td>
<td align="left" colspan="1" rowspan="1">6/NA/36 [<a href="#CR127" class="usa-link" aria-describedby="CR127">127</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Breast cancer</td>
<td align="left" colspan="1" rowspan="1">Advanced</td>
<td align="left" colspan="1" rowspan="1">Ficoll-Hypaque gradient centrifugation</td>
<td align="left" colspan="1" rowspan="1">Organoid condition</td>
<td align="left" colspan="1" rowspan="1">\</td>
<td align="left" colspan="1" rowspan="1">1/NA/50 [<a href="#CR155" class="usa-link" aria-describedby="CR155">155</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Breast cancer</td>
<td align="left" colspan="1" rowspan="1">18 stages I-III and 16 stage IV</td>
<td align="left" colspan="1" rowspan="1">Electromicrofluidic chip</td>
<td align="left" colspan="1" rowspan="1">Similar to *</td>
<td align="left" colspan="1" rowspan="1">CD44<sup>+</sup> CTCs are highly tumorigenic</td>
<td align="left" colspan="1" rowspan="1">NA/13/34 [<a href="#CR156" class="usa-link" aria-describedby="CR156">156</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Breast cancer</td>
<td align="left" colspan="1" rowspan="1">Advanced</td>
<td align="left" colspan="1" rowspan="1">Ficoll-Hypaque gradient centrifugation</td>
<td align="left" colspan="1" rowspan="1">Co-cultured with leukocytes</td>
<td align="left" colspan="1" rowspan="1">CD45<sup>+</sup> cells support CTC growth in vitro</td>
<td align="left" colspan="1" rowspan="1">NA/6/12 [<a href="#CR154" class="usa-link" aria-describedby="CR154">154</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Breast cancer</td>
<td align="left" colspan="1" rowspan="1">Advanced</td>
<td align="left" colspan="1" rowspan="1">FACS or immunomagnetic sorting</td>
<td align="left" colspan="1" rowspan="1">Organoid condition with 4% O<sub>2</sub>
</td>
<td align="left" colspan="1" rowspan="1">NRG1-HER3 and FGFR signaling promote CTC survival</td>
<td align="left" colspan="1" rowspan="1">NA/6/NA [<a href="#CR132" class="usa-link" aria-describedby="CR132">132</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CRC</td>
<td align="left" colspan="1" rowspan="1">Advanced</td>
<td align="left" colspan="1" rowspan="1">Negative selection</td>
<td align="left" colspan="1" rowspan="1">Similar to *</td>
<td align="left" colspan="1" rowspan="1">High CTC count (Total ≥ 300)</td>
<td align="left" colspan="1" rowspan="1">
<p>1/2/50 [<a href="#CR157" class="usa-link" aria-describedby="CR157">157</a>]</p>
<p>9/1/168 [<a href="#CR158" class="usa-link" aria-describedby="CR158">158</a>]</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CRC</td>
<td align="left" colspan="1" rowspan="1">Advanced</td>
<td align="left" colspan="1" rowspan="1">Filtration method</td>
<td align="left" colspan="1" rowspan="1">Organoid condition</td>
<td align="left" colspan="1" rowspan="1">CTCs enter a slow proliferation phase after passage</td>
<td align="left" colspan="1" rowspan="1">1/14/26 [<a href="#CR159" class="usa-link" aria-describedby="CR159">159</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Gastroesophageal &amp; gastric adenocarcinoma</td>
<td align="left" colspan="1" rowspan="1">Advanced</td>
<td align="left" colspan="1" rowspan="1">Human CD45 Depletion</td>
<td align="left" colspan="1" rowspan="1">Similar to *</td>
<td align="left" colspan="1" rowspan="1">CTCs are from patients rapidly progressing on treatment</td>
<td align="left" colspan="1" rowspan="1">2/NA/23 [<a href="#CR160" class="usa-link" aria-describedby="CR160">160</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Melanoma</td>
<td align="left" colspan="1" rowspan="1">Advanced</td>
<td align="left" colspan="1" rowspan="1">CTC-iChip</td>
<td align="left" colspan="1" rowspan="1">Similar to *</td>
<td align="left" colspan="1" rowspan="1">\</td>
<td align="left" colspan="1" rowspan="1">5/NA/37 [<a href="#CR161" class="usa-link" aria-describedby="CR161">161</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">NSCLC</td>
<td align="left" colspan="1" rowspan="1">IIa</td>
<td align="left" colspan="1" rowspan="1">Ficoll-Hypaque gradient centrifugation</td>
<td align="left" colspan="1" rowspan="1">Similar to *</td>
<td align="left" colspan="1" rowspan="1">High CTC count (Total ≥ 100)</td>
<td align="left" colspan="1" rowspan="1">1/2/89 [<a href="#CR162" class="usa-link" aria-describedby="CR162">162</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">NSCLC</td>
<td align="left" colspan="1" rowspan="1">30 stages I-III and 40 stage IV</td>
<td align="left" colspan="1" rowspan="1">Human CD45 Depletion</td>
<td align="left" colspan="1" rowspan="1">Clevers media in 1–2% O<sub>2</sub> condition</td>
<td align="left" colspan="1" rowspan="1">\</td>
<td align="left" colspan="1" rowspan="1">NA/9/70 [<a href="#CR163" class="usa-link" aria-describedby="CR163">163</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Pancreatic cancer</td>
<td align="left" colspan="1" rowspan="1">Locally advanced</td>
<td align="left" colspan="1" rowspan="1">Size-based CTC isolation</td>
<td align="left" colspan="1" rowspan="1">Organoid condition (fibronectin coating)</td>
<td align="left" colspan="1" rowspan="1">\</td>
<td align="left" colspan="1" rowspan="1">3/3/10 [<a href="#CR164" class="usa-link" aria-describedby="CR164">164</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Pancreatic cancer</td>
<td align="left" colspan="1" rowspan="1">Advanced</td>
<td align="left" colspan="1" rowspan="1">Human CD45 Depletion</td>
<td align="left" colspan="1" rowspan="1">Organoid condition</td>
<td align="left" colspan="1" rowspan="1">\</td>
<td align="left" colspan="1" rowspan="1">1/14/40 [<a href="#CR165" class="usa-link" aria-describedby="CR165">165</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PDAC</td>
<td align="left" colspan="1" rowspan="1">5 stages II-III and 36 stage IV</td>
<td align="left" colspan="1" rowspan="1">Ficoll-Hypaque gradient centrifugation</td>
<td align="left" colspan="1" rowspan="1">Organoid condition</td>
<td align="left" colspan="1" rowspan="1">3D plates with platelet lysate-based culture medium</td>
<td align="left" colspan="1" rowspan="1">NA/36/41 [<a href="#CR166" class="usa-link" aria-describedby="CR166">166</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Prostate cancer</td>
<td align="left" colspan="1" rowspan="1">Advanced</td>
<td align="left" colspan="1" rowspan="1">Human CD45 Depletion</td>
<td align="left" colspan="1" rowspan="1">Organoid condition</td>
<td align="left" colspan="1" rowspan="1">High CTC count (Total ≥ 300)</td>
<td align="left" colspan="1" rowspan="1">1/NA/17 [<a href="#CR167" class="usa-link" aria-describedby="CR167">167</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">SCLC</td>
<td align="left" colspan="1" rowspan="1">Advanced</td>
<td align="left" colspan="1" rowspan="1">Ficoll-Hypaque gradient centrifugation</td>
<td align="left" colspan="1" rowspan="1">Serum-free medium condition</td>
<td align="left" colspan="1" rowspan="1">\</td>
<td align="left" colspan="1" rowspan="1">3/NA/30 [<a href="#CR168" class="usa-link" aria-describedby="CR168">168</a>]</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p67"><p>Note: No. of successful cases includes those in which CTC can be expanded over one month. CRC: colorectal cancer, SCLC: small cell lung cancer, NSCLC: non-small cell lung cancer, PDAC: pancreatic ductal adenocarcinoma</p></div></div></section></section><section id="Sec12"><h3 class="pmc_sec_title">CTC applications</h3>
<section id="Sec13"><h4 class="pmc_sec_title">Liquid biopsy of CTCs</h4>
<p id="Par58">The identification of CTCs as potential indicators throughout the entire metastatic cascade has garnered significant interest in clinical translational research (Fig. <a href="#Fig3" class="usa-link">3</a>A).</p>
<figure class="fig xbox font-sm" id="Fig3"><h5 class="obj_head">Fig. 3.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374358_13045_2025_1733_Fig3_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc14/12374358/fdf7fee9e47d/13045_2025_1733_Fig3_HTML.jpg" loading="lazy" id="d33e1728" height="1015" width="774" alt="Fig. 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Potential applications of CTCs. CTCs can be used for <strong>(A)</strong> liquid biopsy during disease progression. <strong>(B)</strong> Drug susceptibility test (DST) and screening of potentially efficient drugs for cancer patients with metastasis. <strong>(C)</strong> Multiomics analysis can be integrated for constructing the evolutionary trajectory of tumor cells from primary to metastatic sites. <strong>(D)</strong> After in vitro passage over time, CTCs must be evaluated for consistency in their genetic background. <strong>(E)</strong> CTCs collected from a single patient at different timepoints can be used to evaluate clonal evolution. <strong>(F)</strong> CTC-derived xenografts (CTC-DXs) can be developed for preclinical analysis</p></figcaption></figure><section id="Sec14"><h5 class="pmc_sec_title">Early diagnosis</h5>
<p id="Par60">Several studies have suggested the occurrence of metastatic transmission of CTCs during the initial phases of cancer progression. Barriere and colleagues successfully detected CTCs in the peripheral blood of patients diagnosed with two types of early breast cancer, specifically those with stage T1 and axillary lymph node-negative disease [<a href="#CR169" class="usa-link" aria-describedby="CR169">169</a>]. Some researchers suggest that CTCs could indicate potential cancer progression before primary tumors are detectable through imaging [<a href="#CR170" class="usa-link" aria-describedby="CR170">170</a>]. By leveraging the biological characteristics of CTCs, clinicians can improve early cancer diagnosis and prevention. For example, detecting biomarkers such as MART1, gp100, and S100β in blood samples from patients with uveal melanoma could aid in the early identification of cancer risk [<a href="#CR171" class="usa-link" aria-describedby="CR171">171</a>]. However, the use of CTCs for early diagnosis remains limited due to their scarcity and the low sensitivity of current detection methods.</p></section><section id="Sec15"><h5 class="pmc_sec_title">Prognosis</h5>
<p id="Par61">The primary goal of CTC biology is to provide prognostic insights in cancer [<a href="#CR172" class="usa-link" aria-describedby="CR172">172</a>]. A growing body of evidence demonstrates that CTCs can effectively predict the prognosis of patients with metastatic cancers, particularly in mBC, metastatic colorectal cancer (mCRC) and metastatic castration-resistant prostate cancer (mCRPC), as detected by the CellSearch system [<a href="#CR173" class="usa-link" aria-describedby="CR173">173</a>–<a href="#CR175" class="usa-link" aria-describedby="CR175">175</a>]. For example, in mBC, foundational studies dating back to 2004 assessed the relationship between CTC count and OS using data from 177 mBC patients [<a href="#CR176" class="usa-link" aria-describedby="CR176">176</a>]. The study compared two groups based on base line CTC count (≥ 5/7.5 mL whole blood vs. &lt; 5/7.5 mL whole blood), revealing that pretreatment CTC count is a reliable and independent predictor of PFS (2.7 months vs. 7.0 months; <em>P</em> &lt; 0.001) and OS (8.2 months vs. &gt;18 months; <em>P</em> &lt; 0.001) in patients with mBC. Subsequently, researchers focused on using CTC count to monitor survival variations across different therapies. These studies showed that persistent high or elevated CTC count during treatment are indicative of a worse prognosis for mBC patients [<a href="#CR177" class="usa-link" aria-describedby="CR177">177</a>, <a href="#CR178" class="usa-link" aria-describedby="CR178">178</a>]. Similarly, CTC enumeration has proven to be a valuable, non-invasive tool for predicting recurrence and metastasis in NSCLC, hepatocellular carcinoma (HCC), and gastric cancer [<a href="#CR179" class="usa-link" aria-describedby="CR179">179</a>–<a href="#CR182" class="usa-link" aria-describedby="CR182">182</a>].</p></section><section id="Sec16"><h5 class="pmc_sec_title">Therapy decision making</h5>
<p id="Par62">A series of studies have focused on whether CTC count can inform treatment choices and improve patient outcomes. In a STIC CTC randomized phase 3 trial, researchers compared the efficacy of clinician-driven versus CTC-driven first-line therapy choices (ClinicalTrials.gov: <a href="https://clinicaltrials.gov/ct2/show/NCT01710605" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT01710605</a>). In this study, 755 patients with hormone receptor-positive, ERBB2-negative mBC were randomized into two groups, patients received chemotherapy or endocrine therapy based on CTC count (chemotherapy if CTC count ≥ 5/7.5 mL whole blood; endocrine therapy if CTC count &lt; 5/7.5 mL whole blood). The result showed the median PFS was 15.5 months (95% CI, 12.7–17.3) in the CTC arm and 13.9 months (95% CI, 12.2–16.3) in the standard arm, with a hazard ratio (HR) of 0.94 (90% CI, 0.81–1.09) [<a href="#CR183" class="usa-link" aria-describedby="CR183">183</a>]. Additionally, after a median follow-up of 4.7 years, the OS was reported as 51.3 months (95% CI, 46.8 to 55.1) and 45.5 months (95% CI, 40.9 to 51.1) in the two arms (HR, 0.85; 95% CI, 0.69 to 1.03; <em>P</em> = 0.11) [<a href="#CR184" class="usa-link" aria-describedby="CR184">184</a>]. These findings suggest that CTC count has clinical potential as a reliable biomarker to guide therapy decision making. However, some studies have shown that CTC count failed to guide clinical chemotherapy in mBC [<a href="#CR173" class="usa-link" aria-describedby="CR173">173</a>, <a href="#CR185" class="usa-link" aria-describedby="CR185">185</a>]. A well-known negative study comes from the SWOG S0500 clinical trial, conducted by Hayes and his team. In this study, mBC patients with persistent CTCs ≥ 5/7.5 mL whole blood before receiving first-line chemotherapy and after 21 days of first-line chemotherapy were randomized into switch therapy and maintain therapy groups. The switch therapy group experienced early switching to an alternate cytotoxic treatment. However, the switch therapy group did not show a significant improvement in OS compared to the maintain therapy group (10.7 vs. 12.5 months, respectively; <em>P</em> = 0.98) [<a href="#CR173" class="usa-link" aria-describedby="CR173">173</a>]. The negative results may be due to the low sensitivity of CTC detection by the CellSearch system and the insufficient duration of the intervention. In addition to CTC count guiding therapy decisions, the integration of CTC biomarkers is a promising direction for targeted therapy decision making. For example, Scher and his colleagues conducted a clinical trial to determine whether the nuclear-localized androgen receptor splice variant 7 (AR-V7) positive CTC test for patients with progressing metastatic castration-resistant prostate cancer could improve therapy decision making at second line or later therapies [<a href="#CR116" class="usa-link" aria-describedby="CR116">116</a>]. The results showed that patients with detectable AR-V7<sup>+</sup> CTCs had superior survival when treated with taxanes compared to androgen receptor signaling inhibitors.</p></section><section id="Sec17"><h5 class="pmc_sec_title">Patient follow-up</h5>
<p id="Par63">A recent study that enrolled data from 4,436 mBC patients, with CTC results from both baseline and one follow-up, demonstrated that follow-up CTC enumeration is a strong predictor of OS independent of tumor subtype and treatment [<a href="#CR186" class="usa-link" aria-describedby="CR186">186</a>]. This suggests that CTC monitoring could serve as an early response marker in mBC, highlighting the importance of CTC monitoring in patient follow-up.</p>
<p id="Par64">It is worth noting that most clinical trials relating to CTC count or biomarkers rely on the FDA-approved CellSearch system. However, CTC detection technologies have evolved from single-parameter enumeration to multimodal integration. Advances in technical frontiers, such as microfluidics and metabolic labeling, are improving non-structive capture and singe-cell analysis, addressing the challenges of heterogeneity [<a href="#CR122" class="usa-link" aria-describedby="CR122">122</a>, <a href="#CR187" class="usa-link" aria-describedby="CR187">187</a>]. Furthermore, the integration of CTC molecular profiling enables the prediction of responses to targeted therapies, though larger-scale clinical trials are required to validate these findings [<a href="#CR188" class="usa-link" aria-describedby="CR188">188</a>]. As multicenter trials rigorously compare platform performance, CTCs, as a crucial tool in liquid biopsy, have the potential to cover the full spectrum from early diagnosis and prognosis to therapy decision making, real-time therapeutic efficacy monitoring and patient follow-up.</p></section></section><section id="Sec18"><h4 class="pmc_sec_title">Drug susceptibility testing</h4>
<p id="Par65">Once CTCs are effectively cultured and propagated in vitro, extensive molecular and functional investigations can be carried out (Fig. <a href="#Fig3" class="usa-link">3</a>B-3F). These CTCs can be utilized for drug susceptibility testing (DST) and screening potentially efficient drugs for cancer patients with metastasis, as well as for monitoring drug responses in vitro [<a href="#CR127" class="usa-link" aria-describedby="CR127">127</a>, <a href="#CR189" class="usa-link" aria-describedby="CR189">189</a>]. In the first reported ex vivo expansion of CTCs, Yu et al.., employed breast cancer CTC lines to identify changing patterns of drug susceptibility. Genome sequencing of these CTCs unveiled the presence of <em>PIK3CA</em> and newly acquired mutations in <em>ESR1</em> and <em>FGFR2</em>. Notably, combinatorial drug targeting of mutant <em>ESR1</em> and <em>PIK3CA</em> suggested potential new therapeutic avenues using these CTC lines [<a href="#CR73" class="usa-link" aria-describedby="CR73">73</a>]. Another group focused on CTC lines derived from circulating colorectal cancer cells to monitor therapy-driven tumor changes. Nine CTC lines were isolated from a patient with metastatic colorectal cancer, with blood samples collected before and after multi-therapy, as well as during cancer progression. These cell lines showed changes in mRNA and protein expression (e.g., DEFA6, ABCB1 and GAL), indicating that phenotypic characteristics were selected over time [<a href="#CR158" class="usa-link" aria-describedby="CR158">158</a>]. Furthermore, the researchers compared the gene expression profiles of these CTC lines and revealed that some upregulated genes were involved in mTOR and PI3K/AKT signaling pathways. High expression of cytidine deaminase was associated with resistance to 5-fluorouracil-based treatments, while dysregulation of xenobiotic and energy metabolism pathways was also observed following selective treatment pressure [<a href="#CR190" class="usa-link" aria-describedby="CR190">190</a>].</p>
<p id="Par66">Long-term maintenance of CTC line expansion in vitro is often time-consuming and inefficient, limiting the ability to evaluate drug response for cancer patients. To address this issue, Lim et al.. developed a microfluidics-based culture approach that facilitates the co-culture of immune cells and CTCs from the same patient blood sample within specially designed microwells. This innovative method enables CTC cluster formation within 2 weeks, achieving an efficiency of approximately 50% [<a href="#CR191" class="usa-link" aria-describedby="CR191">191</a>]. In their study, drug screening was facilitated through the incorporation of a gradient generator, allowing for parallel exposure to two or more drugs at various concentrations. A total of 24 breast cancer samples were used for this drug evaluation, and the potential for cluster formation was found to correlate inversely with increased drug concentration [<a href="#CR192" class="usa-link" aria-describedby="CR192">192</a>]. The rapid evaluation may help clinicians better assess drug responses in patients, ultimately enabling personalized therapy.</p></section><section id="Sec19"><h4 class="pmc_sec_title">Multiomics analysis</h4>
<p id="Par67">Recent improvements in multiomics technologies at single-cell resolution have allowed extensive exploration of CTC biology and its molecular profiles. Multiomics analysis can be integrated across various levels including genomic, epigenetic, transcriptomic, proteomic and metabolic features, enabling researchers to construct a complete revolution trajectory of tumor cells from primary to metastatic sites [<a href="#CR193" class="usa-link" aria-describedby="CR193">193</a>, <a href="#CR194" class="usa-link" aria-describedby="CR194">194</a>]. For example, Ebright et al.. conducted an in vivo genome-wide CRISPR activation screen in breast cancer CTCs to identify genes that promote distant metastasis in mice [<a href="#CR195" class="usa-link" aria-describedby="CR195">195</a>]. This identified the enrichment of ribosomal proteins and their regulators of translation. Among them, <em>RPL15</em>, which encodes a component of large ribosomal subunits, was correlated with increased metastatic growth in multiple organs. It’s expression also enhanced the translation of other ribosomal proteins and cell cycle regulators. Notably, in vivo CRISPR-Cas9 studies of CTCs can provide a valuable tool to examine spontaneous cancer metastasis, and reveal specific factors in promoting each step of the metastatic process.</p>
<p id="Par68">Additionally, exploring the epigenetic landscape of CTCs has been increasingly studied, particularly DNA methylation. A comparative analysis of the methylome of breast cancer CTCs revealed that CTC clusters exhibited a hypomethylation pattern in DNA binding sites for stemness- and proliferation- associated transcription factors (OCT4, NANOG, SOX2, and SIN3A). And CTC cluster hypomethylated regions at the primary tumor levels in breast cancers were associated with poor prognosis, suggesting its prognostic value [<a href="#CR196" class="usa-link" aria-describedby="CR196">196</a>]. More recently, Guo et al.. conducted high-resolution genome-wide single-cell DNA methylation sequencing to identify the correlation of hypomethylation and tumorigenesis. In the CTCs from the earliest detectable stages of prostate malignancy, transcriptionally silenced genes within the core hypomethylated domains were enriched for immune-related genes, particularly CD1 and IFI16. The re-expression of CD1 or IFI16 murine orthologs in immuno-competent mice abrogated tumorigenesis, which was consistent with the activation of anti-tumor immunity [<a href="#CR197" class="usa-link" aria-describedby="CR197">197</a>]. Thus, the comprehensive analysis of the CTC methylome has revealed the active expression of genes associated with proliferation and stemness, and silenced expression of anti-tumor immune genes. Further investigation of histone marks or transcription factor binding through omics techniques will provide more information on CTC regulation.</p></section><section id="Sec20"><h4 class="pmc_sec_title">Consistency evaluation of genetic background</h4>
<p id="Par69">Cultivation of CTCs in vitro imposes a strong selection pressure on CTCs, potentially leading to genomic variations. Research using gene expression profiling has revealed that short-term in vitro culture facilitates the differentiation process of CTCs growing on a membrane, indicating that their genomes have adapted to this process [<a href="#CR198" class="usa-link" aria-describedby="CR198">198</a>]. In a study analyzing CNA inferring in 1,110 PDX samples across multiple cancer types, nearly 60% of samples acquired at least one large chromosomal abnormality within a single passage, and this increased to 90% after the first four passages [<a href="#CR199" class="usa-link" aria-describedby="CR199">199</a>]. Despite these findings, there have been no systematic evaluations of the consistency of the genetic background in CTCs.</p>
<p id="Par70">To ensure that in vitro drug susceptibility testing of CTCs reliably reflects patient responses to multiple treatment courses, it is crucial to assess the genetic consistency of CTCs passaged in vitro over time. High-throughput sequencing technologies, such as whole-genome sequencing, exome sequencing, and scRNA sequencing can be employed to provide a comprehensive view of the genetic landscape. This will enable researchers to conduct longitudinal studies to examine how genetic backgrounds evolve and their implications for treatment, ultimately leading to better-targeted therapies and improved patient outcomes.</p></section><section id="Sec21"><h4 class="pmc_sec_title">Evaluation of clonal evolution</h4>
<p id="Par71">Clonal evolution is a fundamental biological phenomenon. Alix-Panabières and colleagues established nine permanent colon CTC lines from peripheral blood samples of a single patient with metastatic colon cancer [<a href="#CR190" class="usa-link" aria-describedby="CR190">190</a>]. These CTCs were collected before treatment initiation, after the first- and second-line treatments, and one week before the patient’s death, providing valuable insights into the trajectory of clonal evolution during treatment and cancer progression. To compare the gene expression profiles of these CTC lines, they identified the mTOR and PI3K/AKT signaling pathways, cytidine deaminase metabolism, and stem cell properties, all of which were associated with drug resistance and clonal evolution of CTCs. Additionally, they recently conducted proteomic profiling and functional analysis of extracellular vesicles derived from these CTCs [<a href="#CR200" class="usa-link" aria-describedby="CR200">200</a>]. This analysis revealed that integrin family proteins were significantly enriched in extracellular vesicles from CTC lines derived after therapy failure. These studies further underscore that in vitro-expanded CTCs are an ideal tool for studying clonal evolution and other biological changes related to therapy.</p></section><section id="Sec22"><h4 class="pmc_sec_title">CTC-derived xenograft models</h4>
<p id="Par72">CTCs can be utilized to establish CTC-derived xenograft models (CDXs), which effectively recapitulate the genetic and morphological characteristics of the tumors from donor patients, as well as their responses to various drugs. For example, Drapkin et al.. generated PDXs using biopsies and CTCs from small-cell lung cancer (SCLC) patients. CTCs were enriched using CTC-iChip<sup>neg</sup> device and subsequently injected subcutaneously into the flanks of NSG mice. The mice were monitored for tumorigenesis, and then tumor cells were serially passaged, resulting in the generation of 17 CDXs with 38% efficiency. In conjunction with biopsy-derived xenografts, a total of 30 PDX models underwent in vivo treatment with etoposide and platinum (EP). The results demonstrated greater sensitivity in PDXs from EP-naïve patients, while resistance to EP was associated with an upregulated <em>MYC</em> gene signature. Notably, serial CDXs obtained from an individual patient at different time points accurately reflected the evolving drug susceptibilities of that patient’s disease [<a href="#CR201" class="usa-link" aria-describedby="CR201">201</a>]. Later, Stewart et al.. employed SCLC-CDXs to investigate intra-tumoral heterogeneity (ITH) through single-cell RNA sequencing of both chemo-sensitive and -resistant CDXs, as well as patient-derived CTCs. Their findings indicated that platinum-resistant CDXs exhibited increased ITH, characterized by heterogeneous expression of therapeutic targets and EMT-related genes [<a href="#CR202" class="usa-link" aria-describedby="CR202">202</a>]. Additionally, researchers used the BR16 breast cancer CTC line to conduct an in vivo loss-of-function genome-wide CRISPR screen in BR16 CDXs. In this study, BR16-Cas9-GFP cells were transduced with genome-wide sgRNA library and injected in the mammary fat pad of NSG mice. After 5–7 months, primary tumors, single CTCs, CTC clusters, and organs with metastasis were isolated and subjected to next-generation sequencing for sgRNA readout. This revealed that the deletion of <em>IL18R1</em>, <em>ITGA2</em>, <em>CSNK1A1L</em>, and <em>CSNK2A2</em> led to decreased CTC cluster formation and reduced metastatic burden in vivo. Furthermore, PLK1 was found to be essential for the intravasation of both single CTCs and CTC clusters, suggesting that it’s inhibitors could efficiently prevent CTC intravasation [<a href="#CR203" class="usa-link" aria-describedby="CR203">203</a>].</p>
<p id="Par73">The low efficiency in generating CDXs, whether through the direct injection of freshly isolated CTCs or in vitro CTC expansion, presents a significant challenge. Addressing this issue will require further technical advancements in isolating viable CTCs and improving the efficiency of CTC expansion. Another limitation of CDXs is the scarcity of archival tissue samples, which hinders comparisons of ITH between patient tumor biopsies, CDXs and CTCs. As CDX libraries and banking of patient samples continue to expand, researchers will be better positioned to investigate how ITH is influenced by specific transcriptional subtypes. Additionally, longitudinal samples from individual patients both pre- and post-treatment may provide valuable insights into tumor evolution that underlies shifts in treatment sensitivity.</p></section></section></section><section id="Sec23"><h2 class="pmc_sec_title">Immune escape mechanisms of CTCs</h2>
<p id="Par74">Shedding of tumor cells from the primary site is a common event, yet only a small fraction of CTCs successfully complete metastasis due to various unfavorable conditions in the blood environment [<a href="#CR204" class="usa-link" aria-describedby="CR204">204</a>, <a href="#CR205" class="usa-link" aria-describedby="CR205">205</a>]. The immune system plays a pivotal role in monitoring and eliminating CTCs. Research on how CTCs evade immune detection has become a significant focus. We explore recent findings on the mechanisms and pathways of immune evasion employed by CTCs. Specifically, we investigate the roles of immune dampening, antigen deficiency, and camouflage (Fig. <a href="#Fig4" class="usa-link">4</a>).</p>
<figure class="fig xbox font-sm" id="Fig4"><h3 class="obj_head">Fig. 4.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374358_13045_2025_1733_Fig4_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc14/12374358/6d726a3c8def/13045_2025_1733_Fig4_HTML.jpg" loading="lazy" id="d33e2002" height="1016" width="754" alt="Fig. 4"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Immune escape mechanisms of CTCs. CTCs evade immune surveillance in the circulation mainly through the following mechanisms: (<strong>A</strong>) Immune dampening: <strong>a</strong>. Immune checkpoint regulation; <strong>b</strong>. Cytokine secretion or immunosuppressive cell recruitment by CTCs or other cells; <strong>c</strong>. FAS/FASL-mediated CTL apoptosis. (<strong>B</strong>) Antigen deficiency: the downregulation or loss of MHC-I contributes to impaired CTL recognition. (<strong>C</strong>) Camouflage: <strong>a</strong>. CTCs fuse with macrophages, effectively camouflaging themselves to escape immune surveillance; <strong>b</strong>. Platelets coat the surface of CTCs, presenting their MHC-I to CTLs and helping the CTCs evade immune attacks; <strong>c</strong>. CTCs are shielded by CD45, attenuating TCR signaling to escape T cell killing</p></figcaption></figure><section id="Sec241"><h3 class="pmc_sec_title">Immune dampening</h3>
<section id="Sec24"><h4 class="pmc_sec_title">Immune checkpoint regulation</h4>
<p id="Par76">Immune checkpoints are widely recognized as crucial mechanisms facilitating immune evasion by tumor cells. Key immune checkpoints such as PD-L1/PD-1 and CD47/SIRPα are known to interact between CTCs and CTLs or macrophages [<a href="#CR206" class="usa-link" aria-describedby="CR206">206</a>]. Recently, the discovery of a novel immune checkpoint, HLA-E: CD94/NKG2A, has generated significant interest. This study reveals a significant enhancement in the inhibition of tumor metastasis in vivo and the killing of CTCs in vitro when NKG2A is blocked or HLA-E on CTCs is knocked down, leading to increased activity of NK cells. This research ultimately establishes HLA-E: CD94/NKG2A as a functional immune checkpoint between CTCs and NK cells. Furthermore, it was found that the protective impact of this immune checkpoint against CTCs is associated with the AKT-GSK3β-CREB signaling pathway, which involves regulation from platelet-derived RGS18 [<a href="#CR193" class="usa-link" aria-describedby="CR193">193</a>]. A recent study also reported that CTCs evade NK cell killing via immune checkpoint CD155-TIGIT [<a href="#CR207" class="usa-link" aria-describedby="CR207">207</a>]. These promising findings underscore the potential of immune checkpoint inhibitors as a powerful strategy for cancer treatment.</p>
<p id="Par77">CTCs interact extensively with various blood cells, including platelets, MSCs, myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), regulatory T cells (Tregs), and neutrophils [<a href="#CR2" class="usa-link" aria-describedby="CR2">2</a>, <a href="#CR208" class="usa-link" aria-describedby="CR208">208</a>]. Their interactions usually escort CTCs to evade immune surveillance. For instance, CTCs interact with MSCs through cGAMP delivery in a gap junction-dependent manner. The cGAMP-STING signaling activation leads to increased production of IFNβ by MSCs. IFNβ in turn enhances IFN-I signaling in CTCs and promotes the expression of HLA-I, thereby protecting CTCs from NK cell killing [<a href="#CR209" class="usa-link" aria-describedby="CR209">209</a>]. Similarly, platelets aid CTC evasion by directly adhering to CTCs, activating the FAK/JNK/c-Jun cascade to upregulate the inhibitory checkpoint CD155 [<a href="#CR207" class="usa-link" aria-describedby="CR207">207</a>]. Further investigation into these CTC-blood cell clusters could facilitate the identification of novel therapeutic targets.</p></section><section id="Sec25"><h4 class="pmc_sec_title">Cytokine secretion and immunosuppressive cell recruitment</h4>
<p id="Par78">Cytokine secretion or immunosuppressive cell recruitment by CTCs plays a crucial role in the immune evasion of CTCs. Anti-inflammatory cytokines such as TGF-β, PGE2, secreted by CTCs or platelets can directly inhibit immune surveillance functions of CTLs, NK cells, and macrophages [<a href="#CR2" class="usa-link" aria-describedby="CR2">2</a>, <a href="#CR208" class="usa-link" aria-describedby="CR208">208</a>]. For example, TGF-β from platelets down-regulates the expression of immune receptor NKG2D on NK cells, reducing their anti-tumor reactivity. In addition, CTCs secret CCL5 to recruit Tregs, facilitating their immune escape through the release of various immunosuppressive cytokines, including TGF-β and IL-10 [<a href="#CR210" class="usa-link" aria-describedby="CR210">210</a>, <a href="#CR211" class="usa-link" aria-describedby="CR211">211</a>]. Tregs also express surface proteins such as CTLA-4, which binds to CD80/CD86 on dendritic cells, inhibiting T cell activation [<a href="#CR212" class="usa-link" aria-describedby="CR212">212</a>]. Furthermore, the expression of CD25 (IL2Rα) allows Tregs to compete with effector T cells for IL-2, thereby inhibiting CD8<sup>+</sup> T lymphocyte proliferation [<a href="#CR213" class="usa-link" aria-describedby="CR213">213</a>]. Additionally, granzyme B and perforin released by Treg cells further suppress the activity of NK and CTL cells, exacerbating tumor-induced immunosuppression [<a href="#CR214" class="usa-link" aria-describedby="CR214">214</a>].</p></section><section id="Sec26"><h4 class="pmc_sec_title">FAS/FASL-mediated apoptosis of T cells</h4>
<p id="Par79">The FAS/FASL apoptotic pathway plays a significant role in helping CTCs evade immune surveillance. The loss or downregulation of FAS on CTCs reduces their susceptibility to apoptosis. Conversely, CTCs expressing FASL can induce apoptosis in T cells through their FAS receptors [<a href="#CR208" class="usa-link" aria-describedby="CR208">208</a>, <a href="#CR215" class="usa-link" aria-describedby="CR215">215</a>]. Though the precise extent to which FAS and FASL surface expression contributes to T cell apoptosis remains elusive, there’s no doubt that FASL/FAS-mediated apoptosis of T cells is a key mechanism of immune evasion for CTCs.</p></section></section><section id="Sec27"><h3 class="pmc_sec_title">Antigen deficiency</h3>
<p id="Par80">Abnormal antigen presentation has been shown to protect CTCs from recognition by CTLs and NK cells. Platelets can transfer their MHC-Ⅰ molecules to the surface of CTCs, thereby preventing recognition by NK and T cells [<a href="#CR216" class="usa-link" aria-describedby="CR216">216</a>]. Additionally, CTCs may downregulate or completely lose MHC-I expression, further interfering with TCR recognition of MHC-I molecules [<a href="#CR208" class="usa-link" aria-describedby="CR208">208</a>]. Furthermore, the surface expression of cytokeratin 8 in cancer cells can restrict the interaction between MHC-I and TCR on CTLs [<a href="#CR217" class="usa-link" aria-describedby="CR217">217</a>]. These mechanisms collectively enable CTCs to evade MHC-I-mediated recognition by both NK and T cells.</p></section><section id="Sec28"><h3 class="pmc_sec_title">Camouflage</h3>
<p id="Par81">CTCs fused with macrophage or shielded by platelets/CD45, can camouflage themselves to evade immune surveillance. CTC-macrophage hybrid cells have been linked to increased tumor metastasis and poorer overall survival in several cancers [<a href="#CR218" class="usa-link" aria-describedby="CR218">218</a>, <a href="#CR219" class="usa-link" aria-describedby="CR219">219</a>]. A study detects uveal melanoma disseminated hybrid cells and verifies they highly express CD74, which may contribute to immune evasion [<a href="#CR220" class="usa-link" aria-describedby="CR220">220</a>]. Understanding the fusion mechanism between CTCs and macrophages, as well as its role in immune evasion, is of great significance for identifying potential therapeutic targets. Recent studies have highlighted how platelets facilitate CTC immune evasion, with barrier protection emerging as a key mechanism [<a href="#CR221" class="usa-link" aria-describedby="CR221">221</a>, <a href="#CR222" class="usa-link" aria-describedby="CR222">222</a>]. Platelets aggregate to form a protective shield around CTCs to defend them against NK cell killing [<a href="#CR223" class="usa-link" aria-describedby="CR223">223</a>]. Several studies have reported the presence of CD45<sup>+</sup> CTCs in patients with various types of tumors, but their origin and biological characteristics remains unclear [<a href="#CR224" class="usa-link" aria-describedby="CR224">224</a>–<a href="#CR226" class="usa-link" aria-describedby="CR226">226</a>]. Our recent research indicates that CTCs shielded with extracellular vesicle-derived CD45 can escape T cell killing via attenuating TCR signaling, indicating that this pseudo-immune-like identity may further enable CTCs to evade immune surveillance [<a href="#CR227" class="usa-link" aria-describedby="CR227">227</a>].</p></section></section><section id="Sec29"><h2 class="pmc_sec_title">Drug resistance mechanisms of CTCs</h2>
<p id="Par82">CTCs exhibit extensive phenotypic and molecular heterogeneities that enable their survival in circulation and resistance to chemotherapy. Factors such as drug selection, circadian rhythm regulation and circulation pressure significantly contribute to the specific drug resistance observed in CTCs (Fig. <a href="#Fig5" class="usa-link">5</a>).</p>
<figure class="fig xbox font-sm" id="Fig5"><h3 class="obj_head">Fig. 5.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374358_13045_2025_1733_Fig5_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc14/12374358/f91715bc2cce/13045_2025_1733_Fig5_HTML.jpg" loading="lazy" id="d33e2156" height="473" width="669" alt="Fig. 5"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Drug resistance mechanisms of CTCs. <strong>(A)</strong> CTC clusters are more resistant to chemotherapy. <strong>(B)</strong> CTCs undergo phenotypic transition after cytotoxic chemotherapy. <strong>(C)</strong> CTC release is influenced by circadian rhythm, meaning that the timing of drug administration may not align with peak CTC release into circulation. ZT4 is defined as a typical rest-phase time, while ZTx refers to time points distinct from ZT4. <strong>(D)</strong> CTC heterogeneity such as CTCs with intracellular bacteria or with EMT/stemness/dormancy states, leads to various drug-resistance phenotypes. <strong>(E)</strong> CTCs protected by adjacent cells such as platelets, and neutrophils, can evade immune surveillance and resist chemotherapy. <strong>(F)</strong> CTCs with high levels of SREBP2 expression exhibit resistance to oxidative stress, thereby avoiding ferroptosis. <strong>(G)</strong> immune suppressive environment contributes to the immune evasion of CTCs/DTCs</p></figcaption></figure><p id="Par84">Cytotoxic chemotherapy can induce reversible changes in the molecular phenotype of CTCs. In HER2-negative breast cancer patients, CTCs may develop a HER2<sup>+</sup> subpopulation after multiple courses of therapy. Both HER2<sup>+</sup> and HER2<sup>−</sup> CTCs demonstrate comparable tumor-initiating potential, but HER2<sup>+</sup> CTCs exhibit stronger proliferation capability. Additionally, oxidative stress or cytotoxic chemotherapy can promote the transition from HER2<sup>+</sup> CTCs to HER2<sup>−</sup> CTCs [<a href="#CR228" class="usa-link" aria-describedby="CR228">228</a>]. This suggests the interconverting phenotypes within CTCs contribute to cancer progression and drug resistance. In prostate cancer, resistant CTCs in patients treated with androgen receptor (AR) inhibitors show notable expression of non-classical WNT signaling, particularly WNT5A, which enhances the survival of LNCaP cells after treatment [<a href="#CR229" class="usa-link" aria-describedby="CR229">229</a>].</p>
<p id="Par85">CTC release is influenced by circadian rhythm. Diamantopoulouthat et al.. reported that most spontaneous CTC intravasation events occur during sleep, termed “rest-phase CTCs”. These rest-phase CTCs are particularly prone to metastasis [<a href="#CR230" class="usa-link" aria-describedby="CR230">230</a>]. Consequently, administering drugs at varied times may result in inefficient plasma drug concentrations when the number of metastasis-prone CTCs is at its peak. This temporal mismatch can allow rest-phase CTCs to evade cytotoxic chemotherapy, facilitating their spread to distant organs. This highlights the importance of considering circadian rhythms in the timing of therapeutic interventions for improved treatment efficacy.</p>
<p id="Par86">Circulation pressures, such as shear stress, anoikis, oxidative stress and immune surveillance, play crucial roles in the evolution of CTCs. These pressures finally enhance CTCs surviving and resisting to chemotherapy. Notably, CTCs harboring intracellular bacteria show enhanced resistance to fluid shear stress by reorganizing actin cytoskeleton [<a href="#CR231" class="usa-link" aria-describedby="CR231">231</a>]. This adaptation underscores the complex interplay between external pressures and CTC resilience.</p>
<p id="Par87">During cancer metastasis, various CTCs undergo EMT, seen in breast, non-small cell lung, colorectal, prostate, and pancreatic cancers [<a href="#CR225" class="usa-link" aria-describedby="CR225">225</a>, <a href="#CR232" class="usa-link" aria-describedby="CR232">232</a>]. CTCs with mesenchymal or epithelial-mesenchymal mixed phenotypes exhibit enhanced migration and invasion abilities, but also display reduced sensitively to chemotherapy and immunotherapy [<a href="#CR233" class="usa-link" aria-describedby="CR233">233</a>]. Recent research has demonstrated that FGL1, a ligand for the tumor immune checkpoint LAG-3, exhibits significant expression in CTCs with a mixed epithelial-mesenchymal phenotype. Elevated FGL1 expression in these cells is more prone to immunotherapy resistance, thus following increased distal metastasis and unfavorable prognosis. While the precise association between FGL1 expression and EMT is still being explored, this suggests that the resistance mechanism of CTCs to immunotherapy is closely linked to the EMT process [<a href="#CR234" class="usa-link" aria-describedby="CR234">234</a>]. It is worth mentioning that dynamic changes in the epithelial and mesenchymal composition of CTCs accompany therapy resistance and disease progression [<a href="#CR14" class="usa-link" aria-describedby="CR14">14</a>].</p>
<p id="Par88">The dormant state of CTCs significantly contributes to the development of drug resistance. Most CTCs enter a dormant state to evade various challenges within the circulatory system. Research has demonstrated that the endosseous microenvironment offers direct attachment and protection for CTCs, allowing them to colonize the bone marrow during the metastatic process or even earlier, where they can remain dormant for extended periods [<a href="#CR235" class="usa-link" aria-describedby="CR235">235</a>]. Chemotherapy drugs primarily target rapidly proliferating tumor cells, making dormant CTCs highly resistant to their effects. In patients with SCLC under chemotherapy, have been observed that their CTC spheroids exist in a hypoxic and nearly quiescent state. Additionally, the limited penetration of drugs into these spheroids further aids their evasion from therapy, offering a plausible explanation for the widespread occurrence of drug resistance in advanced SCLC [<a href="#CR236" class="usa-link" aria-describedby="CR236">236</a>].</p>
<p id="Par89">CTC clusters have been linked to increased stemness, drug resistance and metastatic potential [<a href="#CR237" class="usa-link" aria-describedby="CR237">237</a>, <a href="#CR238" class="usa-link" aria-describedby="CR238">238</a>]. Gkountela et al. reported that specific binding sites for transcription factors in CTC clusters, including OCT4, NANOG, SOX2, and SIN3A, which are correlated to stemness and proliferation, are hypomethylated in CTC clusters [<a href="#CR196" class="usa-link" aria-describedby="CR196">196</a>]. In addition, chemotherapy-evasive CTC clusters tend to be relatively quiescent with glycoprotein hyposialylation [<a href="#CR239" class="usa-link" aria-describedby="CR239">239</a>]. Certain membrane and adhesive proteins, such as CD44, Plakoglobin, Fibronectin, ICAM1, DSC2, and PKP1, promote the formation of CTC clusters [<a href="#CR104" class="usa-link" aria-describedby="CR104">104</a>, <a href="#CR113" class="usa-link" aria-describedby="CR113">113</a>, <a href="#CR141" class="usa-link" aria-describedby="CR141">141</a>, <a href="#CR237" class="usa-link" aria-describedby="CR237">237</a>, <a href="#CR240" class="usa-link" aria-describedby="CR240">240</a>]. CTCs can also be protected by other circulating cells. For instance, platelets can induce resistance to anoikis by promoting RhoA-MYPT1-PP1-mediated YAP1 nuclear translocation, leading to a pro-survival gene expression signature [<a href="#CR241" class="usa-link" aria-describedby="CR241">241</a>]. Furthermore, the adipogenesis regulatory factor SREBP2 can directly induce the transcription of iron carrier transferrin (TF), thereby reducing intracellular iron pool, reactive oxygen species, and lipid peroxidation. These effects promote CTC resistance to ferroptosis [<a href="#CR161" class="usa-link" aria-describedby="CR161">161</a>]. Finally, various immune evasion mechanisms discussed earlier also play a significant role in the drug resistance of CTCs.</p>
<p id="Par90">In conclusion, the unique microenvironment and distinct states of CTCs, differed from primary tumors, play a crucial role in promoting their drug resistance.</p></section><section id="Sec30"><h2 class="pmc_sec_title">Clinical treatment strategies targeting CTCs</h2>
<p id="Par91">The presence of CTCs in the blood is a dynamic process, with their dissemination occurring early and continuing throughout the entire metastatic cascade [<a href="#CR242" class="usa-link" aria-describedby="CR242">242</a>]. Conversely, CTCs may originate from specific subpopulations within tumors and evolve in the bone marrow, making current strategies for eliminating primary tumors limited in their ability to eradicate CTCs to prevent metastatic disease. Although there is currently no specific targeted therapy for CTCs, targeting these cells from multiple perspectives within the metastatic cascade holds promise for effectively disrupting metastatic progression (Fig. <a href="#Fig6" class="usa-link">6</a>).</p>
<figure class="fig xbox font-sm" id="Fig6"><h3 class="obj_head">Fig. 6.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374358_13045_2025_1733_Fig6_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc14/12374358/28f15889127e/13045_2025_1733_Fig6_HTML.jpg" loading="lazy" id="d33e2293" height="1016" width="768" alt="Fig. 6"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig6/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>CTC-based targeting strategies. CTCs can be targeted from various perspectives including: <strong>(A)</strong> targeting EMT/stemness signaling pathways, such as TGF-β, NOTCH, WNT/β-catenin and YAP/TEAD signaling pathways. <strong>(B)</strong> Targeting CTC/DTC dormancy. <strong>(C)</strong> Targeting neutrophil/platelet/NET-CTC interactions. <strong>(D)</strong> CTC cluster dissociation. <strong>(E)</strong> Immune checkpoint inhibitions. <strong>(F)</strong> Targeting vulnerabilities of CTCs. <strong>(G)</strong> Chronotherapy</p></figcaption></figure><p id="Par93">Significant progress has been made toward developing pharmacological interventions to inhibit EMT/stemness signaling pathways such as the inhibition of TGF-β, NOTCH, WNT/β-catenin, and YAP/TEAD signaling pathways (Table <a href="#Tab4" class="usa-link">4</a>). However, these efforts are still in the clinical trial phase. It’s worth mentioning that bispecific antibodies such as SHR-1701, which target PD-L1/TGF-βRII protein, have shown promising clinical trial results in unresectable stage III NSCLC and recurrent or metastatic cervical cancer patients [<a href="#CR243" class="usa-link" aria-describedby="CR243">243</a>, <a href="#CR244" class="usa-link" aria-describedby="CR244">244</a>]. Ongoing clinical trials are exploring the bispecific antibodies to treat multiple advanced tumors [<a href="#CR245" class="usa-link" aria-describedby="CR245">245</a>]. Recently, a netrin-1-blocking monoclonal antibody, NP137, demonstrated significant efficacy in clinical trials for human cancer (ClinicalTrials.gov: <a href="https://clinicaltrials.gov/ct2/show/NCT02977195" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT02977195</a>) by effectively inhibiting EMT in skin squamous cell carcinoma (SCC) and reducing metastasis [<a href="#CR246" class="usa-link" aria-describedby="CR246">246</a>]. This inspiring result indicates the feasibility of targeting EMT to prevent metastasis. However, it is important to recognize that CTCs have different states including epithelial, mesenchymal and epithelial-mesenchymal hybrid states. Therefore, when considering targeting EMT, it’s necessary to understand the roles and the mechanisms by which EMT regulates the biological phenotypes of CTCs.</p>
<section class="tw xbox font-sm" id="Tab4"><h3 class="obj_head">Table 4.</h3>
<div class="caption p"><p>The potential CTC-based targeting strategies for the Inhibition of metastasis</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Targeting strategy</th>
<th align="left" colspan="1" rowspan="1">Agent</th>
<th align="left" colspan="1" rowspan="1">Tumor type</th>
<th align="left" colspan="1" rowspan="1">Effect</th>
<th align="left" colspan="1" rowspan="1">Clinical Trial No.</th>
<th align="left" colspan="1" rowspan="1">Study phase</th>
</tr></thead>
<tbody>
<tr>
<td align="left" rowspan="22" colspan="1">
<strong>Targeting EMT/stemness</strong>
</td>
<td align="left" colspan="1" rowspan="1"><a href="https://www.ncbi.nlm.nih.gov/protein/QLS31901" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">QLS31901</a></td>
<td align="left" colspan="1" rowspan="1">Advanced malignant tumors</td>
<td align="left" colspan="1" rowspan="1">Anti-PD-L1/TGF-β antibody</td>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT04954456" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04954456</a></td>
<td align="left" colspan="1" rowspan="1">I</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">LY3200882</td>
<td align="left" colspan="1" rowspan="1">Solid tumors</td>
<td align="left" colspan="1" rowspan="1">TGF-βRI inhibitor</td>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT02937272" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT02937272</a></td>
<td align="left" colspan="1" rowspan="1">I</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PF-06952229</td>
<td align="left" colspan="1" rowspan="1">Advanced solid tumors</td>
<td align="left" colspan="1" rowspan="1">TGF-β1 inhibitor</td>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT03685591" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03685591</a></td>
<td align="left" colspan="1" rowspan="1">I</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">LY2157299</td>
<td align="left" colspan="1" rowspan="1">Advanced NPC</td>
<td align="left" colspan="1" rowspan="1">TGF-βRI inhibitor</td>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT04605562" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04605562</a></td>
<td align="left" colspan="1" rowspan="1">II</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">AVID200</td>
<td align="left" colspan="1" rowspan="1">Malignant solid tumors</td>
<td align="left" colspan="1" rowspan="1">TGF-β inhibitor</td>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT03834662" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03834662</a></td>
<td align="left" colspan="1" rowspan="1">I</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">TEW-7197</td>
<td align="left" colspan="1" rowspan="1">
<p>Metastatic gastric cancer;</p>
<p>Advanced NSCLC;</p>
<p>Metastatic PDAC</p>
</td>
<td align="left" colspan="1" rowspan="1">ALK4/ALK5 inhibitor</td>
<td align="left" colspan="1" rowspan="1">
<p><a href="https://clinicaltrials.gov/ct2/show/NCT03698825" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03698825</a></p>
<p><a href="https://clinicaltrials.gov/ct2/show/NCT03732274" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03732274</a></p>
<p><a href="https://clinicaltrials.gov/ct2/show/NCT03666832" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03666832</a></p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>I/II</p>
<p>I/II</p>
<p>I</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GFH018</td>
<td align="left" colspan="1" rowspan="1">Advanced solid tumors</td>
<td align="left" colspan="1" rowspan="1">TGF-β inhibitor</td>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT04914286" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04914286</a></td>
<td align="left" colspan="1" rowspan="1">I/II</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">M7824</td>
<td align="left" colspan="1" rowspan="1">Multiple tumors</td>
<td align="left" colspan="1" rowspan="1">Anti-PD-L1/TGF-βRII fusion protein</td>
<td align="left" colspan="1" rowspan="1">Multiple clinical trials [<a href="#CR245" class="usa-link" aria-describedby="CR245">245</a>]</td>
<td align="left" colspan="1" rowspan="1">I or II</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">JS201</td>
<td align="left" colspan="1" rowspan="1">Advanced malignant tumors</td>
<td align="left" colspan="1" rowspan="1">Anti-PD-L1/TGF-βRII fusion protein</td>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT04956926" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04956926</a></td>
<td align="left" colspan="1" rowspan="1">I</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">TST005</td>
<td align="left" colspan="1" rowspan="1">Locally advanced or metastatic solid tumors</td>
<td align="left" colspan="1" rowspan="1">Anti-PD-L1/TGF-β fusion protein</td>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT04958434" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04958434</a></td>
<td align="left" colspan="1" rowspan="1">I</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">ABBV151</td>
<td align="left" colspan="1" rowspan="1">Advanced solid tumors</td>
<td align="left" colspan="1" rowspan="1">Antibody inhibitor of GARP-TGF-β1</td>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT03821935" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03821935</a></td>
<td align="left" colspan="1" rowspan="1">I</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">NIS793</td>
<td align="left" colspan="1" rowspan="1">Metastatic PDAC</td>
<td align="left" colspan="1" rowspan="1">Anti-TGF-β antibody</td>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT04935359" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04935359</a></td>
<td align="left" colspan="1" rowspan="1">III</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">SHR-1701</td>
<td align="left" colspan="1" rowspan="1">
<p>Unresectable stage III NSCLC;</p>
<p>Recurrent or metastatic cervical cancer</p>
</td>
<td align="left" colspan="1" rowspan="1">Anti-PD-L1/TGF-βRII fusion protein</td>
<td align="left" colspan="1" rowspan="1">
<p>NA</p>
<p><a href="https://clinicaltrials.gov/ct2/show/NCT03774979" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03774979</a> [<a href="#CR243" class="usa-link" aria-describedby="CR243">243</a>, <a href="#CR244" class="usa-link" aria-describedby="CR244">244</a>]</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>II</p>
<p>I</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">NP137</td>
<td align="left" colspan="1" rowspan="1">Advanced endometrial cancer</td>
<td align="left" colspan="1" rowspan="1">Anti-netrin-1 antibody</td>
<td align="left" colspan="1" rowspan="1">
<a href="https://clinicaltrials.gov/ct2/show/NCT02977195" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT02977195</a> [<a href="#CR263" class="usa-link" aria-describedby="CR263">263</a>]</td>
<td align="left" colspan="1" rowspan="1">I</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Ciclopirox</td>
<td align="left" colspan="1" rowspan="1">Advanced solid tumors</td>
<td align="left" colspan="1" rowspan="1">HGM2 inhibitor</td>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT03348514" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03348514</a></td>
<td align="left" colspan="1" rowspan="1">I</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Metformin</td>
<td align="left" colspan="1" rowspan="1">Multiple tumors</td>
<td align="left" colspan="1" rowspan="1">SNAIL and TWIST inhibitor</td>
<td align="left" colspan="1" rowspan="1">Multiple clinical trials</td>
<td align="left" colspan="1" rowspan="1">I-III</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Tegavivint</td>
<td align="left" colspan="1" rowspan="1">Desmoid tumor</td>
<td align="left" colspan="1" rowspan="1">β-catenin inhibitor</td>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT03459469" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03459469</a></td>
<td align="left" colspan="1" rowspan="1">I</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">ST316</td>
<td align="left" colspan="1" rowspan="1">Advanced unresectable and metastatic solid tumors</td>
<td align="left" colspan="1" rowspan="1">β-catenin inhibitor</td>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT05848739" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05848739</a></td>
<td align="left" colspan="1" rowspan="1">I/II</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">FOG-001</td>
<td align="left" colspan="1" rowspan="1">Locally advanced or metastatic solid tumors</td>
<td align="left" colspan="1" rowspan="1">β-catenin/TCF inhibitor</td>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT05919264" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05919264</a></td>
<td align="left" colspan="1" rowspan="1">I/II</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CB-103</td>
<td align="left" colspan="1" rowspan="1">Advanced ACC</td>
<td align="left" colspan="1" rowspan="1">NOTCH inhibitor</td>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT05774899" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05774899</a></td>
<td align="left" colspan="1" rowspan="1">I/II</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">OMP-59R5</td>
<td align="left" colspan="1" rowspan="1">Stage IV SCLC</td>
<td align="left" colspan="1" rowspan="1">NOTCH2/3 inhibitor</td>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT01859741" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT01859741</a></td>
<td align="left" colspan="1" rowspan="1">I/II</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">MK-6070</td>
<td align="left" colspan="1" rowspan="1">Advanced SCLC and neuroendocrine carcinoma</td>
<td align="left" colspan="1" rowspan="1">T cell conjugates targeting DLL3</td>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT04471727" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04471727</a></td>
<td align="left" colspan="1" rowspan="1">I/II</td>
</tr>
<tr>
<td align="left" rowspan="6" colspan="1">
<strong>Cluster dissociation</strong>
</td>
<td align="left" colspan="1" rowspan="1">SGN-B6A</td>
<td align="left" colspan="1" rowspan="1">Advanced solid tumors</td>
<td align="left" colspan="1" rowspan="1">Integrin β6</td>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT06549816" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT06549816</a></td>
<td align="left" colspan="1" rowspan="1">I</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">ProAgio</td>
<td align="left" colspan="1" rowspan="1">
<p>Advanced pancreatic cancer and</p>
<p>solid tumor malignancies;</p>
<p>Advanced pancreatic cancer;</p>
<p>Metastatic TNBC</p>
</td>
<td align="left" colspan="1" rowspan="1">Integrin αVβ3</td>
<td align="left" colspan="1" rowspan="1">
<p><a href="https://clinicaltrials.gov/ct2/show/NCT05085548" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05085548</a></p>
<p><a href="https://clinicaltrials.gov/ct2/show/NCT06182072" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT06182072</a></p>
<p><a href="https://clinicaltrials.gov/ct2/show/NCT06460298" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT06460298</a></p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>I</p>
<p>I</p>
<p>II</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">ISM6331</td>
<td align="left" colspan="1" rowspan="1">Advanced/​metastatic malignant mesothelioma or other solid tumors</td>
<td align="left" colspan="1" rowspan="1">TEAD inhibitor</td>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT06566079" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT06566079</a></td>
<td align="left" colspan="1" rowspan="1">I</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">SW-682</td>
<td align="left" colspan="1" rowspan="1">Advanced solid tumors</td>
<td align="left" colspan="1" rowspan="1">TEAD inhibitor</td>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT06251310" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT06251310</a></td>
<td align="left" colspan="1" rowspan="1">I</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Digoxin</td>
<td align="left" colspan="1" rowspan="1">Breast cancer</td>
<td align="left" colspan="1" rowspan="1">Na<sup>+</sup>/K<sup>+</sup> ATPase inhibitor</td>
<td align="left" colspan="1" rowspan="1">
<a href="https://clinicaltrials.gov/ct2/show/NCT03928210" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03928210</a> [<a href="#CR251" class="usa-link" aria-describedby="CR251">251</a>]</td>
<td align="left" colspan="1" rowspan="1">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Aspirin</td>
<td align="left" colspan="1" rowspan="1">Metastatic breast cancer and colorectal cancer</td>
<td align="left" colspan="1" rowspan="1">Cox inhibitor</td>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT02602938" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT02602938</a></td>
<td align="left" colspan="1" rowspan="1">NA</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">
<strong>Targeting dormancy</strong>
</td>
<td align="left" colspan="1" rowspan="1">LY3007113</td>
<td align="left" colspan="1" rowspan="1">Advanced cancer</td>
<td align="left" colspan="1" rowspan="1">p38 MAPK inhibitor</td>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT01463631" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT01463631</a></td>
<td align="left" colspan="1" rowspan="1">I</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">LY2228820</td>
<td align="left" colspan="1" rowspan="1">Advanced or metastatic breast cancer</td>
<td align="left" colspan="1" rowspan="1">p38 MAPK inhibitor</td>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT02322853" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT02322853</a></td>
<td align="left" colspan="1" rowspan="1">II</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<strong>Immune checkpoint inhibition</strong>
</td>
<td align="left" colspan="1" rowspan="1">SHR-1210 and apatinib</td>
<td align="left" colspan="1" rowspan="1">Advanced NSCLC, soft tissue sarcoma, uterine cancer</td>
<td align="left" colspan="1" rowspan="1">PD-1 monoclonal antibody</td>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT04239443" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04239443</a></td>
<td align="left" colspan="1" rowspan="1">NA</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p139"><p>Note: ACC: advanced adenoid cystic carcinoma, NPC: nasopharyngeal carcinoma, NSCLC: non-small cell lung cancer, PDAC: pancreatic ductal adenocarcinoma, SCLC: small cell lung cancer, TNBC: triple-negative breast cancer</p></div></div></section><p id="Par94">When considering targeting dormant CTCs/DTCs, three strategies can be summarized as a priori concept: (i) Awakening strategy followed by anti-proliferative therapy; (ii) Sleeping strategy to maintain CTCs/DTCs in a dormant state; and (iii) Killing strategy to directly eradicate CTCs/DTCs [<a href="#CR247" class="usa-link" aria-describedby="CR247">247</a>]. The awakening strategy involves inhibiting the p38, TGF-β, STING, and WNT signaling pathways. It’s important to note that the awakening of CTCs/DTCs should be followed by the administration of highly effective anti-proliferative agents to eradicate them, to prevent reactivated cells from becoming more aggressive and worsening the patient’s prognosis. This concern is underscored by the observation that inhibition of the TGFβ-p38 signaling pathway can reactivate dormant head and neck squamous cell carcinoma, lading to their multiorgan metastasis [<a href="#CR64" class="usa-link" aria-describedby="CR64">64</a>]. The sleeping strategy focuses on keeping CTCs/DTCs in a dormant state by inhibiting proliferative signaling (e.g., ERK signaling inhibition), sustaining dormant signaling (e.g., CDK4/6 inhibitor palbociclib), or providing components for dormant niches (e.g., GAS6, BMP4, BMP7, TGF-β2) [<a href="#CR247" class="usa-link" aria-describedby="CR247">247</a>, <a href="#CR248" class="usa-link" aria-describedby="CR248">248</a>]. However, this strategy faces challenges due to the risk that dormant cells may eventually proliferate without continuous supplementation of dormancy-agents. The killing strategy aims for a permanent solution; however, existing drugs show limited effectiveness in eradicating dormant tumor cells. Potential methods, such as ferroptosis activation (e.g., GPX4 inhibitors), epigenetic treatments (e.g., HDAC inhibitors), and the synergistic inhibition of dormancy and survival signaling pathways (e.g., the combination of Src and ERK inhibitors), have shown promising efficacy to kill dormant cells [<a href="#CR161" class="usa-link" aria-describedby="CR161">161</a>, <a href="#CR247" class="usa-link" aria-describedby="CR247">247</a>, <a href="#CR249" class="usa-link" aria-describedby="CR249">249</a>, <a href="#CR250" class="usa-link" aria-describedby="CR250">250</a>].</p>
<p id="Par95">Destruction of CTC clusters could significantly decrease their survival and metastatic potential. Various molecules such as CD44, Plakoglobin, Fibronectin, and ICAM1 have been implicated in the formation of CTC clusters, making them promising targets for intervention [<a href="#CR104" class="usa-link" aria-describedby="CR104">104</a>, <a href="#CR113" class="usa-link" aria-describedby="CR113">113</a>, <a href="#CR237" class="usa-link" aria-describedby="CR237">237</a>, <a href="#CR240" class="usa-link" aria-describedby="CR240">240</a>]. Recently, a single-arm phase I study investigated whether the Na<sup>+</sup>/K<sup>+</sup> ATPase inhibitor digoxin could disrupt CTC clusters in patients with advanced or metastatic breast cancer (ClinicalTrials.gov: <a href="https://clinicaltrials.gov/ct2/show/NCT03928210" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03928210</a>) [<a href="#CR251" class="usa-link" aria-describedby="CR251">251</a>]. The results showed that nine patients treated daily with a maintenance digoxin dose (0.7–1.4 ng ml<sup>− 1</sup> serum level) experienced a reduction in the mean cluster size by -2.2 cells per cluster (<em>P</em> = 0.003). Additionally, transcriptome profiling of CTCs revealed downregulation of cell-cell adhesion and cell-cycle-related genes following treatment with digoxin. These promising findings lay the groundwork for larger follow-up studies involving refined Na<sup>+</sup>/K<sup>+</sup> ATPase inhibitors. Additionally, disrupting immune cell and platelet-mediated protection on CTCs may expose more vulnerabilities of CTCs to immune surveillance. For instance, VCAM1 functionally mediates the formation of CTC-neutrophil clusters that enhance the survival of CTCs; thus, inhibiting VCAM1 can prevent these interactions between CTCs and neutrophils [<a href="#CR252" class="usa-link" aria-describedby="CR252">252</a>]. A study examining the effects of aspirin on the number and subtype of CTCs in metastatic breast and colorectal cancer showed positive efficacy in reducing CTC counts (ClinicalTrials.gov: <a href="https://clinicaltrials.gov/ct2/show/NCT02602938" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT02602938</a>) [<a href="#CR253" class="usa-link" aria-describedby="CR253">253</a>]. Further research in this area is advancing efforts to dismantle CTC clusters [<a href="#CR254" class="usa-link" aria-describedby="CR254">254</a>, <a href="#CR255" class="usa-link" aria-describedby="CR255">255</a>]. Additionally, NETs are also a therapeutic target in the treatment of CTC-NET interactions to mitigate metastasis [<a href="#CR256" class="usa-link" aria-describedby="CR256">256</a>]. Furthermore, the formation of these clusters and the processes of intravasation and extravasation are influenced by adhesion molecules such as integrin-β1, P-selectin, and ICAM1 [<a href="#CR257" class="usa-link" aria-describedby="CR257">257</a>–<a href="#CR259" class="usa-link" aria-describedby="CR259">259</a>]. Targeting these adhesion molecules may effectively disrupt these processes [<a href="#CR260" class="usa-link" aria-describedby="CR260">260</a>]. Furthermore, focusing on invadopodia and other molecules regulating intravasation and extravasation could also help decrease metastasis [<a href="#CR203" class="usa-link" aria-describedby="CR203">203</a>, <a href="#CR261" class="usa-link" aria-describedby="CR261">261</a>].</p>
<p id="Par96">Targeting immune evasion-related molecules is an applicable direction to clear CTCs. Immune checkpoint inhibitors against PD-1/PD-L1, CTLA4, CD47, CD155/TIGIT, and NKG2 can significantly enhance cancer cell killing by immune cells [<a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>, <a href="#CR262" class="usa-link" aria-describedby="CR262">262</a>]. These inhibitors have shown great therapeutic efficacy against both primary and metastatic tumors, with one mechanism potentially involving immune cell-mediated CTC clearance. However, the extent to which immune checkpoint inhibitors contribute to CTC clearance remains unclear. Further research is needed to fully understand their impact on the elimination of CTCs and optimize therapeutic targets to improve clinical outcomes.</p>
<p id="Par97">Other strategies for targeting CTCs include interfering with their metabolism vulnerabilities, developing CTC vaccine, and implementing CTC-based chronotherapy, etc [<a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>, <a href="#CR4" class="usa-link" aria-describedby="CR4">4</a>]. Despite these approaches direct exciting explorations for targeting CTCs, most clinical trials to date have primarily focused on the detection, isolation, and expansion of CTCs for research and prognosis monitoring. Hence, the clinical application of targeting CTCs still faces significant challenges and has a long way to go before being fully realized.</p></section><section id="Sec31"><h2 class="pmc_sec_title">Conclusions</h2>
<p id="Par99">It’s indisputable that CTCs play a pivotal role in initiating cancer metastasis. Therefore, enhancing our comprehension of targeting strategies for CTCs is essential to impede cancer progression and its metastatic spread. As previously stated, CTCs can adapt to diverse states for survival during metastasis. In that case, CTCs exhibit distinctive biological characteristics and phenotypes compared to stromal cells. Therefore, it is crucial to further investigate the alternative states of CTCs within the tumor microenvironment and develop or refine approaches for their comprehensive characterization. Clarifying these two aspects will provide a solid foundation for a deeper understanding of CTCs.</p>
<p id="Par100">Despite the ongoing comprehensive investigation into CTCs, the current landscape remains highly challenging. First, the metastasis of CTCs is an intricate and inefficient process, compounded by a hostile circulatory environment, which leads to their scarcity and hampers research progress. Second, though CTC-related technologies have significantly advanced over the past decade, they still fall short of meeting the scientific community’s aspirations for thorough exploration. Techniques for enriching, capturing, separating, and detecting CTCs often rely on size, density, deformability, and electrical properties, but these conventional methods are insufficient despite their cost-effectiveness. Enrichment approaches based on antigen-antibody interactions, particularly those using EpCAM, are widely used; however, their reliability may be compromised by the considerable heterogeneity of CTC surface antigens. As a result, the CTC research field lacks a universally accepted technological benchmark, and while advanced techniques using nanomaterials and microfluidic chips have emerged, achieving specific detection of CTCs remains a significant challenge. Third, investigations into the genomic, transcriptomic, epigenomic, and proteomic characteristics of CTCs face bottlenecks due to these aforementioned limitations. Despite the significant advancements in single-cell transcriptome sequencing technology in recent years, the analysis of the proteome of CTCs remains stagnant. Proteomics can reveal additional biological characteristics and specific membrane proteins, making multi-omics characterization a promising avenue for future research. Finally, the continuous analysis of CTC genomes and phenotypes relies heavily on effective in vitro CTC expansion, which currently suffers from low efficiency and success rates, limiting further drug susceptibility tests and exploration of drug resistance mechanisms. Nevertheless, ongoing research provides encouraging prospects for overcoming these challenges, and it is imperative to remain optimistic about CTC research’s potential to identify precise therapeutic targets for reversing or eradicating metastasis-related mortality.</p></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>We use Adobe Illustrator to create figures.</p></section><section id="glossary1" class="glossary"><h2 class="pmc_sec_title">Abbreviations</h2>
<dl class="def-list">
<dt>ALDH1</dt>
<dd><p id="Par104">Acetaldehyde dehydrogenase 1</p></dd>
<dt>AR</dt>
<dd><p id="Par105">Androgen receptor</p></dd>
<dt>CTCs</dt>
<dd><p id="Par106">Circulating tumor cells</p></dd>
<dt>COX-2</dt>
<dd><p id="Par107">Cyclooxygenase 2</p></dd>
<dt>CKs</dt>
<dd><p id="Par108">Cytokeratins</p></dd>
<dt>CSCs</dt>
<dd><p id="Par109">Cancer stem cells</p></dd>
<dt>CNNs</dt>
<dd><p id="Par110">Convolutional neural networks</p></dd>
<dt>CR</dt>
<dd><p id="Par111">Conditional reprogramming</p></dd>
<dt>CAFs</dt>
<dd><p id="Par112">Cancer-associated fibroblasts</p></dd>
<dt>CRPC</dt>
<dd><p id="Par113">Castration-resistant prostate cancer</p></dd>
<dt>CDXs</dt>
<dd><p id="Par114">CTC-derived xenograft models</p></dd>
<dt>DTCs</dt>
<dd><p id="Par115">Disseminated tumor cells</p></dd>
<dt>DCs</dt>
<dd><p id="Par116">Dendritic cells</p></dd>
<dt>DFS</dt>
<dd><p id="Par117">Disease-free survival</p></dd>
<dt>DST</dt>
<dd><p id="Par118">Drug susceptibility testing</p></dd>
<dt>EMT</dt>
<dd><p id="Par119">Epithelial-mesenchymal transition</p></dd>
<dt>EMP</dt>
<dd><p id="Par120">Epithelial–mesenchymal plasticity</p></dd>
<dt>EBS</dt>
<dd><p id="Par121">Evolving barcode system</p></dd>
<dt>ECM</dt>
<dd><p id="Par122">Extracellular matrix</p></dd>
<dt>EP</dt>
<dd><p id="Par123">Etoposide and platinum</p></dd>
<dt>FCM</dt>
<dd><p id="Par124">Flow cytometry</p></dd>
<dt>FISH</dt>
<dd><p id="Par125">Fluorescent in situ hybridization</p></dd>
<dt>FACS</dt>
<dd><p id="Par126">Fluorescence-activated cell sorting</p></dd>
<dt>HSCs</dt>
<dd><p id="Par127">Hematopoietic stem cells</p></dd>
<dt>HCC</dt>
<dd><p id="Par128">Hepatocellular carcinoma</p></dd>
<dt>IIA / IIV</dt>
<dd><p id="Par129">Intra-iliac artery / vein</p></dd>
<dt>iFCS</dt>
<dd><p id="Par130">Integrated ferrohydrodynamic cell separation</p></dd>
<dt>IF</dt>
<dd><p id="Par131">Immunofluorescence</p></dd>
<dt>ITH</dt>
<dd><p id="Par132">Intra-tumoral heterogeneity</p></dd>
<dt>MET</dt>
<dd><p id="Par133">Mesenchymal-epithelial transition</p></dd>
<dt>MMP1 / 9</dt>
<dd><p id="Par134">Matrix metalloproteinase 1 / 9</p></dd>
<dt>MSCs</dt>
<dd><p id="Par135">Mesenchymal stem cells</p></dd>
<dt>MFP</dt>
<dd><p id="Par136">Mammary fat pad</p></dd>
<dt>MDSCs</dt>
<dd><p id="Par137">Myeloid-derived suppressor cells</p></dd>
<dt>mBC</dt>
<dd><p id="Par138">Metastatic breast cancer</p></dd>
<dt>mCRC</dt>
<dd><p id="Par139">Metastatic colorectal cancer</p></dd>
<dt>mCRPC</dt>
<dd><p id="Par140">Metastatic castration-resistant prostate cancer</p></dd>
<dt>NETs</dt>
<dd><p id="Par141">Neutrophil extracellular traps</p></dd>
<dt>NSCLC</dt>
<dd><p id="Par142">Non-small cell lung cancer</p></dd>
<dt>NRG1</dt>
<dd><p id="Par143">Neuregulin 1</p></dd>
<dt>OS</dt>
<dd><p id="Par144">Overall survival</p></dd>
<dt>PMN-MDSCs</dt>
<dd><p id="Par145">Polymorphonuclear myeloid-derived suppressor cells</p></dd>
<dt>PVN</dt>
<dd><p id="Par146">Perivascular niches</p></dd>
<dt>PGE2</dt>
<dd><p id="Par147">Prostaglandin E2</p></dd>
<dt>PDXs</dt>
<dd><p id="Par148">Patient-derived xenografts</p></dd>
<dt>PFS</dt>
<dd><p id="Par149">Progression-free survival</p></dd>
<dt>qRT-PCR</dt>
<dd><p id="Par150">Quantitative real-time polymerase chain reaction</p></dd>
<dt>ROCK</dt>
<dd><p id="Par151">RHO-related protein kinase</p></dd>
<dt>RCC</dt>
<dd><p id="Par152">Renal cell carcinoma</p></dd>
<dt>Tregs</dt>
<dd><p id="Par153">Regulatory T cells</p></dd>
<dt>SCLC</dt>
<dd><p id="Par154">Small-cell lung cancer</p></dd>
<dt>SCC</dt>
<dd><p id="Par155">Skin squamous cell carcinoma</p></dd>
<dt>TDO2<sup>+</sup> MFs</dt>
<dd><p id="Par156">Tryptophan 2,3-dioxygenase-positive matrix fibroblasts</p></dd>
<dt>TAMs</dt>
<dd><p id="Par157">Tumor-associated macrophages</p></dd>
<dt>TF</dt>
<dd><p id="Par158">Iron carrier transferrin</p></dd>
<dt>3D</dt>
<dd><p id="Par159">Three-dimension</p></dd>
<dt>WBCs</dt>
<dd><p id="Par160">White blood cells</p></dd>
<dt>Zos</dt>
<dd><p id="Par161">Zonula occludens</p></dd>
</dl></section><section id="notes1"><h2 class="pmc_sec_title">Author contributions</h2>
<p>C. Y. and C. L. wrote the main manuscript text. C. Y., CL. X. and LW. F. revised the manuscript. LW. F. and CL. X. supervised the work. The authors read and approved the final manuscript.</p></section><section id="notes2"><h2 class="pmc_sec_title">Funding</h2>
<p>This work was funded by grants from the National Key R&amp;D Program of China (No: 2022YFE0209700), the National Natural Science Foundation of China (No: U21A20421), Guangdong Basic and Applied Basic Research Foundation (No: 2023B1515130009), the Postdoctoral Fellowship Program of CPSF (No: GZB20240903), the China Postdoctoral Science Foundation (No: 2024M763784).</p></section><section id="notes3"><h2 class="pmc_sec_title">Data availability</h2>
<p>No datasets were generated or analysed during the current study.</p></section><section id="notes4"><h2 class="pmc_sec_title">Abbreviations</h2>
<section id="FPar1"><h3 class="pmc_sec_title">Ethics approval and consent to participate</h3>
<p id="Par101">Not applicable.</p></section><section id="FPar2"><h3 class="pmc_sec_title">Consent for publication</h3>
<p id="Par102">Not applicable.</p></section><section id="FPar3"><h3 class="pmc_sec_title">Competing interests</h3>
<p id="Par103">The authors declare no competing interests.</p></section></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="fn1">
<p><strong>Publisher’s note</strong></p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</div>
<div class="fn p" id="fn2"><p>Chuan Yang and Can Liu contributed equally to this work.</p></div>
</div></section><section id="_ci93_" lang="en" class="contrib-info"><h2 class="pmc_sec_title">Contributor Information</h2>
<p>Chenglai Xia, Email: xiachenglai@smu.edu.cn.</p>
<p>Liwu Fu, Email: fulw@mail.sysu.edu.cn.</p></section><section id="Bib1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="Bib1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="CR1">
<span class="label">1.</span><cite>Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147:275–92. 10.1016/j.cell.2011.09.024.
</cite> [<a href="https://doi.org/10.1016/j.cell.2011.09.024" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3261217/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22000009/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Valastyan%20S,%20Weinberg%20RA.%20Tumor%20metastasis:%20molecular%20insights%20and%20evolving%20paradigms.%20Cell.%202011;147:275%E2%80%9392.%2010.1016/j.cell.2011.09.024." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR2">
<span class="label">2.</span><cite>Lin D, et al. Circulating tumor cells: biology and clinical significance. Signal Transduct Target Ther. 2021;6:404. 10.1038/s41392-021-00817-8.
</cite> [<a href="https://doi.org/10.1038/s41392-021-00817-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8606574/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34803167/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lin%20D,%20et%20al.%20Circulating%20tumor%20cells:%20biology%20and%20clinical%20significance.%20Signal%20Transduct%20Target%20Ther.%202021;6:404.%2010.1038/s41392-021-00817-8." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR3">
<span class="label">3.</span><cite>Ring A, Nguyen-Sträuli BD, Wicki A, Aceto N. Biology, vulnerabilities and clinical applications of Circulating tumour cells. Nat Rev Cancer. 2023;23:95–111. 10.1038/s41568-022-00536-4.
</cite> [<a href="https://doi.org/10.1038/s41568-022-00536-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9734934/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36494603/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ring%20A,%20Nguyen-Str%C3%A4uli%20BD,%20Wicki%20A,%20Aceto%20N.%20Biology,%20vulnerabilities%20and%20clinical%20applications%20of%20Circulating%20tumour%20cells.%20Nat%20Rev%20Cancer.%202023;23:95%E2%80%93111.%2010.1038/s41568-022-00536-4." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR4">
<span class="label">4.</span><cite>Gerstberger S, Jiang Q, Ganesh K. Metastasis Cell. 2023;186:1564–79. 10.1016/j.cell.2023.03.003.
</cite> [<a href="https://doi.org/10.1016/j.cell.2023.03.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10511214/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37059065/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gerstberger%20S,%20Jiang%20Q,%20Ganesh%20K.%20Metastasis%20Cell.%202023;186:1564%E2%80%9379.%2010.1016/j.cell.2023.03.003." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR5">
<span class="label">5.</span><cite>Driemel C, et al. Context-dependent adaption of EpCAM expression in early systemic esophageal cancer. Oncogene. 2014;33:4904–15. 10.1038/onc.2013.441.
</cite> [<a href="https://doi.org/10.1038/onc.2013.441" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24141784/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Driemel%20C,%20et%20al.%20Context-dependent%20adaption%20of%20EpCAM%20expression%20in%20early%20systemic%20esophageal%20cancer.%20Oncogene.%202014;33:4904%E2%80%9315.%2010.1038/onc.2013.441." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR6">
<span class="label">6.</span><cite>Zhang L, et al. The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci Transl Med. 2013;5:180ra148. 10.1126/scitranslmed.3005109.</cite> [<a href="https://doi.org/10.1126/scitranslmed.3005109" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3863909/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23576814/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20L,%20et%20al.%20The%20identification%20and%20characterization%20of%20breast%20cancer%20CTCs%20competent%20for%20brain%20metastasis.%20Sci%20Transl%20Med.%202013;5:180ra148.%2010.1126/scitranslmed.3005109." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR7">
<span class="label">7.</span><cite>Rao CG, et al. Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. Int J Oncol. 2005;27:49–57.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/15942643/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rao%20CG,%20et%20al.%20Expression%20of%20epithelial%20cell%20adhesion%20molecule%20in%20carcinoma%20cells%20present%20in%20blood%20and%20primary%20and%20metastatic%20tumors.%20Int%20J%20Oncol.%202005;27:49%E2%80%9357." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR8">
<span class="label">8.</span><cite>Gorges TM, et al. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC Cancer. 2012;12:178. 10.1186/1471-2407-12-178.
</cite> [<a href="https://doi.org/10.1186/1471-2407-12-178" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3502112/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22591372/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gorges%20TM,%20et%20al.%20Circulating%20tumour%20cells%20escape%20from%20EpCAM-based%20detection%20due%20to%20epithelial-to-mesenchymal%20transition.%20BMC%20Cancer.%202012;12:178.%2010.1186/1471-2407-12-178." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR9">
<span class="label">9.</span><cite>Kallergi G, et al. Epithelial to mesenchymal transition markers expressed in Circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Res. 2011;13:R59. 10.1186/bcr2896.
</cite> [<a href="https://doi.org/10.1186/bcr2896" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3218948/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21663619/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kallergi%20G,%20et%20al.%20Epithelial%20to%20mesenchymal%20transition%20markers%20expressed%20in%20Circulating%20tumour%20cells%20of%20early%20and%20metastatic%20breast%20cancer%20patients.%20Breast%20Cancer%20Res.%202011;13:R59.%2010.1186/bcr2896." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR10">
<span class="label">10.</span><cite>Huaman J, Naidoo M, Zang X, Ogunwobi OO. Fibronectin regulation of integrin B1 and SLUG in Circulating tumor cells. Cells. 2019;8. 10.3390/cells8060618.</cite> [<a href="https://doi.org/10.3390/cells8060618" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6627780/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31226820/" class="usa-link">PubMed</a>]</li>
<li id="CR11">
<span class="label">11.</span><cite>Zhang Z, et al. Dynamic monitoring of EMT in CTCs as an indicator of cancer metastasis. Anal Chem. 2021;93:16787–95. 10.1021/acs.analchem.1c03167.
</cite> [<a href="https://doi.org/10.1021/acs.analchem.1c03167" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34889595/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20Z,%20et%20al.%20Dynamic%20monitoring%20of%20EMT%20in%20CTCs%20as%20an%20indicator%20of%20cancer%20metastasis.%20Anal%20Chem.%202021;93:16787%E2%80%9395.%2010.1021/acs.analchem.1c03167." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR12">
<span class="label">12.</span><cite>Cierna Z, et al. Matrix metalloproteinase 1 and Circulating tumor cells in early breast cancer. BMC Cancer. 2014;14:472. 10.1186/1471-2407-14-472.
</cite> [<a href="https://doi.org/10.1186/1471-2407-14-472" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4079912/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24972610/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cierna%20Z,%20et%20al.%20Matrix%20metalloproteinase%201%20and%20Circulating%20tumor%20cells%20in%20early%20breast%20cancer.%20BMC%20Cancer.%202014;14:472.%2010.1186/1471-2407-14-472." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR13">
<span class="label">13.</span><cite>Mego M, et al. Circulating tumor cells with Epithelial-to-mesenchymal transition phenotypes associated with inferior outcomes in primary breast cancer. Anticancer Res. 2019;39:1829–37. 10.21873/anticanres.13290.
</cite> [<a href="https://doi.org/10.21873/anticanres.13290" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30952723/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mego%20M,%20et%20al.%20Circulating%20tumor%20cells%20with%20Epithelial-to-mesenchymal%20transition%20phenotypes%20associated%20with%20inferior%20outcomes%20in%20primary%20breast%20cancer.%20Anticancer%20Res.%202019;39:1829%E2%80%9337.%2010.21873/anticanres.13290." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR14">
<span class="label">14.</span><cite>Yu M, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013;339:580–4. 10.1126/science.1228522.
</cite> [<a href="https://doi.org/10.1126/science.1228522" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3760262/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23372014/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yu%20M,%20et%20al.%20Circulating%20breast%20tumor%20cells%20exhibit%20dynamic%20changes%20in%20epithelial%20and%20mesenchymal%20composition.%20Science.%202013;339:580%E2%80%934.%2010.1126/science.1228522." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR15">
<span class="label">15.</span><cite>Yang J, et al. Guidelines and definitions for research on epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2020;21:341–52. 10.1038/s41580-020-0237-9.
</cite> [<a href="https://doi.org/10.1038/s41580-020-0237-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7250738/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32300252/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yang%20J,%20et%20al.%20Guidelines%20and%20definitions%20for%20research%20on%20epithelial-mesenchymal%20transition.%20Nat%20Rev%20Mol%20Cell%20Biol.%202020;21:341%E2%80%9352.%2010.1038/s41580-020-0237-9." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR16">
<span class="label">16.</span><cite>Padmanaban V, et al. E-cadherin is required for metastasis in multiple models of breast cancer. Nature. 2019;573:439–44. 10.1038/s41586-019-1526-3.
</cite> [<a href="https://doi.org/10.1038/s41586-019-1526-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7365572/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31485072/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Padmanaban%20V,%20et%20al.%20E-cadherin%20is%20required%20for%20metastasis%20in%20multiple%20models%20of%20breast%20cancer.%20Nature.%202019;573:439%E2%80%9344.%2010.1038/s41586-019-1526-3." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR17">
<span class="label">17.</span><cite>Fischer KR, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. 2015;527:472–6. 10.1038/nature15748.
</cite> [<a href="https://doi.org/10.1038/nature15748" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4662610/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26560033/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Fischer%20KR,%20et%20al.%20Epithelial-to-mesenchymal%20transition%20is%20not%20required%20for%20lung%20metastasis%20but%20contributes%20to%20chemoresistance.%20Nature.%202015;527:472%E2%80%936.%2010.1038/nature15748." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR18">
<span class="label">18.</span><cite>Liu X, et al. Epithelial-type systemic breast carcinoma cells with a restricted mesenchymal transition are a major source of metastasis. Sci Adv. 2019;5:eaav4275. 10.1126/sciadv.aav4275.
</cite> [<a href="https://doi.org/10.1126/sciadv.aav4275" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6584608/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31223646/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liu%20X,%20et%20al.%20Epithelial-type%20systemic%20breast%20carcinoma%20cells%20with%20a%20restricted%20mesenchymal%20transition%20are%20a%20major%20source%20of%20metastasis.%20Sci%20Adv.%202019;5:eaav4275.%2010.1126/sciadv.aav4275." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR19">
<span class="label">19.</span><cite>Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20:576–90. 10.1016/j.ccr.2011.09.009.
</cite> [<a href="https://doi.org/10.1016/j.ccr.2011.09.009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3487108/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22094253/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Labelle%20M,%20Begum%20S,%20Hynes%20RO.%20Direct%20signaling%20between%20platelets%20and%20cancer%20cells%20induces%20an%20epithelial-mesenchymal-like%20transition%20and%20promotes%20metastasis.%20Cancer%20Cell.%202011;20:576%E2%80%9390.%2010.1016/j.ccr.2011.09.009." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR20">
<span class="label">20.</span><cite>Sprouse ML, et al. PMN-MDSCs enhance CTC metastatic properties through reciprocal interactions via ros/notch/nodal signaling. Int J Mol Sci. 2019;20. 10.3390/ijms20081916.</cite> [<a href="https://doi.org/10.3390/ijms20081916" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6514876/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31003475/" class="usa-link">PubMed</a>]</li>
<li id="CR21">
<span class="label">21.</span><cite>Sun YF, et al. Circulating tumor cells from different vascular sites exhibit Spatial heterogeneity in epithelial and mesenchymal composition and distinct clinical significance in hepatocellular carcinoma. Clin Cancer Res. 2018;24:547–59. 10.1158/1078-0432.Ccr-17-1063.
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-17-1063" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29070526/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sun%20YF,%20et%20al.%20Circulating%20tumor%20cells%20from%20different%20vascular%20sites%20exhibit%20Spatial%20heterogeneity%20in%20epithelial%20and%20mesenchymal%20composition%20and%20distinct%20clinical%20significance%20in%20hepatocellular%20carcinoma.%20Clin%20Cancer%20Res.%202018;24:547%E2%80%9359.%2010.1158/1078-0432.Ccr-17-1063." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR22">
<span class="label">22.</span><cite>Wang SH, Lin SY. Tumor dormancy: potential therapeutic target in tumor recurrence and metastasis prevention. Exp Hematol Oncol. 2013;2:29. 10.1186/2162-3619-2-29.
</cite> [<a href="https://doi.org/10.1186/2162-3619-2-29" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4176492/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24502434/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20SH,%20Lin%20SY.%20Tumor%20dormancy:%20potential%20therapeutic%20target%20in%20tumor%20recurrence%20and%20metastasis%20prevention.%20Exp%20Hematol%20Oncol.%202013;2:29.%2010.1186/2162-3619-2-29." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR23">
<span class="label">23.</span><cite>Giancotti FG. Mechanisms governing metastatic dormancy and reactivation. Cell. 2013;155:750–64. 10.1016/j.cell.2013.10.029.
</cite> [<a href="https://doi.org/10.1016/j.cell.2013.10.029" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4354734/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24209616/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Giancotti%20FG.%20Mechanisms%20governing%20metastatic%20dormancy%20and%20reactivation.%20Cell.%202013;155:750%E2%80%9364.%2010.1016/j.cell.2013.10.029." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR24">
<span class="label">24.</span><cite>Solomayer EF, et al. Influence of Zoledronic acid on disseminated tumor cells in primary breast cancer patients. Ann Oncol. 2012;23:2271–7. 10.1093/annonc/mdr612.
</cite> [<a href="https://doi.org/10.1093/annonc/mdr612" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22383680/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Solomayer%20EF,%20et%20al.%20Influence%20of%20Zoledronic%20acid%20on%20disseminated%20tumor%20cells%20in%20primary%20breast%20cancer%20patients.%20Ann%20Oncol.%202012;23:2271%E2%80%937.%2010.1093/annonc/mdr612." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR25">
<span class="label">25.</span><cite>Braun S, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med. 2000;342:525–33. 10.1056/nejm200002243420801.
</cite> [<a href="https://doi.org/10.1056/NEJM200002243420801" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10684910/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Braun%20S,%20et%20al.%20Cytokeratin-positive%20cells%20in%20the%20bone%20marrow%20and%20survival%20of%20patients%20with%20stage%20I,%20II,%20or%20III%20breast%20cancer.%20N%20Engl%20J%20Med.%202000;342:525%E2%80%9333.%2010.1056/nejm200002243420801." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR26">
<span class="label">26.</span><cite>Janni W, et al. Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse–a European pooled analysis. Clin Cancer Res. 2011;17:2967–76. 10.1158/1078-0432.Ccr-10-2515.
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-10-2515" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21415211/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Janni%20W,%20et%20al.%20Persistence%20of%20disseminated%20tumor%20cells%20in%20the%20bone%20marrow%20of%20breast%20cancer%20patients%20predicts%20increased%20risk%20for%20relapse%E2%80%93a%20European%20pooled%20analysis.%20Clin%20Cancer%20Res.%202011;17:2967%E2%80%9376.%2010.1158/1078-0432.Ccr-10-2515." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR27">
<span class="label">27.</span><cite>Wiedswang G, et al. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol. 2003;21:3469–78. 10.1200/jco.2003.02.009.
</cite> [<a href="https://doi.org/10.1200/JCO.2003.02.009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12972522/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wiedswang%20G,%20et%20al.%20Detection%20of%20isolated%20tumor%20cells%20in%20bone%20marrow%20is%20an%20independent%20prognostic%20factor%20in%20breast%20cancer.%20J%20Clin%20Oncol.%202003;21:3469%E2%80%9378.%2010.1200/jco.2003.02.009." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR28">
<span class="label">28.</span><cite>Hüsemann Y, et al. Systemic spread is an early step in breast cancer. Cancer Cell. 2008;13:58–68. 10.1016/j.ccr.2007.12.003.
</cite> [<a href="https://doi.org/10.1016/j.ccr.2007.12.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18167340/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?H%C3%BCsemann%20Y,%20et%20al.%20Systemic%20spread%20is%20an%20early%20step%20in%20breast%20cancer.%20Cancer%20Cell.%202008;13:58%E2%80%9368.%2010.1016/j.ccr.2007.12.003." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR29">
<span class="label">29.</span><cite>Demeulemeester J, et al. Tracing the origin of disseminated tumor cells in breast cancer using single-cell sequencing. Genome Biol. 2016;17:250. 10.1186/s13059-016-1109-7.
</cite> [<a href="https://doi.org/10.1186/s13059-016-1109-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5146893/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27931250/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Demeulemeester%20J,%20et%20al.%20Tracing%20the%20origin%20of%20disseminated%20tumor%20cells%20in%20breast%20cancer%20using%20single-cell%20sequencing.%20Genome%20Biol.%202016;17:250.%2010.1186/s13059-016-1109-7." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR30">
<span class="label">30.</span><cite>Merugu S, et al. Detection of Circulating and disseminated neuroblastoma cells using the imagestream flow cytometer for use as predictive and pharmacodynamic biomarkers. Clin Cancer Res. 2020;26:122–34. 10.1158/1078-0432.Ccr-19-0656.
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-19-0656" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31767563/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Merugu%20S,%20et%20al.%20Detection%20of%20Circulating%20and%20disseminated%20neuroblastoma%20cells%20using%20the%20imagestream%20flow%20cytometer%20for%20use%20as%20predictive%20and%20pharmacodynamic%20biomarkers.%20Clin%20Cancer%20Res.%202020;26:122%E2%80%9334.%2010.1158/1078-0432.Ccr-19-0656." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR31">
<span class="label">31.</span><cite>Carlsson A, et al. Paired High-Content analysis of prostate cancer cells in bone marrow and blood characterizes increased androgen receptor expression in tumor cell clusters. Clin Cancer Res. 2017;23:1722–32. 10.1158/1078-0432.Ccr-16-1355.
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-16-1355" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5661959/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27702818/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Carlsson%20A,%20et%20al.%20Paired%20High-Content%20analysis%20of%20prostate%20cancer%20cells%20in%20bone%20marrow%20and%20blood%20characterizes%20increased%20androgen%20receptor%20expression%20in%20tumor%20cell%20clusters.%20Clin%20Cancer%20Res.%202017;23:1722%E2%80%9332.%2010.1158/1078-0432.Ccr-16-1355." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR32">
<span class="label">32.</span><cite>Magbanua MJM, et al. Synchronous detection of Circulating tumor cells in blood and disseminated tumor cells in bone marrow predicts adverse outcome in early breast cancer. Clin Cancer Res. 2019;25:5388–97. 10.1158/1078-0432.Ccr-18-3888.
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-18-3888" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6726564/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31142502/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Magbanua%20MJM,%20et%20al.%20Synchronous%20detection%20of%20Circulating%20tumor%20cells%20in%20blood%20and%20disseminated%20tumor%20cells%20in%20bone%20marrow%20predicts%20adverse%20outcome%20in%20early%20breast%20cancer.%20Clin%20Cancer%20Res.%202019;25:5388%E2%80%9397.%2010.1158/1078-0432.Ccr-18-3888." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR33">
<span class="label">33.</span><cite>Gröbe A, et al. Prognostic relevance of Circulating tumor cells in blood and disseminated tumor cells in bone marrow of patients with squamous cell carcinoma of the oral cavity. Clin Cancer Res. 2014;20:425–33. 10.1158/1078-0432.Ccr-13-1101.
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-13-1101" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24218516/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gr%C3%B6be%20A,%20et%20al.%20Prognostic%20relevance%20of%20Circulating%20tumor%20cells%20in%20blood%20and%20disseminated%20tumor%20cells%20in%20bone%20marrow%20of%20patients%20with%20squamous%20cell%20carcinoma%20of%20the%20oral%20cavity.%20Clin%20Cancer%20Res.%202014;20:425%E2%80%9333.%2010.1158/1078-0432.Ccr-13-1101." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR34">
<span class="label">34.</span><cite>Leong SP, Tseng WW. Micrometastatic cancer cells in lymph nodes, bone marrow, and blood: clinical significance and biologic implications. CA Cancer J Clin. 2014;64:195–206. 10.3322/caac.21217.
</cite> [<a href="https://doi.org/10.3322/caac.21217" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24500995/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Leong%20SP,%20Tseng%20WW.%20Micrometastatic%20cancer%20cells%20in%20lymph%20nodes,%20bone%20marrow,%20and%20blood:%20clinical%20significance%20and%20biologic%20implications.%20CA%20Cancer%20J%20Clin.%202014;64:195%E2%80%93206.%2010.3322/caac.21217." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR35">
<span class="label">35.</span><cite>Price TT, et al. Dormant breast cancer micrometastases reside in specific bone marrow niches that regulate their transit to and from bone. Sci Transl Med. 2016;8:340ra373. 10.1126/scitranslmed.aad4059.</cite> [<a href="https://doi.org/10.1126/scitranslmed.aad4059" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8722465/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27225183/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Price%20TT,%20et%20al.%20Dormant%20breast%20cancer%20micrometastases%20reside%20in%20specific%20bone%20marrow%20niches%20that%20regulate%20their%20transit%20to%20and%20from%20bone.%20Sci%20Transl%20Med.%202016;8:340ra373.%2010.1126/scitranslmed.aad4059." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR36">
<span class="label">36.</span><cite>Shiozawa Y, et al. Human prostate cancer metastases target the hematopoietic stem cell niche to Establish footholds in mouse bone marrow. J Clin Invest. 2011;121:1298–312. 10.1172/jci43414.
</cite> [<a href="https://doi.org/10.1172/JCI43414" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3069764/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21436587/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shiozawa%20Y,%20et%20al.%20Human%20prostate%20cancer%20metastases%20target%20the%20hematopoietic%20stem%20cell%20niche%20to%20Establish%20footholds%20in%20mouse%20bone%20marrow.%20J%20Clin%20Invest.%202011;121:1298%E2%80%93312.%2010.1172/jci43414." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR37">
<span class="label">37.</span><cite>Shiozawa Y, et al. GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia. 2010;12:116–27. 10.1593/neo.91384.
</cite> [<a href="https://doi.org/10.1593/neo.91384" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2814350/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20126470/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shiozawa%20Y,%20et%20al.%20GAS6/AXL%20axis%20regulates%20prostate%20cancer%20invasion,%20proliferation,%20and%20survival%20in%20the%20bone%20marrow%20niche.%20Neoplasia.%202010;12:116%E2%80%9327.%2010.1593/neo.91384." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR38">
<span class="label">38.</span><cite>Yu-Lee LY, et al. Osteoblast-Secreted factors mediate dormancy of metastatic prostate cancer in the bone via activation of the TGFβRIII-p38MAPK-pS249/T252RB pathway. Cancer Res. 2018;78:2911–24. 10.1158/0008-5472.Can-17-1051.
</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-17-1051" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5984689/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29514796/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yu-Lee%20LY,%20et%20al.%20Osteoblast-Secreted%20factors%20mediate%20dormancy%20of%20metastatic%20prostate%20cancer%20in%20the%20bone%20via%20activation%20of%20the%20TGF%CE%B2RIII-p38MAPK-pS249/T252RB%20pathway.%20Cancer%20Res.%202018;78:2911%E2%80%9324.%2010.1158/0008-5472.Can-17-1051." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR39">
<span class="label">39.</span><cite>Yumoto K, et al. Axl is required for TGF-β2-induced dormancy of prostate cancer cells in the bone marrow. Sci Rep. 2016;6:36520. 10.1038/srep36520.
</cite> [<a href="https://doi.org/10.1038/srep36520" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5098246/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27819283/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yumoto%20K,%20et%20al.%20Axl%20is%20required%20for%20TGF-%CE%B22-induced%20dormancy%20of%20prostate%20cancer%20cells%20in%20the%20bone%20marrow.%20Sci%20Rep.%202016;6:36520.%2010.1038/srep36520." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR40">
<span class="label">40.</span><cite>Nobre AR, et al. Bone marrow NG2(+)/Nestin(+) mesenchymal stem cells drive DTC dormancy via TGFβ2. Nat Cancer. 2021;2:327–39. 10.1038/s43018-021-00179-8.
</cite> [<a href="https://doi.org/10.1038/s43018-021-00179-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8730384/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34993493/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Nobre%20AR,%20et%20al.%20Bone%20marrow%20NG2(+)/Nestin(+)%20mesenchymal%20stem%20cells%20drive%20DTC%20dormancy%20via%20TGF%CE%B22.%20Nat%20Cancer.%202021;2:327%E2%80%9339.%2010.1038/s43018-021-00179-8." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR41">
<span class="label">41.</span><cite>Sharma S, et al. Secreted protein acidic and rich in cysteine (SPARC) mediates metastatic dormancy of prostate cancer in bone. J Biol Chem. 2016;291:19351–63. 10.1074/jbc.M116.737379.
</cite> [<a href="https://doi.org/10.1074/jbc.M116.737379" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5016675/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27422817/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sharma%20S,%20et%20al.%20Secreted%20protein%20acidic%20and%20rich%20in%20cysteine%20(SPARC)%20mediates%20metastatic%20dormancy%20of%20prostate%20cancer%20in%20bone.%20J%20Biol%20Chem.%202016;291:19351%E2%80%9363.%2010.1074/jbc.M116.737379." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR42">
<span class="label">42.</span><cite>Ghajar CM, et al. The perivascular niche regulates breast tumour dormancy. Nat Cell Biol. 2013;15:807–17. 10.1038/ncb2767.
</cite> [<a href="https://doi.org/10.1038/ncb2767" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3826912/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23728425/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ghajar%20CM,%20et%20al.%20The%20perivascular%20niche%20regulates%20breast%20tumour%20dormancy.%20Nat%20Cell%20Biol.%202013;15:807%E2%80%9317.%2010.1038/ncb2767." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR43">
<span class="label">43.</span><cite>Liu Y, et al. Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-γ-induced Immunologic dormancy of tumor-repopulating cells. Nat Commun. 2017;8:15207. 10.1038/ncomms15207.
</cite> [<a href="https://doi.org/10.1038/ncomms15207" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5436221/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28488695/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liu%20Y,%20et%20al.%20Blockade%20of%20IDO-kynurenine-AhR%20metabolic%20circuitry%20abrogates%20IFN-%CE%B3-induced%20Immunologic%20dormancy%20of%20tumor-repopulating%20cells.%20Nat%20Commun.%202017;8:15207.%2010.1038/ncomms15207." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR44">
<span class="label">44.</span><cite>Brabletz T. To differentiate or not–routes towards metastasis. Nat Rev Cancer. 2012;12:425–36. 10.1038/nrc3265.
</cite> [<a href="https://doi.org/10.1038/nrc3265" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22576165/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Brabletz%20T.%20To%20differentiate%20or%20not%E2%80%93routes%20towards%20metastasis.%20Nat%20Rev%20Cancer.%202012;12:425%E2%80%9336.%2010.1038/nrc3265." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR45">
<span class="label">45.</span><cite>Brown D, et al. Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations. Nat Commun. 2017;8:14944. 10.1038/ncomms14944.
</cite> [<a href="https://doi.org/10.1038/ncomms14944" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5474888/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28429735/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Brown%20D,%20et%20al.%20Phylogenetic%20analysis%20of%20metastatic%20progression%20in%20breast%20cancer%20using%20somatic%20mutations%20and%20copy%20number%20aberrations.%20Nat%20Commun.%202017;8:14944.%2010.1038/ncomms14944." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR46">
<span class="label">46.</span><cite>Wang R, et al. The clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. BMC Cancer. 2019;19:1091. 10.1186/s12885-019-6311-z.
</cite> [<a href="https://doi.org/10.1186/s12885-019-6311-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6852913/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31718602/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20R,%20et%20al.%20The%20clinicopathological%20features%20and%20survival%20outcomes%20of%20patients%20with%20different%20metastatic%20sites%20in%20stage%20IV%20breast%20cancer.%20BMC%20Cancer.%202019;19:1091.%2010.1186/s12885-019-6311-z." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR47">
<span class="label">47.</span><cite>Zhang W, et al. The bone microenvironment invigorates metastatic seeds for further dissemination. Cell. 2021;184:2471–e24862420. 10.1016/j.cell.2021.03.011.
</cite> [<a href="https://doi.org/10.1016/j.cell.2021.03.011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8087656/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33878291/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20W,%20et%20al.%20The%20bone%20microenvironment%20invigorates%20metastatic%20seeds%20for%20further%20dissemination.%20Cell.%202021;184:2471%E2%80%93e24862420.%2010.1016/j.cell.2021.03.011." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR48">
<span class="label">48.</span><cite>Bado IL, et al. The bone microenvironment increases phenotypic plasticity of ER(+) breast cancer cells. Dev Cell. 2021;56:1100–e11171109. 10.1016/j.devcel.2021.03.008.
</cite> [<a href="https://doi.org/10.1016/j.devcel.2021.03.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8062036/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33878299/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bado%20IL,%20et%20al.%20The%20bone%20microenvironment%20increases%20phenotypic%20plasticity%20of%20ER(+)%20breast%20cancer%20cells.%20Dev%20Cell.%202021;56:1100%E2%80%93e11171109.%2010.1016/j.devcel.2021.03.008." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR49">
<span class="label">49.</span><cite>Patras L, Shaashua L, Matei I, Lyden D. Immune determinants of the pre-metastatic niche. Cancer Cell. 2023;41:546–72. 10.1016/j.ccell.2023.02.018.
</cite> [<a href="https://doi.org/10.1016/j.ccell.2023.02.018" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10170403/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36917952/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Patras%20L,%20Shaashua%20L,%20Matei%20I,%20Lyden%20D.%20Immune%20determinants%20of%20the%20pre-metastatic%20niche.%20Cancer%20Cell.%202023;41:546%E2%80%9372.%2010.1016/j.ccell.2023.02.018." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR50">
<span class="label">50.</span><cite>Hoshino A, et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015;527:329–35. 10.1038/nature15756.
</cite> [<a href="https://doi.org/10.1038/nature15756" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4788391/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26524530/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hoshino%20A,%20et%20al.%20Tumour%20exosome%20integrins%20determine%20organotropic%20metastasis.%20Nature.%202015;527:329%E2%80%9335.%2010.1038/nature15756." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR51">
<span class="label">51.</span><cite>Liu Y, Cao X. Characteristics and significance of the Pre-metastatic niche. Cancer Cell. 2016;30:668–81. 10.1016/j.ccell.2016.09.011.
</cite> [<a href="https://doi.org/10.1016/j.ccell.2016.09.011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27846389/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liu%20Y,%20Cao%20X.%20Characteristics%20and%20significance%20of%20the%20Pre-metastatic%20niche.%20Cancer%20Cell.%202016;30:668%E2%80%9381.%2010.1016/j.ccell.2016.09.011." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR52">
<span class="label">52.</span><cite>Liu Y, et al. Tryptophan 2,3-dioxygenase-positive matrix fibroblasts fuel breast cancer lung metastasis via kynurenine-mediated ferroptosis resistance of metastatic cells and T cell dysfunction. Cancer Commun (Lond). 2024. 10.1002/cac2.12608.
</cite> [<a href="https://doi.org/10.1002/cac2.12608" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11570772/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39221971/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liu%20Y,%20et%20al.%20Tryptophan%202,3-dioxygenase-positive%20matrix%20fibroblasts%20fuel%20breast%20cancer%20lung%20metastasis%20via%20kynurenine-mediated%20ferroptosis%20resistance%20of%20metastatic%20cells%20and%20T%20cell%20dysfunction.%20Cancer%20Commun%20(Lond).%202024.%2010.1002/cac2.12608." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR53">
<span class="label">53.</span><cite>Gong Z, et al. Lung fibroblasts facilitate pre-metastatic niche formation by remodeling the local immune microenvironment. Immunity. 2022;55:1483–e15001489. 10.1016/j.immuni.2022.07.001.
</cite> [<a href="https://doi.org/10.1016/j.immuni.2022.07.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9830653/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35908547/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gong%20Z,%20et%20al.%20Lung%20fibroblasts%20facilitate%20pre-metastatic%20niche%20formation%20by%20remodeling%20the%20local%20immune%20microenvironment.%20Immunity.%202022;55:1483%E2%80%93e15001489.%2010.1016/j.immuni.2022.07.001." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR54">
<span class="label">54.</span><cite>Alix-Panabières C, Riethdorf S, Pantel K. Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res. 2008;14:5013–21. 10.1158/1078-0432.Ccr-07-5125.
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-07-5125" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18698019/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Alix-Panabi%C3%A8res%20C,%20Riethdorf%20S,%20Pantel%20K.%20Circulating%20tumor%20cells%20and%20bone%20marrow%20micrometastasis.%20Clin%20Cancer%20Res.%202008;14:5013%E2%80%9321.%2010.1158/1078-0432.Ccr-07-5125." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR55">
<span class="label">55.</span><cite>Peinado H, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012;18:883–91. 10.1038/nm.2753.
</cite> [<a href="https://doi.org/10.1038/nm.2753" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3645291/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22635005/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Peinado%20H,%20et%20al.%20Melanoma%20exosomes%20educate%20bone%20marrow%20progenitor%20cells%20toward%20a%20pro-metastatic%20phenotype%20through%20MET.%20Nat%20Med.%202012;18:883%E2%80%9391.%2010.1038/nm.2753." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR56">
<span class="label">56.</span><cite>Carvajal RD, et al. Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol. 2017;101:38–44. 10.1136/bjophthalmol-2016-309034.
</cite> [<a href="https://doi.org/10.1136/bjophthalmol-2016-309034" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5256122/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27574175/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Carvajal%20RD,%20et%20al.%20Metastatic%20disease%20from%20uveal%20melanoma:%20treatment%20options%20and%20future%20prospects.%20Br%20J%20Ophthalmol.%202017;101:38%E2%80%9344.%2010.1136/bjophthalmol-2016-309034." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR57">
<span class="label">57.</span><cite>Lim AR, Ghajar CM. Thorny ground, Rocky soil: Tissue-specific mechanisms of tumor dormancy and relapse. Semin Cancer Biol. 2022;78:104–23. 10.1016/j.semcancer.2021.05.007.
</cite> [<a href="https://doi.org/10.1016/j.semcancer.2021.05.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9595433/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33979673/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lim%20AR,%20Ghajar%20CM.%20Thorny%20ground,%20Rocky%20soil:%20Tissue-specific%20mechanisms%20of%20tumor%20dormancy%20and%20relapse.%20Semin%20Cancer%20Biol.%202022;78:104%E2%80%9323.%2010.1016/j.semcancer.2021.05.007." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR58">
<span class="label">58.</span><cite>Correia AL, et al. Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy. Nature. 2021;594:566–71. 10.1038/s41586-021-03614-z.
</cite> [<a href="https://doi.org/10.1038/s41586-021-03614-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34079127/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Correia%20AL,%20et%20al.%20Hepatic%20stellate%20cells%20suppress%20NK%20cell-sustained%20breast%20cancer%20dormancy.%20Nature.%202021;594:566%E2%80%9371.%2010.1038/s41586-021-03614-z." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR59">
<span class="label">59.</span><cite>Barkan D, et al. Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment. Cancer Res. 2010;70:5706–16. 10.1158/0008-5472.Can-09-2356.
</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-09-2356" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3436125/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20570886/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Barkan%20D,%20et%20al.%20Metastatic%20growth%20from%20dormant%20cells%20induced%20by%20a%20col-I-enriched%20fibrotic%20environment.%20Cancer%20Res.%202010;70:5706%E2%80%9316.%2010.1158/0008-5472.Can-09-2356." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR60">
<span class="label">60.</span><cite>Fane ME, et al. Stromal changes in the aged lung induce an emergence from melanoma dormancy. Nature. 2022;606:396–405. 10.1038/s41586-022-04774-2.
</cite> [<a href="https://doi.org/10.1038/s41586-022-04774-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9554951/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35650435/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Fane%20ME,%20et%20al.%20Stromal%20changes%20in%20the%20aged%20lung%20induce%20an%20emergence%20from%20melanoma%20dormancy.%20Nature.%202022;606:396%E2%80%93405.%2010.1038/s41586-022-04774-2." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR61">
<span class="label">61.</span><cite>Albrengues J, et al. Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science. 2018;361. 10.1126/science.aao4227.</cite> [<a href="https://doi.org/10.1126/science.aao4227" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6777850/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30262472/" class="usa-link">PubMed</a>]</li>
<li id="CR62">
<span class="label">62.</span><cite>Teijeira Á, et al. CXCR1 and CXCR2 chemokine receptor agonists produced by tumors induce neutrophil extracellular traps that interfere with immune cytotoxicity. Immunity. 2020;52:856–e871858. 10.1016/j.immuni.2020.03.001.
</cite> [<a href="https://doi.org/10.1016/j.immuni.2020.03.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32289253/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Teijeira%20%C3%81,%20et%20al.%20CXCR1%20and%20CXCR2%20chemokine%20receptor%20agonists%20produced%20by%20tumors%20induce%20neutrophil%20extracellular%20traps%20that%20interfere%20with%20immune%20cytotoxicity.%20Immunity.%202020;52:856%E2%80%93e871858.%2010.1016/j.immuni.2020.03.001." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR63">
<span class="label">63.</span><cite>Hu J, et al. STING inhibits the reactivation of dormant metastasis in lung adenocarcinoma. Nature. 2023;616:806–13. 10.1038/s41586-023-05880-5.
</cite> [<a href="https://doi.org/10.1038/s41586-023-05880-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10569211/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36991128/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hu%20J,%20et%20al.%20STING%20inhibits%20the%20reactivation%20of%20dormant%20metastasis%20in%20lung%20adenocarcinoma.%20Nature.%202023;616:806%E2%80%9313.%2010.1038/s41586-023-05880-5." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR64">
<span class="label">64.</span><cite>Bragado P, et al. TGF-β2 dictates disseminated tumour cell fate in target organs through TGF-β-RIII and p38α/β signalling. Nat Cell Biol. 2013;15:1351–61. 10.1038/ncb2861.
</cite> [<a href="https://doi.org/10.1038/ncb2861" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4006312/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24161934/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bragado%20P,%20et%20al.%20TGF-%CE%B22%20dictates%20disseminated%20tumour%20cell%20fate%20in%20target%20organs%20through%20TGF-%CE%B2-RIII%20and%20p38%CE%B1/%CE%B2%20signalling.%20Nat%20Cell%20Biol.%202013;15:1351%E2%80%9361.%2010.1038/ncb2861." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR65">
<span class="label">65.</span><cite>Gilkes DM, Semenza GL, Wirtz D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer. 2014;14:430–9. 10.1038/nrc3726.
</cite> [<a href="https://doi.org/10.1038/nrc3726" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4283800/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24827502/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gilkes%20DM,%20Semenza%20GL,%20Wirtz%20D.%20Hypoxia%20and%20the%20extracellular%20matrix:%20drivers%20of%20tumour%20metastasis.%20Nat%20Rev%20Cancer.%202014;14:430%E2%80%939.%2010.1038/nrc3726." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR66">
<span class="label">66.</span><cite>Boedtkjer E, Pedersen SF. The acidic tumor microenvironment as a driver of cancer. Annu Rev Physiol. 2020;82:103–26. 10.1146/annurev-physiol-021119-034627.
</cite> [<a href="https://doi.org/10.1146/annurev-physiol-021119-034627" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31730395/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Boedtkjer%20E,%20Pedersen%20SF.%20The%20acidic%20tumor%20microenvironment%20as%20a%20driver%20of%20cancer.%20Annu%20Rev%20Physiol.%202020;82:103%E2%80%9326.%2010.1146/annurev-physiol-021119-034627." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR67">
<span class="label">67.</span><cite>Gires O, Pan M, Schinke H, Canis M, Baeuerle PA. Expression and function of epithelial cell adhesion molecule epcam: where are we after 40 years? Cancer Metastasis Rev. 2020;39:969–87. 10.1007/s10555-020-09898-3.
</cite> [<a href="https://doi.org/10.1007/s10555-020-09898-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7497325/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32507912/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gires%20O,%20Pan%20M,%20Schinke%20H,%20Canis%20M,%20Baeuerle%20PA.%20Expression%20and%20function%20of%20epithelial%20cell%20adhesion%20molecule%20epcam:%20where%20are%20we%20after%2040%20years?%20Cancer%20Metastasis%20Rev.%202020;39:969%E2%80%9387.%2010.1007/s10555-020-09898-3." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR68">
<span class="label">68.</span><cite>Li Y, Yang J, Luo JH, Dedhar S, Liu Y. Tubular epithelial cell dedifferentiation is driven by the helix-loop-helix transcriptional inhibitor Id1. J Am Soc Nephrol. 2007;18:449–60. 10.1681/asn.2006030236.
</cite> [<a href="https://doi.org/10.1681/ASN.2006030236" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17202424/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20Y,%20Yang%20J,%20Luo%20JH,%20Dedhar%20S,%20Liu%20Y.%20Tubular%20epithelial%20cell%20dedifferentiation%20is%20driven%20by%20the%20helix-loop-helix%20transcriptional%20inhibitor%20Id1.%20J%20Am%20Soc%20Nephrol.%202007;18:449%E2%80%9360.%2010.1681/asn.2006030236." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR69">
<span class="label">69.</span><cite>Lou C, Wu K, Shi J, Dai Z, Xu Q. N-cadherin protects oral cancer cells from NK cell killing in the circulation by inducing NK cell functional exhaustion via the KLRG1 receptor. J Immunother Cancer. 2022;10. 10.1136/jitc-2022-005061.</cite> [<a href="https://doi.org/10.1136/jitc-2022-005061" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9472211/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36096526/" class="usa-link">PubMed</a>]</li>
<li id="CR70">
<span class="label">70.</span><cite>Po JW, et al. Improved ovarian cancer EMT-CTC isolation by immunomagnetic targeting of epithelial EpCAM and mesenchymal N-cadherin. J Circ Biomark. 2018;7:1849454418782617. 10.1177/1849454418782617.
</cite> [<a href="https://doi.org/10.1177/1849454418782617" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6043919/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30013673/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Po%20JW,%20et%20al.%20Improved%20ovarian%20cancer%20EMT-CTC%20isolation%20by%20immunomagnetic%20targeting%20of%20epithelial%20EpCAM%20and%20mesenchymal%20N-cadherin.%20J%20Circ%20Biomark.%202018;7:1849454418782617.%2010.1177/1849454418782617." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR71">
<span class="label">71.</span><cite>Zhou J, et al. Epithelial-mesenchymal transition status of Circulating tumor cells in breast cancer and its clinical relevance. Cancer Biol Med. 2020;17:169–80. 10.20892/j.issn.2095-3941.2019.0118.
</cite> [<a href="https://doi.org/10.20892/j.issn.2095-3941.2019.0118" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7142848/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32296584/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhou%20J,%20et%20al.%20Epithelial-mesenchymal%20transition%20status%20of%20Circulating%20tumor%20cells%20in%20breast%20cancer%20and%20its%20clinical%20relevance.%20Cancer%20Biol%20Med.%202020;17:169%E2%80%9380.%2010.20892/j.issn.2095-3941.2019.0118." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR72">
<span class="label">72.</span><cite>Hu HF, et al. Identification of miR-515-3p and its targets, vimentin and MMP3, as a key regulatory mechanism in esophageal cancer metastasis: functional and clinical significance. Signal Transduct Target Ther. 2020;5:271. 10.1038/s41392-020-00275-8.
</cite> [<a href="https://doi.org/10.1038/s41392-020-00275-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7693265/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33243974/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hu%20HF,%20et%20al.%20Identification%20of%20miR-515-3p%20and%20its%20targets,%20vimentin%20and%20MMP3,%20as%20a%20key%20regulatory%20mechanism%20in%20esophageal%20cancer%20metastasis:%20functional%20and%20clinical%20significance.%20Signal%20Transduct%20Target%20Ther.%202020;5:271.%2010.1038/s41392-020-00275-8." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR73">
<span class="label">73.</span><cite>Gu J, et al. URI expression in cervical cancer cells is associated with higher invasion capacity and resistance to cisplatin. Am J Cancer Res. 2015;5:1353–67.
</cite> [<a href="/articles/PMC4473315/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26101702/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gu%20J,%20et%20al.%20URI%20expression%20in%20cervical%20cancer%20cells%20is%20associated%20with%20higher%20invasion%20capacity%20and%20resistance%20to%20cisplatin.%20Am%20J%20Cancer%20Res.%202015;5:1353%E2%80%9367." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR74">
<span class="label">74.</span><cite>Zhao XH, et al. Molecular detection of epithelial-mesenchymal transition markers in Circulating tumor cells from pancreatic cancer patients: potential role in clinical practice. World J Gastroenterol. 2019;25:138–50. 10.3748/wjg.v25.i1.138.
</cite> [<a href="https://doi.org/10.3748/wjg.v25.i1.138" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6328963/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30643364/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhao%20XH,%20et%20al.%20Molecular%20detection%20of%20epithelial-mesenchymal%20transition%20markers%20in%20Circulating%20tumor%20cells%20from%20pancreatic%20cancer%20patients:%20potential%20role%20in%20clinical%20practice.%20World%20J%20Gastroenterol.%202019;25:138%E2%80%9350.%2010.3748/wjg.v25.i1.138." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR75">
<span class="label">75.</span><cite>De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013;13:97–110. 10.1038/nrc3447.
</cite> [<a href="https://doi.org/10.1038/nrc3447" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23344542/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?De%20Craene%20B,%20Berx%20G.%20Regulatory%20networks%20defining%20EMT%20during%20cancer%20initiation%20and%20progression.%20Nat%20Rev%20Cancer.%202013;13:97%E2%80%93110.%2010.1038/nrc3447." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR76">
<span class="label">76.</span><cite>Hugo HJ, et al. Direct repression of MYB by ZEB1 suppresses proliferation and epithelial gene expression during epithelial-to-mesenchymal transition of breast cancer cells. Breast Cancer Res. 2013;15:R113. 10.1186/bcr3580.
</cite> [<a href="https://doi.org/10.1186/bcr3580" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3979034/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24283570/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hugo%20HJ,%20et%20al.%20Direct%20repression%20of%20MYB%20by%20ZEB1%20suppresses%20proliferation%20and%20epithelial%20gene%20expression%20during%20epithelial-to-mesenchymal%20transition%20of%20breast%20cancer%20cells.%20Breast%20Cancer%20Res.%202013;15:R113.%2010.1186/bcr3580." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR77">
<span class="label">77.</span><cite>Lu M, Jolly MK, Levine H, Onuchic JN, Ben-Jacob E. MicroRNA-based regulation of epithelial-hybrid-mesenchymal fate determination. Proc Natl Acad Sci U S A. 2013;110:18144–9. 10.1073/pnas.1318192110.
</cite> [<a href="https://doi.org/10.1073/pnas.1318192110" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3831488/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24154725/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lu%20M,%20Jolly%20MK,%20Levine%20H,%20Onuchic%20JN,%20Ben-Jacob%20E.%20MicroRNA-based%20regulation%20of%20epithelial-hybrid-mesenchymal%20fate%20determination.%20Proc%20Natl%20Acad%20Sci%20U%20S%20A.%202013;110:18144%E2%80%939.%2010.1073/pnas.1318192110." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR78">
<span class="label">78.</span><cite>Maharati A, Moghbeli M. PI3K/AKT signaling pathway as a critical regulator of epithelial-mesenchymal transition in colorectal tumor cells. Cell Commun Signal. 2023;21:201. 10.1186/s12964-023-01225-x.
</cite> [<a href="https://doi.org/10.1186/s12964-023-01225-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10424373/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37580737/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Maharati%20A,%20Moghbeli%20M.%20PI3K/AKT%20signaling%20pathway%20as%20a%20critical%20regulator%20of%20epithelial-mesenchymal%20transition%20in%20colorectal%20tumor%20cells.%20Cell%20Commun%20Signal.%202023;21:201.%2010.1186/s12964-023-01225-x." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR79">
<span class="label">79.</span><cite>Yokobori T, et al. Plastin3 is a novel marker for Circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res. 2013;73:2059–69. 10.1158/0008-5472.Can-12-0326.
</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-12-0326" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23378342/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yokobori%20T,%20et%20al.%20Plastin3%20is%20a%20novel%20marker%20for%20Circulating%20tumor%20cells%20undergoing%20the%20epithelial-mesenchymal%20transition%20and%20is%20associated%20with%20colorectal%20cancer%20prognosis.%20Cancer%20Res.%202013;73:2059%E2%80%9369.%2010.1158/0008-5472.Can-12-0326." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR80">
<span class="label">80.</span><cite>Mai Y, Su J, Yang C, Xia C, Fu L. The strategies to cure cancer patients by eradicating cancer stem-like cells. Mol Cancer. 2023;22:171. 10.1186/s12943-023-01867-y.
</cite> [<a href="https://doi.org/10.1186/s12943-023-01867-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10583358/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37853413/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mai%20Y,%20Su%20J,%20Yang%20C,%20Xia%20C,%20Fu%20L.%20The%20strategies%20to%20cure%20cancer%20patients%20by%20eradicating%20cancer%20stem-like%20cells.%20Mol%20Cancer.%202023;22:171.%2010.1186/s12943-023-01867-y." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR81">
<span class="label">81.</span><cite>Fasanya HO, Dopico PJ, Yeager Z, Fan ZH, Siemann DW. Using a combination of gangliosides and cell surface vimentin as surface biomarkers for isolating osteosarcoma cells in microfluidic devices. J Bone Oncol. 2021;28:100357. 10.1016/j.jbo.2021.100357.
</cite> [<a href="https://doi.org/10.1016/j.jbo.2021.100357" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8065304/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33912384/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Fasanya%20HO,%20Dopico%20PJ,%20Yeager%20Z,%20Fan%20ZH,%20Siemann%20DW.%20Using%20a%20combination%20of%20gangliosides%20and%20cell%20surface%20vimentin%20as%20surface%20biomarkers%20for%20isolating%20osteosarcoma%20cells%20in%20microfluidic%20devices.%20J%20Bone%20Oncol.%202021;28:100357.%2010.1016/j.jbo.2021.100357." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR82">
<span class="label">82.</span><cite>Theodoropoulos PA, et al. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett. 2010;288:99–106. 10.1016/j.canlet.2009.06.027.
</cite> [<a href="https://doi.org/10.1016/j.canlet.2009.06.027" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19619935/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Theodoropoulos%20PA,%20et%20al.%20Circulating%20tumor%20cells%20with%20a%20putative%20stem%20cell%20phenotype%20in%20peripheral%20blood%20of%20patients%20with%20breast%20cancer.%20Cancer%20Lett.%202010;288:99%E2%80%93106.%2010.1016/j.canlet.2009.06.027." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR83">
<span class="label">83.</span><cite>Galanzha EI, et al. In vivo liquid biopsy using cytophone platform for photoacoustic detection of Circulating tumor cells in patients with melanoma. Sci Transl Med. 2019;11. 10.1126/scitranslmed.aat5857.</cite> [<a href="https://doi.org/10.1126/scitranslmed.aat5857" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9235419/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31189720/" class="usa-link">PubMed</a>]</li>
<li id="CR84">
<span class="label">84.</span><cite>Na TY, Schecterson L, Mendonsa AM, Gumbiner BM. The functional activity of E-cadherin controls tumor cell metastasis at multiple steps. Proc Natl Acad Sci U S A. 2020;117:5931–7. 10.1073/pnas.1918167117.
</cite> [<a href="https://doi.org/10.1073/pnas.1918167117" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7084067/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32127478/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Na%20TY,%20Schecterson%20L,%20Mendonsa%20AM,%20Gumbiner%20BM.%20The%20functional%20activity%20of%20E-cadherin%20controls%20tumor%20cell%20metastasis%20at%20multiple%20steps.%20Proc%20Natl%20Acad%20Sci%20U%20S%20A.%202020;117:5931%E2%80%937.%2010.1073/pnas.1918167117." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR85">
<span class="label">85.</span><cite>Venhuizen JH, Jacobs FJC, Span PN, Zegers MM. P120 and E-cadherin: Double-edged swords in tumor metastasis. Semin Cancer Biol. 2020;60:107–20. 10.1016/j.semcancer.2019.07.020.
</cite> [<a href="https://doi.org/10.1016/j.semcancer.2019.07.020" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31369816/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Venhuizen%20JH,%20Jacobs%20FJC,%20Span%20PN,%20Zegers%20MM.%20P120%20and%20E-cadherin:%20Double-edged%20swords%20in%20tumor%20metastasis.%20Semin%20Cancer%20Biol.%202020;60:107%E2%80%9320.%2010.1016/j.semcancer.2019.07.020." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR86">
<span class="label">86.</span><cite>Mihalcioiu C, et al. Improved platform for breast cancer Circulating tumor cell enrichment and characterization with next-generation sequencing technology. Am J Cancer Res. 2023;13:25–44.
</cite> [<a href="/articles/PMC9906071/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36777514/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mihalcioiu%20C,%20et%20al.%20Improved%20platform%20for%20breast%20cancer%20Circulating%20tumor%20cell%20enrichment%20and%20characterization%20with%20next-generation%20sequencing%20technology.%20Am%20J%20Cancer%20Res.%202023;13:25%E2%80%9344." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR87">
<span class="label">87.</span><cite>Vaiopoulos AG, et al. Detection of Circulating tumor cells in colorectal and gastric cancer using a multiplex PCR assay. Anticancer Res. 2014;34:3083–92.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/24922677/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Vaiopoulos%20AG,%20et%20al.%20Detection%20of%20Circulating%20tumor%20cells%20in%20colorectal%20and%20gastric%20cancer%20using%20a%20multiplex%20PCR%20assay.%20Anticancer%20Res.%202014;34:3083%E2%80%9392." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR88">
<span class="label">88.</span><cite>Lustberg MB, et al. Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients. Breast Cancer Res. 2014;16:R23. 10.1186/bcr3622.
</cite> [<a href="https://doi.org/10.1186/bcr3622" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4053256/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24602188/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lustberg%20MB,%20et%20al.%20Heterogeneous%20atypical%20cell%20populations%20are%20present%20in%20blood%20of%20metastatic%20breast%20cancer%20patients.%20Breast%20Cancer%20Res.%202014;16:R23.%2010.1186/bcr3622." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR89">
<span class="label">89.</span><cite>Zhang X, et al. Decreased expression of ZO-1 is associated with tumor metastases in liver cancer. Oncol Lett. 2019;17:1859–64. 10.3892/ol.2018.9765.
</cite> [<a href="https://doi.org/10.3892/ol.2018.9765" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6341828/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30675248/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20X,%20et%20al.%20Decreased%20expression%20of%20ZO-1%20is%20associated%20with%20tumor%20metastases%20in%20liver%20cancer.%20Oncol%20Lett.%202019;17:1859%E2%80%9364.%2010.3892/ol.2018.9765." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR90">
<span class="label">90.</span><cite>Lekva T, et al. Epithelial splicing regulator protein 1 and alternative splicing in somatotroph adenomas. Endocrinology. 2013;154:3331–43. 10.1210/en.2013-1051.
</cite> [<a href="https://doi.org/10.1210/en.2013-1051" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23825128/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lekva%20T,%20et%20al.%20Epithelial%20splicing%20regulator%20protein%201%20and%20alternative%20splicing%20in%20somatotroph%20adenomas.%20Endocrinology.%202013;154:3331%E2%80%9343.%2010.1210/en.2013-1051." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR91">
<span class="label">91.</span><cite>Walser TC, et al. Silencing the Snail-Dependent RNA splice regulator ESRP1 drives malignant transformation of human pulmonary epithelial cells. Cancer Res. 2018;78:1986–99. 10.1158/0008-5472.Can-17-0315.
</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-17-0315" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5899686/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29431637/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Walser%20TC,%20et%20al.%20Silencing%20the%20Snail-Dependent%20RNA%20splice%20regulator%20ESRP1%20drives%20malignant%20transformation%20of%20human%20pulmonary%20epithelial%20cells.%20Cancer%20Res.%202018;78:1986%E2%80%9399.%2010.1158/0008-5472.Can-17-0315." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR92">
<span class="label">92.</span><cite>Wei T, et al. Vimentin-positive Circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer. Cancer Lett. 2019;452:237–43. 10.1016/j.canlet.2019.03.009.
</cite> [<a href="https://doi.org/10.1016/j.canlet.2019.03.009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30905814/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wei%20T,%20et%20al.%20Vimentin-positive%20Circulating%20tumor%20cells%20as%20a%20biomarker%20for%20diagnosis%20and%20treatment%20monitoring%20in%20patients%20with%20pancreatic%20cancer.%20Cancer%20Lett.%202019;452:237%E2%80%9343.%2010.1016/j.canlet.2019.03.009." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR93">
<span class="label">93.</span><cite>Cao ZQ, Wang Z, Leng P. Aberrant N-cadherin expression in cancer. Biomed Pharmacother. 2019;118:109320. 10.1016/j.biopha.2019.109320.
</cite> [<a href="https://doi.org/10.1016/j.biopha.2019.109320" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31545265/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cao%20ZQ,%20Wang%20Z,%20Leng%20P.%20Aberrant%20N-cadherin%20expression%20in%20cancer.%20Biomed%20Pharmacother.%202019;118:109320.%2010.1016/j.biopha.2019.109320." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR94">
<span class="label">94.</span><cite>Jhi JH, et al. Circulating tumor cells and TWIST expression in patients with metastatic gastric cancer: A preliminary study. J Clin Med. 2021;10. 10.3390/jcm10194481.</cite> [<a href="https://doi.org/10.3390/jcm10194481" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8509658/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34640500/" class="usa-link">PubMed</a>]</li>
<li id="CR95">
<span class="label">95.</span><cite>Lee HJ, et al. Clinical significance of TWIST-Positive Circulating tumor cells in patients with esophageal squamous cell carcinoma. Gut Liver. 2021;15:553–61. 10.5009/gnl20194.
</cite> [<a href="https://doi.org/10.5009/gnl20194" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8283289/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33293482/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lee%20HJ,%20et%20al.%20Clinical%20significance%20of%20TWIST-Positive%20Circulating%20tumor%20cells%20in%20patients%20with%20esophageal%20squamous%20cell%20carcinoma.%20Gut%20Liver.%202021;15:553%E2%80%9361.%2010.5009/gnl20194." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR96">
<span class="label">96.</span><cite>Alonso-Alconada L, et al. Molecular profiling of Circulating tumor cells links plasticity to the metastatic process in endometrial cancer. Mol Cancer. 2014;13:223. 10.1186/1476-4598-13-223.
</cite> [<a href="https://doi.org/10.1186/1476-4598-13-223" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4190574/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25261936/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Alonso-Alconada%20L,%20et%20al.%20Molecular%20profiling%20of%20Circulating%20tumor%20cells%20links%20plasticity%20to%20the%20metastatic%20process%20in%20endometrial%20cancer.%20Mol%20Cancer.%202014;13:223.%2010.1186/1476-4598-13-223." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR97">
<span class="label">97.</span><cite>Le Du F, et al. EpCAM-independent isolation of Circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream<sup>®</sup> in patients with breast cancer treated with primary systemic therapy. PLoS ONE. 2020;15:e0229903. 10.1371/journal.pone.0229903.
</cite> [<a href="https://doi.org/10.1371/journal.pone.0229903" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7098555/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32214335/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Le%20Du%20F,%20et%20al.%20EpCAM-independent%20isolation%20of%20Circulating%20tumor%20cells%20with%20epithelial-to-mesenchymal%20transition%20and%20cancer%20stem%20cell%20phenotypes%20using%20ApoStream%C2%AE%20in%20patients%20with%20breast%20cancer%20treated%20with%20primary%20systemic%20therapy.%20PLoS%20ONE.%202020;15:e0229903.%2010.1371/journal.pone.0229903." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR98">
<span class="label">98.</span><cite>Warzecha CC, Carstens RP. Complex changes in alternative pre-mRNA splicing play a central role in the epithelial-to-mesenchymal transition (EMT). Semin Cancer Biol. 2012;22:417–27. 10.1016/j.semcancer.2012.04.003.
</cite> [<a href="https://doi.org/10.1016/j.semcancer.2012.04.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3413750/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22548723/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Warzecha%20CC,%20Carstens%20RP.%20Complex%20changes%20in%20alternative%20pre-mRNA%20splicing%20play%20a%20central%20role%20in%20the%20epithelial-to-mesenchymal%20transition%20(EMT).%20Semin%20Cancer%20Biol.%202012;22:417%E2%80%9327.%2010.1016/j.semcancer.2012.04.003." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR99">
<span class="label">99.</span><cite>Kuroda K, et al. Circulating tumor cells with FGFR2 expression might be useful to identify patients with existing FGFR2-overexpressing tumor. Cancer Sci. 2020;111:4500–9. 10.1111/cas.14654.
</cite> [<a href="https://doi.org/10.1111/cas.14654" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7734156/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32946655/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kuroda%20K,%20et%20al.%20Circulating%20tumor%20cells%20with%20FGFR2%20expression%20might%20be%20useful%20to%20identify%20patients%20with%20existing%20FGFR2-overexpressing%20tumor.%20Cancer%20Sci.%202020;111:4500%E2%80%939.%2010.1111/cas.14654." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR100">
<span class="label">100.</span><cite>Zhu P, et al. Circulating tumor cells expressing Krüppel-Like factor 8 and vimentin as predictors of poor prognosis in pancreatic cancer patients. Cancer Control. 2021;28:10732748211027163. 10.1177/10732748211027163.
</cite> [<a href="https://doi.org/10.1177/10732748211027163" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8361509/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34378430/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhu%20P,%20et%20al.%20Circulating%20tumor%20cells%20expressing%20Kr%C3%BCppel-Like%20factor%208%20and%20vimentin%20as%20predictors%20of%20poor%20prognosis%20in%20pancreatic%20cancer%20patients.%20Cancer%20Control.%202021;28:10732748211027163.%2010.1177/10732748211027163." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR101">
<span class="label">101.</span><cite>Hassan S, Blick T, Thompson EW, Williams ED. Diversity of Epithelial-Mesenchymal phenotypes in Circulating tumour cells from prostate cancer Patient-Derived xenograft models. Cancers (Basel). 2021;13. 10.3390/cancers13112750.</cite> [<a href="https://doi.org/10.3390/cancers13112750" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8198708/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34206049/" class="usa-link">PubMed</a>]</li>
<li id="CR102">
<span class="label">102.</span><cite>Yang L, et al. Hexokinase 2 discerns a novel Circulating tumor cell population associated with poor prognosis in lung cancer patients. Proc Natl Acad Sci U S A. 2021;118. 10.1073/pnas.2012228118.</cite> [<a href="https://doi.org/10.1073/pnas.2012228118" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7980452/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33836566/" class="usa-link">PubMed</a>]</li>
<li id="CR103">
<span class="label">103.</span><cite>Mimeault M, Batra SK. Molecular biomarkers of cancer stem/progenitor cells associated with progression, metastases, and treatment resistance of aggressive cancers. Cancer Epidemiol Biomarkers Prev. 2014;23:234–54. 10.1158/1055-9965.Epi-13-0785.
</cite> [<a href="https://doi.org/10.1158/1055-9965.EPI-13-0785" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3977531/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24273063/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mimeault%20M,%20Batra%20SK.%20Molecular%20biomarkers%20of%20cancer%20stem/progenitor%20cells%20associated%20with%20progression,%20metastases,%20and%20treatment%20resistance%20of%20aggressive%20cancers.%20Cancer%20Epidemiol%20Biomarkers%20Prev.%202014;23:234%E2%80%9354.%2010.1158/1055-9965.Epi-13-0785." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR104">
<span class="label">104.</span><cite>Liu X, et al. Homophilic CD44 interactions mediate tumor cell aggregation and polyclonal metastasis in Patient-Derived breast cancer models. Cancer Discov. 2019;9:96–113. 10.1158/2159-8290.Cd-18-0065.
</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-18-0065" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6328322/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30361447/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liu%20X,%20et%20al.%20Homophilic%20CD44%20interactions%20mediate%20tumor%20cell%20aggregation%20and%20polyclonal%20metastasis%20in%20Patient-Derived%20breast%20cancer%20models.%20Cancer%20Discov.%202019;9:96%E2%80%93113.%2010.1158/2159-8290.Cd-18-0065." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR105">
<span class="label">105.</span><cite>Tian S, Xing YN, Xia P. The prognostic roles of Circulating ALDH1(+) tumor cell in the patients with non-small cell lung cancer. Biosci Rep. 2018;38. 10.1042/bsr20180914.</cite> [<a href="https://doi.org/10.1042/BSR20180914" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6209584/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30305380/" class="usa-link">PubMed</a>]</li>
<li id="CR106">
<span class="label">106.</span><cite>Grillet F, et al. Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks in ex vivo culture. Gut. 2017;66:1802–10. 10.1136/gutjnl-2016-311447.
</cite> [<a href="https://doi.org/10.1136/gutjnl-2016-311447" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5595103/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27456153/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Grillet%20F,%20et%20al.%20Circulating%20tumour%20cells%20from%20patients%20with%20colorectal%20cancer%20have%20cancer%20stem%20cell%20hallmarks%20in%20ex%20vivo%20culture.%20Gut.%202017;66:1802%E2%80%9310.%2010.1136/gutjnl-2016-311447." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR107">
<span class="label">107.</span><cite>Seigel GM, Campbell LM, Narayan M, Gonzalez-Fernandez F. Cancer stem cell characteristics in retinoblastoma. Mol Vis. 2005;11:729–37.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/16179903/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Seigel%20GM,%20Campbell%20LM,%20Narayan%20M,%20Gonzalez-Fernandez%20F.%20Cancer%20stem%20cell%20characteristics%20in%20retinoblastoma.%20Mol%20Vis.%202005;11:729%E2%80%9337." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR108">
<span class="label">108.</span><cite>Sun YF, et al. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology. 2013;57:1458–68. 10.1002/hep.26151.
</cite> [<a href="https://doi.org/10.1002/hep.26151" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23175471/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sun%20YF,%20et%20al.%20Circulating%20stem%20cell-like%20epithelial%20cell%20adhesion%20molecule-positive%20tumor%20cells%20indicate%20poor%20prognosis%20of%20hepatocellular%20carcinoma%20after%20curative%20resection.%20Hepatology.%202013;57:1458%E2%80%9368.%2010.1002/hep.26151." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR109">
<span class="label">109.</span><cite>Chen CL, et al. Profiling of Circulating tumor cells for screening of selective inhibitors of tumor-Initiating Stem-Like cells. Adv Sci (Weinh). 2023;10:e2206812. 10.1002/advs.202206812.
</cite> [<a href="https://doi.org/10.1002/advs.202206812" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10190641/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36949364/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20CL,%20et%20al.%20Profiling%20of%20Circulating%20tumor%20cells%20for%20screening%20of%20selective%20inhibitors%20of%20tumor-Initiating%20Stem-Like%20cells.%20Adv%20Sci%20(Weinh).%202023;10:e2206812.%2010.1002/advs.202206812." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="/articles/PMC12079357/" class="text-red">Retracted</a>]</li>
<li id="CR110">
<span class="label">110.</span><cite>Varillas JI, et al. Microfluidic isolation of Circulating tumor cells and cancer Stem-Like cells from patients with pancreatic ductal adenocarcinoma. Theranostics. 2019;9:1417–25. 10.7150/thno.28745.
</cite> [<a href="https://doi.org/10.7150/thno.28745" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6401494/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30867841/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Varillas%20JI,%20et%20al.%20Microfluidic%20isolation%20of%20Circulating%20tumor%20cells%20and%20cancer%20Stem-Like%20cells%20from%20patients%20with%20pancreatic%20ductal%20adenocarcinoma.%20Theranostics.%202019;9:1417%E2%80%9325.%2010.7150/thno.28745." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR111">
<span class="label">111.</span><cite>Fusi A, Ochsenreither S, Busse A, Rietz A, Keilholz U. Expression of the stem cell marker Nestin in peripheral blood of patients with melanoma. Br J Dermatol. 2010;163:107–14. 10.1111/j.1365-2133.2010.09779.x.
</cite> [<a href="https://doi.org/10.1111/j.1365-2133.2010.09779.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20346020/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Fusi%20A,%20Ochsenreither%20S,%20Busse%20A,%20Rietz%20A,%20Keilholz%20U.%20Expression%20of%20the%20stem%20cell%20marker%20Nestin%20in%20peripheral%20blood%20of%20patients%20with%20melanoma.%20Br%20J%20Dermatol.%202010;163:107%E2%80%9314.%2010.1111/j.1365-2133.2010.09779.x." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR112">
<span class="label">112.</span><cite>Liu S, et al. Expression of intercellular adhesion molecule 1 by hepatocellular carcinoma stem cells and Circulating tumor cells. Gastroenterology. 2013;144:1031–e10411010. 10.1053/j.gastro.2013.01.046.
</cite> [<a href="https://doi.org/10.1053/j.gastro.2013.01.046" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23376424/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liu%20S,%20et%20al.%20Expression%20of%20intercellular%20adhesion%20molecule%201%20by%20hepatocellular%20carcinoma%20stem%20cells%20and%20Circulating%20tumor%20cells.%20Gastroenterology.%202013;144:1031%E2%80%93e10411010.%2010.1053/j.gastro.2013.01.046." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR113">
<span class="label">113.</span><cite>Taftaf R, et al. ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer. Nat Commun. 2021;12:4867. 10.1038/s41467-021-25189-z.
</cite> [<a href="https://doi.org/10.1038/s41467-021-25189-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8358026/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34381029/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Taftaf%20R,%20et%20al.%20ICAM1%20initiates%20CTC%20cluster%20formation%20and%20trans-endothelial%20migration%20in%20lung%20metastasis%20of%20breast%20cancer.%20Nat%20Commun.%202021;12:4867.%2010.1038/s41467-021-25189-z." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR114">
<span class="label">114.</span><cite>Liang YJ, et al. Differential expression profiles of glycosphingolipids in human breast cancer stem cells vs. cancer non-stem cells. Proc Natl Acad Sci U S A. 2013;110:4968–73. 10.1073/pnas.1302825110.
</cite> [<a href="https://doi.org/10.1073/pnas.1302825110" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3612608/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23479608/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liang%20YJ,%20et%20al.%20Differential%20expression%20profiles%20of%20glycosphingolipids%20in%20human%20breast%20cancer%20stem%20cells%20vs.%20cancer%20non-stem%20cells.%20Proc%20Natl%20Acad%20Sci%20U%20S%20A.%202013;110:4968%E2%80%9373.%2010.1073/pnas.1302825110." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR115">
<span class="label">115.</span><cite>Battula VL, et al. Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Invest. 2012;122:2066–78. 10.1172/jci59735.
</cite> [<a href="https://doi.org/10.1172/JCI59735" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3591166/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22585577/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Battula%20VL,%20et%20al.%20Ganglioside%20GD2%20identifies%20breast%20cancer%20stem%20cells%20and%20promotes%20tumorigenesis.%20J%20Clin%20Invest.%202012;122:2066%E2%80%9378.%2010.1172/jci59735." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR116">
<span class="label">116.</span><cite>Graf RP, et al. Clinical utility of the Nuclear-localized AR-V7 biomarker in Circulating tumor cells in improving physician treatment choice in Castration-resistant prostate cancer. Eur Urol. 2020;77:170–7. 10.1016/j.eururo.2019.08.020.
</cite> [<a href="https://doi.org/10.1016/j.eururo.2019.08.020" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7472426/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31648903/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Graf%20RP,%20et%20al.%20Clinical%20utility%20of%20the%20Nuclear-localized%20AR-V7%20biomarker%20in%20Circulating%20tumor%20cells%20in%20improving%20physician%20treatment%20choice%20in%20Castration-resistant%20prostate%20cancer.%20Eur%20Urol.%202020;77:170%E2%80%937.%2010.1016/j.eururo.2019.08.020." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR117">
<span class="label">117.</span><cite>Gupta S, et al. PSMA-positive Circulating tumor cell detection and outcomes with abiraterone or enzalutamide treatment in men with metastatic Castrate-resistant prostate cancer. Clin Cancer Res. 2023;29:1929–37. 10.1158/1078-0432.Ccr-22-3233.
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-22-3233" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10192124/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36897758/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gupta%20S,%20et%20al.%20PSMA-positive%20Circulating%20tumor%20cell%20detection%20and%20outcomes%20with%20abiraterone%20or%20enzalutamide%20treatment%20in%20men%20with%20metastatic%20Castrate-resistant%20prostate%20cancer.%20Clin%20Cancer%20Res.%202023;29:1929%E2%80%9337.%2010.1158/1078-0432.Ccr-22-3233." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR118">
<span class="label">118.</span><cite>Königsberg R, et al. Detection of EpCAM positive and negative Circulating tumor cells in metastatic breast cancer patients. Acta Oncol. 2011;50:700–10. 10.3109/0284186x.2010.549151.
</cite> [<a href="https://doi.org/10.3109/0284186X.2010.549151" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21261508/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?K%C3%B6nigsberg%20R,%20et%20al.%20Detection%20of%20EpCAM%20positive%20and%20negative%20Circulating%20tumor%20cells%20in%20metastatic%20breast%20cancer%20patients.%20Acta%20Oncol.%202011;50:700%E2%80%9310.%2010.3109/0284186x.2010.549151." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR119">
<span class="label">119.</span><cite>Mikolajczyk SD, et al. Detection of EpCAM-Negative and Cytokeratin-Negative Circulating tumor cells in peripheral blood. J Oncol. 2011;2011(252361). 10.1155/2011/252361.</cite> [<a href="https://doi.org/10.1155/2011/252361" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3090615/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21577258/" class="usa-link">PubMed</a>]</li>
<li id="CR120">
<span class="label">120.</span><cite>Sharma S, et al. Circulating tumor cell isolation, culture, and downstream molecular analysis. Biotechnol Adv. 2018;36:1063–78. 10.1016/j.biotechadv.2018.03.007.
</cite> [<a href="https://doi.org/10.1016/j.biotechadv.2018.03.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5971144/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29559380/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sharma%20S,%20et%20al.%20Circulating%20tumor%20cell%20isolation,%20culture,%20and%20downstream%20molecular%20analysis.%20Biotechnol%20Adv.%202018;36:1063%E2%80%9378.%2010.1016/j.biotechadv.2018.03.007." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR121">
<span class="label">121.</span><cite>Li P, et al. Acoustic separation of Circulating tumor cells. Proc Natl Acad Sci U S A. 2015;112:4970–5. 10.1073/pnas.1504484112.
</cite> [<a href="https://doi.org/10.1073/pnas.1504484112" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4413297/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25848039/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20P,%20et%20al.%20Acoustic%20separation%20of%20Circulating%20tumor%20cells.%20Proc%20Natl%20Acad%20Sci%20U%20S%20A.%202015;112:4970%E2%80%935.%2010.1073/pnas.1504484112." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR122">
<span class="label">122.</span><cite>Lao Z, et al. A phenotype-independent label-capture-release process for isolating viable Circulating tumor cells in real-time drug susceptibility testing. Innov (Camb). 2025;6:100805. 10.1016/j.xinn.2025.100805.</cite> [<a href="https://doi.org/10.1016/j.xinn.2025.100805" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC12105512/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40432772/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lao%20Z,%20et%20al.%20A%20phenotype-independent%20label-capture-release%20process%20for%20isolating%20viable%20Circulating%20tumor%20cells%20in%20real-time%20drug%20susceptibility%20testing.%20Innov%20(Camb).%202025;6:100805.%2010.1016/j.xinn.2025.100805." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR123">
<span class="label">123.</span><cite>Di Trapani M, Manaresi N, Medoro G. DEPArray™ system: an automatic image-based sorter for isolation of pure Circulating tumor cells. Cytometry A. 2018;93:1260–6. 10.1002/cyto.a.23687.
</cite> [<a href="https://doi.org/10.1002/cyto.a.23687" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6590341/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30551261/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Di%20Trapani%20M,%20Manaresi%20N,%20Medoro%20G.%20DEPArray%E2%84%A2%20system:%20an%20automatic%20image-based%20sorter%20for%20isolation%20of%20pure%20Circulating%20tumor%20cells.%20Cytometry%20A.%202018;93:1260%E2%80%936.%2010.1002/cyto.a.23687." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR124">
<span class="label">124.</span><cite>Guadagni S, et al. A pilot study of the predictive potential of chemosensitivity and gene expression assays using Circulating tumour cells from patients with recurrent ovarian cancer. Int J Mol Sci. 2020;21. 10.3390/ijms21134813.</cite> [<a href="https://doi.org/10.3390/ijms21134813" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7370156/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32646060/" class="usa-link">PubMed</a>]</li>
<li id="CR125">
<span class="label">125.</span><cite>Hwang JY, Kim ST, Han HS, Kim K, Han JS. Optical aptamer probes of fluorescent imaging to rapid monitoring of Circulating tumor cell. Sens (Basel). 2016;16. 10.3390/s16111909.</cite> [<a href="https://doi.org/10.3390/s16111909" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5134568/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27886058/" class="usa-link">PubMed</a>]</li>
<li id="CR126">
<span class="label">126.</span><cite>Bobek V, Kacprzak G, Rzechonek A, Kolostova K. Detection and cultivation of Circulating tumor cells in malignant pleural mesothelioma. Anticancer Res. 2014;34:2565–9.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/24778078/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bobek%20V,%20Kacprzak%20G,%20Rzechonek%20A,%20Kolostova%20K.%20Detection%20and%20cultivation%20of%20Circulating%20tumor%20cells%20in%20malignant%20pleural%20mesothelioma.%20Anticancer%20Res.%202014;34:2565%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR127">
<span class="label">127.</span><cite>Yu M, et al. Cancer therapy. Ex vivo culture of Circulating breast tumor cells for individualized testing of drug susceptibility. Science. 2014;345:216–20. 10.1126/science.1253533.
</cite> [<a href="https://doi.org/10.1126/science.1253533" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4358808/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25013076/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yu%20M,%20et%20al.%20Cancer%20therapy.%20Ex%20vivo%20culture%20of%20Circulating%20breast%20tumor%20cells%20for%20individualized%20testing%20of%20drug%20susceptibility.%20Science.%202014;345:216%E2%80%9320.%2010.1126/science.1253533." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR128">
<span class="label">128.</span><cite>Drost J, et al. Organoid culture systems for prostate epithelial and cancer tissue. Nat Protoc. 2016;11:347–58. 10.1038/nprot.2016.006.
</cite> [<a href="https://doi.org/10.1038/nprot.2016.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4793718/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26797458/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Drost%20J,%20et%20al.%20Organoid%20culture%20systems%20for%20prostate%20epithelial%20and%20cancer%20tissue.%20Nat%20Protoc.%202016;11:347%E2%80%9358.%2010.1038/nprot.2016.006." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR129">
<span class="label">129.</span><cite>Yang C, Xia BR, Jin WL, Lou G. Circulating tumor cells in precision oncology: clinical applications in liquid biopsy and 3D organoid model. Cancer Cell Int. 2019;19:341. 10.1186/s12935-019-1067-8.
</cite> [<a href="https://doi.org/10.1186/s12935-019-1067-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6918690/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31866766/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yang%20C,%20Xia%20BR,%20Jin%20WL,%20Lou%20G.%20Circulating%20tumor%20cells%20in%20precision%20oncology:%20clinical%20applications%20in%20liquid%20biopsy%20and%203D%20organoid%20model.%20Cancer%20Cell%20Int.%202019;19:341.%2010.1186/s12935-019-1067-8." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR130">
<span class="label">130.</span><cite>Zhao Z, et al. Organoids Nat Rev Methods Primers. 2022;2. 10.1038/s43586-022-00174-y.</cite> [<a href="https://doi.org/10.1038/s43586-022-00174-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10270325/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37325195/" class="usa-link">PubMed</a>]</li>
<li id="CR131">
<span class="label">131.</span><cite>Phan TG, Croucher PI. The dormant cancer cell life cycle. Nat Rev Cancer. 2020;20:398–411. 10.1038/s41568-020-0263-0.
</cite> [<a href="https://doi.org/10.1038/s41568-020-0263-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32488200/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Phan%20TG,%20Croucher%20PI.%20The%20dormant%20cancer%20cell%20life%20cycle.%20Nat%20Rev%20Cancer.%202020;20:398%E2%80%93411.%2010.1038/s41568-020-0263-0." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR132">
<span class="label">132.</span><cite>Würth R, et al. Circulating tumor cell plasticity determines breast cancer therapy resistance via neuregulin 1-HER3 signaling. Nat Cancer. 2025;6:67–85. 10.1038/s43018-024-00882-2.
</cite> [<a href="https://doi.org/10.1038/s43018-024-00882-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11779641/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39753722/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?W%C3%BCrth%20R,%20et%20al.%20Circulating%20tumor%20cell%20plasticity%20determines%20breast%20cancer%20therapy%20resistance%20via%20neuregulin%201-HER3%20signaling.%20Nat%20Cancer.%202025;6:67%E2%80%9385.%2010.1038/s43018-024-00882-2." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR133">
<span class="label">133.</span><cite>Sato T, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and barrett’s epithelium. Gastroenterology. 2011;141:1762–72. 10.1053/j.gastro.2011.07.050.
</cite> [<a href="https://doi.org/10.1053/j.gastro.2011.07.050" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21889923/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sato%20T,%20et%20al.%20Long-term%20expansion%20of%20epithelial%20organoids%20from%20human%20colon,%20adenoma,%20adenocarcinoma,%20and%20barrett%E2%80%99s%20epithelium.%20Gastroenterology.%202011;141:1762%E2%80%9372.%2010.1053/j.gastro.2011.07.050." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR134">
<span class="label">134.</span><cite>Kalyanaraman B, NAC NAC. Knockin’ on heaven’s door: interpreting the mechanism of action of N-acetylcysteine in tumor and immune cells. Redox Biol. 2022;57:102497. 10.1016/j.redox.2022.102497.
</cite> [<a href="https://doi.org/10.1016/j.redox.2022.102497" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9563555/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36242913/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kalyanaraman%20B,%20NAC%20NAC.%20Knockin%E2%80%99%20on%20heaven%E2%80%99s%20door:%20interpreting%20the%20mechanism%20of%20action%20of%20N-acetylcysteine%20in%20tumor%20and%20immune%20cells.%20Redox%20Biol.%202022;57:102497.%2010.1016/j.redox.2022.102497." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR135">
<span class="label">135.</span><cite>Wu X, et al. Conditional reprogramming: next generation cell culture. Acta Pharm Sin B. 2020;10:1360–81. 10.1016/j.apsb.2020.01.011.
</cite> [<a href="https://doi.org/10.1016/j.apsb.2020.01.011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7488362/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32963937/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wu%20X,%20et%20al.%20Conditional%20reprogramming:%20next%20generation%20cell%20culture.%20Acta%20Pharm%20Sin%20B.%202020;10:1360%E2%80%9381.%2010.1016/j.apsb.2020.01.011." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR136">
<span class="label">136.</span><cite>Hurtado P, Martínez-Pena I, Piñeiro R. Dangerous liaisons: Circulating tumor cells (CTCs) and Cancer-Associated fibroblasts (CAFs). Cancers (Basel). 2020;12. 10.3390/cancers12102861.</cite> [<a href="https://doi.org/10.3390/cancers12102861" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7599894/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33027902/" class="usa-link">PubMed</a>]</li>
<li id="CR137">
<span class="label">137.</span><cite>Ortiz-Otero N, et al. Cancer associated fibroblasts confer shear resistance to Circulating tumor cells during prostate cancer metastatic progression. Oncotarget. 2020;11:1037–50. 10.18632/oncotarget.27510.
</cite> [<a href="https://doi.org/10.18632/oncotarget.27510" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7105166/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32256977/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ortiz-Otero%20N,%20et%20al.%20Cancer%20associated%20fibroblasts%20confer%20shear%20resistance%20to%20Circulating%20tumor%20cells%20during%20prostate%20cancer%20metastatic%20progression.%20Oncotarget.%202020;11:1037%E2%80%9350.%2010.18632/oncotarget.27510." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR138">
<span class="label">138.</span><cite>Miyoshi H, Stappenbeck TS. In vitro expansion and genetic modification of Gastrointestinal stem cells in spheroid culture. Nat Protoc. 2013;8:2471–82. 10.1038/nprot.2013.153.
</cite> [<a href="https://doi.org/10.1038/nprot.2013.153" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3969856/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24232249/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Miyoshi%20H,%20Stappenbeck%20TS.%20In%20vitro%20expansion%20and%20genetic%20modification%20of%20Gastrointestinal%20stem%20cells%20in%20spheroid%20culture.%20Nat%20Protoc.%202013;8:2471%E2%80%9382.%2010.1038/nprot.2013.153." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR139">
<span class="label">139.</span><cite>Heilala M, et al. Fibrin stiffness regulates phenotypic plasticity of metastatic breast cancer cells. Adv Healthc Mater. 2023;12:e2301137. 10.1002/adhm.202301137.
</cite> [<a href="https://doi.org/10.1002/adhm.202301137" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11469292/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37671812/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Heilala%20M,%20et%20al.%20Fibrin%20stiffness%20regulates%20phenotypic%20plasticity%20of%20metastatic%20breast%20cancer%20cells.%20Adv%20Healthc%20Mater.%202023;12:e2301137.%2010.1002/adhm.202301137." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR140">
<span class="label">140.</span><cite>De Angelis ML, et al. An organoid model of colorectal Circulating tumor cells with stem cell features, hybrid EMT state and distinctive therapy response profile. J Exp Clin Cancer Res. 2022;41:86. 10.1186/s13046-022-02263-y.
</cite> [<a href="https://doi.org/10.1186/s13046-022-02263-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8903172/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35260172/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?De%20Angelis%20ML,%20et%20al.%20An%20organoid%20model%20of%20colorectal%20Circulating%20tumor%20cells%20with%20stem%20cell%20features,%20hybrid%20EMT%20state%20and%20distinctive%20therapy%20response%20profile.%20J%20Exp%20Clin%20Cancer%20Res.%202022;41:86.%2010.1186/s13046-022-02263-y." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR141">
<span class="label">141.</span><cite>Li K, Wu R, Zhou M, Tong H, Luo KQ. Desmosomal proteins of DSC2 and PKP1 promote cancer cells survival and metastasis by increasing cluster formation in circulatory system. Sci Adv. 2021;7:eabg7265. 10.1126/sciadv.abg7265.
</cite> [<a href="https://doi.org/10.1126/sciadv.abg7265" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8480931/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34586853/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20K,%20Wu%20R,%20Zhou%20M,%20Tong%20H,%20Luo%20KQ.%20Desmosomal%20proteins%20of%20DSC2%20and%20PKP1%20promote%20cancer%20cells%20survival%20and%20metastasis%20by%20increasing%20cluster%20formation%20in%20circulatory%20system.%20Sci%20Adv.%202021;7:eabg7265.%2010.1126/sciadv.abg7265." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR142">
<span class="label">142.</span><cite>Watanabe K, et al. A ROCK inhibitor permits survival of dissociated human embryonic stem cells. Nat Biotechnol. 2007;25:681–6. 10.1038/nbt1310.
</cite> [<a href="https://doi.org/10.1038/nbt1310" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17529971/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Watanabe%20K,%20et%20al.%20A%20ROCK%20inhibitor%20permits%20survival%20of%20dissociated%20human%20embryonic%20stem%20cells.%20Nat%20Biotechnol.%202007;25:681%E2%80%936.%2010.1038/nbt1310." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR143">
<span class="label">143.</span><cite>Krause C, Guzman A, Knaus P, Noggin. Int J Biochem Cell Biol. 2011;43:478–81. 10.1016/j.biocel.2011.01.007.
</cite> [<a href="https://doi.org/10.1016/j.biocel.2011.01.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21256973/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Krause%20C,%20Guzman%20A,%20Knaus%20P,%20Noggin.%20Int%20J%20Biochem%20Cell%20Biol.%202011;43:478%E2%80%9381.%2010.1016/j.biocel.2011.01.007." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR144">
<span class="label">144.</span><cite>Costa D, et al. SB202190 predicts BRAF-Activating mutations in primary colorectal cancer organoids via Erk1-2 modulation. Cells. 2023;12. 10.3390/cells12040664.</cite> [<a href="https://doi.org/10.3390/cells12040664" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9954675/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36831331/" class="usa-link">PubMed</a>]</li>
<li id="CR145">
<span class="label">145.</span><cite>Fleischauer J, et al. TGFβ inhibitor A83-01 enhances murine HSPC expansion for gene therapy. Cells. 2023;12. 10.3390/cells12151978.</cite> [<a href="https://doi.org/10.3390/cells12151978" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10416825/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37566057/" class="usa-link">PubMed</a>]</li>
<li id="CR146">
<span class="label">146.</span><cite>de Lau W, Peng WC, Gros P, Clevers H. The R-spondin/Lgr5/Rnf43 module: regulator of Wnt signal strength. Genes Dev. 2014;28:305–16. 10.1101/gad.235473.113.
</cite> [<a href="https://doi.org/10.1101/gad.235473.113" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3937510/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24532711/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?de%20Lau%20W,%20Peng%20WC,%20Gros%20P,%20Clevers%20H.%20The%20R-spondin/Lgr5/Rnf43%20module:%20regulator%20of%20Wnt%20signal%20strength.%20Genes%20Dev.%202014;28:305%E2%80%9316.%2010.1101/gad.235473.113." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR147">
<span class="label">147.</span><cite>Figueira MI, Cardoso HJ, Correia S, Maia CJ, Socorro S. The stem cell factor (SCF)/c-KIT system in carcinogenesis of reproductive tissues: what does the hormonal regulation tell us? Cancer Lett. 2017;405:10–21. 10.1016/j.canlet.2017.07.017.
</cite> [<a href="https://doi.org/10.1016/j.canlet.2017.07.017" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28751268/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Figueira%20MI,%20Cardoso%20HJ,%20Correia%20S,%20Maia%20CJ,%20Socorro%20S.%20The%20stem%20cell%20factor%20(SCF)/c-KIT%20system%20in%20carcinogenesis%20of%20reproductive%20tissues:%20what%20does%20the%20hormonal%20regulation%20tell%20us?%20Cancer%20Lett.%202017;405:10%E2%80%9321.%2010.1016/j.canlet.2017.07.017." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR148">
<span class="label">148.</span><cite>Wilson KJ, Gilmore JL, Foley J, Lemmon MA, Riese DJ 2. Functional selectivity of EGF family peptide growth factors: implications for cancer. Pharmacol Ther. 2009;122:1–8. 10.1016/j.pharmthera.2008.11.008.</cite> [<a href="https://doi.org/10.1016/j.pharmthera.2008.11.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2665203/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19135477/" class="usa-link">PubMed</a>]</li>
<li id="CR149">
<span class="label">149.</span><cite>Hu H, et al. Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms. Cancer Cell. 2021;39:1531–e15471510. 10.1016/j.ccell.2021.09.003.
</cite> [<a href="https://doi.org/10.1016/j.ccell.2021.09.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8578451/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34624218/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hu%20H,%20et%20al.%20Three%20subtypes%20of%20lung%20cancer%20fibroblasts%20define%20distinct%20therapeutic%20paradigms.%20Cancer%20Cell.%202021;39:1531%E2%80%93e15471510.%2010.1016/j.ccell.2021.09.003." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR150">
<span class="label">150.</span><cite>Cronauer MV, Schulz WA, Seifert HH, Ackermann R, Burchardt M. Fibroblast growth factors and their receptors in urological cancers: basic research and clinical implications. Eur Urol. 2003;43:309–19. 10.1016/s0302-2838(03)00005-8.
</cite> [<a href="https://doi.org/10.1016/s0302-2838(03)00005-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12600436/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cronauer%20MV,%20Schulz%20WA,%20Seifert%20HH,%20Ackermann%20R,%20Burchardt%20M.%20Fibroblast%20growth%20factors%20and%20their%20receptors%20in%20urological%20cancers:%20basic%20research%20and%20clinical%20implications.%20Eur%20Urol.%202003;43:309%E2%80%9319.%2010.1016/s0302-2838(03)00005-8." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR151">
<span class="label">151.</span><cite>Itoh N. FGF10: A multifunctional mesenchymal-epithelial signaling growth factor in development, health, and disease. Cytokine Growth Factor Rev. 2016;28:63–9. 10.1016/j.cytogfr.2015.10.001.
</cite> [<a href="https://doi.org/10.1016/j.cytogfr.2015.10.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26559461/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Itoh%20N.%20FGF10:%20A%20multifunctional%20mesenchymal-epithelial%20signaling%20growth%20factor%20in%20development,%20health,%20and%20disease.%20Cytokine%20Growth%20Factor%20Rev.%202016;28:63%E2%80%939.%2010.1016/j.cytogfr.2015.10.001." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR152">
<span class="label">152.</span><cite>Wang D, Cabalag CS, Clemons NJ, DuBois RN. Cyclooxygenases and prostaglandins in tumor immunology and microenvironment of Gastrointestinal cancer. Gastroenterology. 2021;161:1813–29. 10.1053/j.gastro.2021.09.059.
</cite> [<a href="https://doi.org/10.1053/j.gastro.2021.09.059" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34606846/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20D,%20Cabalag%20CS,%20Clemons%20NJ,%20DuBois%20RN.%20Cyclooxygenases%20and%20prostaglandins%20in%20tumor%20immunology%20and%20microenvironment%20of%20Gastrointestinal%20cancer.%20Gastroenterology.%202021;161:1813%E2%80%9329.%2010.1053/j.gastro.2021.09.059." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR153">
<span class="label">153.</span><cite>Muilwijk D, et al. Forskolin-induced organoid swelling is associated with long-term cystic fibrosis disease progression. Eur Respir J. 2022;60. 10.1183/13993003.00508-2021.</cite> [<a href="https://doi.org/10.1183/13993003.00508-2021" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9386333/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35086832/" class="usa-link">PubMed</a>]</li>
<li id="CR154">
<span class="label">154.</span><cite>Xiao J, et al. Efficient propagation of Circulating tumor cells: A first step for probing tumor metastasis. Cancers (Basel). 2020;12. 10.3390/cancers12102784.</cite> [<a href="https://doi.org/10.3390/cancers12102784" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7599955/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32998338/" class="usa-link">PubMed</a>]</li>
<li id="CR155">
<span class="label">155.</span><cite>Zhao P, et al. Establishment and characterization of a CTC cell line from peripheral blood of breast cancer patient. J Cancer. 2019;10:6095–104. 10.7150/jca.33157.
</cite> [<a href="https://doi.org/10.7150/jca.33157" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6856591/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31762819/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhao%20P,%20et%20al.%20Establishment%20and%20characterization%20of%20a%20CTC%20cell%20line%20from%20peripheral%20blood%20of%20breast%20cancer%20patient.%20J%20Cancer.%202019;10:6095%E2%80%93104.%2010.7150/jca.33157." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR156">
<span class="label">156.</span><cite>Kwizera EA, et al. Greatly enhanced CTC culture enabled by capturing CTC heterogeneity using a pegylated PDMS-Titanium-Gold electromicrofluidic device with Glutathione-Controlled gentle cell release. ACS Nano. 2022;16:11374–91. 10.1021/acsnano.2c05195.
</cite> [<a href="https://doi.org/10.1021/acsnano.2c05195" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9649890/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35797466/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kwizera%20EA,%20et%20al.%20Greatly%20enhanced%20CTC%20culture%20enabled%20by%20capturing%20CTC%20heterogeneity%20using%20a%20pegylated%20PDMS-Titanium-Gold%20electromicrofluidic%20device%20with%20Glutathione-Controlled%20gentle%20cell%20release.%20ACS%20Nano.%202022;16:11374%E2%80%9391.%2010.1021/acsnano.2c05195." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR157">
<span class="label">157.</span><cite>Cayrefourcq L, et al. Establishment and characterization of a cell line from human Circulating colon cancer cells. Cancer Res. 2015;75:892–901. 10.1158/0008-5472.Can-14-2613.
</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-14-2613" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25592149/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cayrefourcq%20L,%20et%20al.%20Establishment%20and%20characterization%20of%20a%20cell%20line%20from%20human%20Circulating%20colon%20cancer%20cells.%20Cancer%20Res.%202015;75:892%E2%80%93901.%2010.1158/0008-5472.Can-14-2613." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR158">
<span class="label">158.</span><cite>Soler A, et al. Autologous cell lines from Circulating colon cancer cells captured from sequential liquid biopsies as model to study therapy-driven tumor changes. Sci Rep. 2018;8:15931. 10.1038/s41598-018-34365-z.
</cite> [<a href="https://doi.org/10.1038/s41598-018-34365-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6206091/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30374140/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Soler%20A,%20et%20al.%20Autologous%20cell%20lines%20from%20Circulating%20colon%20cancer%20cells%20captured%20from%20sequential%20liquid%20biopsies%20as%20model%20to%20study%20therapy-driven%20tumor%20changes.%20Sci%20Rep.%202018;8:15931.%2010.1038/s41598-018-34365-z." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR159">
<span class="label">159.</span><cite>Zhang L, et al. Establishment and identification of organoids from human Circulating colorectal cancer cells. Clin Transl Med. 2020;10:e247. 10.1002/ctm2.247.
</cite> [<a href="https://doi.org/10.1002/ctm2.247" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7733316/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33377635/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20L,%20et%20al.%20Establishment%20and%20identification%20of%20organoids%20from%20human%20Circulating%20colorectal%20cancer%20cells.%20Clin%20Transl%20Med.%202020;10:e247.%2010.1002/ctm2.247." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR160">
<span class="label">160.</span><cite>Brungs D, et al. Establishment of novel long-term cultures from EpCAM positive and negative Circulating tumour cells from patients with metastatic gastroesophageal cancer. Sci Rep. 2020;10:539. 10.1038/s41598-019-57164-6.
</cite> [<a href="https://doi.org/10.1038/s41598-019-57164-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6968999/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31953491/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Brungs%20D,%20et%20al.%20Establishment%20of%20novel%20long-term%20cultures%20from%20EpCAM%20positive%20and%20negative%20Circulating%20tumour%20cells%20from%20patients%20with%20metastatic%20gastroesophageal%20cancer.%20Sci%20Rep.%202020;10:539.%2010.1038/s41598-019-57164-6." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR161">
<span class="label">161.</span><cite>Hong X, et al. The lipogenic regulator SREBP2 induces transferrin in Circulating melanoma cells and suppresses ferroptosis. Cancer Discov. 2021;11:678–95. 10.1158/2159-8290.Cd-19-1500.
</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-19-1500" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7933049/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33203734/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hong%20X,%20et%20al.%20The%20lipogenic%20regulator%20SREBP2%20induces%20transferrin%20in%20Circulating%20melanoma%20cells%20and%20suppresses%20ferroptosis.%20Cancer%20Discov.%202021;11:678%E2%80%9395.%2010.1158/2159-8290.Cd-19-1500." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR162">
<span class="label">162.</span><cite>Que Z, et al. Establishment and characterization of a patient-derived Circulating lung tumor cell line in vitro and in vivo. Cancer Cell Int. 2019;19:21. 10.1186/s12935-019-0735-z.
</cite> [<a href="https://doi.org/10.1186/s12935-019-0735-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6352330/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30718976/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Que%20Z,%20et%20al.%20Establishment%20and%20characterization%20of%20a%20patient-derived%20Circulating%20lung%20tumor%20cell%20line%20in%20vitro%20and%20in%20vivo.%20Cancer%20Cell%20Int.%202019;19:21.%2010.1186/s12935-019-0735-z." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR163">
<span class="label">163.</span><cite>Kapeleris J, et al. Ex vivo culture of Circulating tumour cells derived from non-small cell lung cancer. Transl Lung Cancer Res. 2020;9:1795–809. 10.21037/tlcr-20-521.
</cite> [<a href="https://doi.org/10.21037/tlcr-20-521" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7653113/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33209602/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kapeleris%20J,%20et%20al.%20Ex%20vivo%20culture%20of%20Circulating%20tumour%20cells%20derived%20from%20non-small%20cell%20lung%20cancer.%20Transl%20Lung%20Cancer%20Res.%202020;9:1795%E2%80%93809.%2010.21037/tlcr-20-521." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR164">
<span class="label">164.</span><cite>Rivera-Báez L, et al. Expansion of Circulating tumor cells from patients with locally advanced pancreatic cancer enable patient derived xenografts and functional studies for personalized medicine. Cancers (Basel). 2020;12. 10.3390/cancers12041011.</cite> [<a href="https://doi.org/10.3390/cancers12041011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7225920/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32326109/" class="usa-link">PubMed</a>]</li>
<li id="CR165">
<span class="label">165.</span><cite>Mout L, et al. Generating human prostate cancer organoids from leukapheresis enriched Circulating tumour cells. Eur J Cancer. 2021;150:179–89. 10.1016/j.ejca.2021.03.023.
</cite> [<a href="https://doi.org/10.1016/j.ejca.2021.03.023" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33932725/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mout%20L,%20et%20al.%20Generating%20human%20prostate%20cancer%20organoids%20from%20leukapheresis%20enriched%20Circulating%20tumour%20cells.%20Eur%20J%20Cancer.%202021;150:179%E2%80%9389.%2010.1016/j.ejca.2021.03.023." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR166">
<span class="label">166.</span><cite>Wu YH, et al. Correlation between drug sensitivity profiles of Circulating tumour cell-derived organoids and clinical treatment response in patients with pancreatic ductal adenocarcinoma. Eur J Cancer. 2022;166:208–18. 10.1016/j.ejca.2022.01.030.
</cite> [<a href="https://doi.org/10.1016/j.ejca.2022.01.030" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35306319/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wu%20YH,%20et%20al.%20Correlation%20between%20drug%20sensitivity%20profiles%20of%20Circulating%20tumour%20cell-derived%20organoids%20and%20clinical%20treatment%20response%20in%20patients%20with%20pancreatic%20ductal%20adenocarcinoma.%20Eur%20J%20Cancer.%202022;166:208%E2%80%9318.%2010.1016/j.ejca.2022.01.030." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR167">
<span class="label">167.</span><cite>Gao D, et al. Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014;159:176–87. 10.1016/j.cell.2014.08.016.
</cite> [<a href="https://doi.org/10.1016/j.cell.2014.08.016" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4237931/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25201530/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gao%20D,%20et%20al.%20Organoid%20cultures%20derived%20from%20patients%20with%20advanced%20prostate%20cancer.%20Cell.%202014;159:176%E2%80%9387.%2010.1016/j.cell.2014.08.016." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR168">
<span class="label">168.</span><cite>Hamilton G, Burghuber O, Zeillinger R. Circulating tumor cells in small cell lung cancer: ex vivo expansion. Lung. 2015;193:451–2. 10.1007/s00408-015-9725-7.
</cite> [<a href="https://doi.org/10.1007/s00408-015-9725-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25821178/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hamilton%20G,%20Burghuber%20O,%20Zeillinger%20R.%20Circulating%20tumor%20cells%20in%20small%20cell%20lung%20cancer:%20ex%20vivo%20expansion.%20Lung.%202015;193:451%E2%80%932.%2010.1007/s00408-015-9725-7." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR169">
<span class="label">169.</span><cite>Barrière G, Riouallon A, Renaudie J, Tartary M, Rigaud M. Mesenchymal and stemness Circulating tumor cells in early breast cancer diagnosis. BMC Cancer. 2012;12:114. 10.1186/1471-2407-12-114.
</cite> [<a href="https://doi.org/10.1186/1471-2407-12-114" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3364860/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22443102/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Barri%C3%A8re%20G,%20Riouallon%20A,%20Renaudie%20J,%20Tartary%20M,%20Rigaud%20M.%20Mesenchymal%20and%20stemness%20Circulating%20tumor%20cells%20in%20early%20breast%20cancer%20diagnosis.%20BMC%20Cancer.%202012;12:114.%2010.1186/1471-2407-12-114." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR170">
<span class="label">170.</span><cite>Thery L, et al. Circulating tumor cells in early breast cancer. JNCI Cancer Spectr. 2019;3:pkz026. 10.1093/jncics/pkz026.
</cite> [<a href="https://doi.org/10.1093/jncics/pkz026" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6649836/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31360902/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Thery%20L,%20et%20al.%20Circulating%20tumor%20cells%20in%20early%20breast%20cancer.%20JNCI%20Cancer%20Spectr.%202019;3:pkz026.%2010.1093/jncics/pkz026." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR171">
<span class="label">171.</span><cite>Beasley A, et al. Clinical application of Circulating tumor cells and Circulating tumor DNA in uveal melanoma. JCO Precis Oncol. 2018;2. 10.1200/po.17.00279.</cite> [<a href="https://doi.org/10.1200/PO.17.00279" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7446501/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32913999/" class="usa-link">PubMed</a>]</li>
<li id="CR172">
<span class="label">172.</span><cite>Magbanua MJM, et al. Serial analysis of Circulating tumor cells in metastatic breast cancer receiving First-Line chemotherapy. J Natl Cancer Inst. 2021;113:443–52. 10.1093/jnci/djaa113.
</cite> [<a href="https://doi.org/10.1093/jnci/djaa113" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8023821/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32770247/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Magbanua%20MJM,%20et%20al.%20Serial%20analysis%20of%20Circulating%20tumor%20cells%20in%20metastatic%20breast%20cancer%20receiving%20First-Line%20chemotherapy.%20J%20Natl%20Cancer%20Inst.%202021;113:443%E2%80%9352.%2010.1093/jnci/djaa113." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR173">
<span class="label">173.</span><cite>Smerage JB, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol. 2014;32:3483–9. 10.1200/jco.2014.56.2561.
</cite> [<a href="https://doi.org/10.1200/JCO.2014.56.2561" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4209100/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24888818/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Smerage%20JB,%20et%20al.%20Circulating%20tumor%20cells%20and%20response%20to%20chemotherapy%20in%20metastatic%20breast%20cancer:%20SWOG%20S0500.%20J%20Clin%20Oncol.%202014;32:3483%E2%80%939.%2010.1200/jco.2014.56.2561." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR174">
<span class="label">174.</span><cite>Cohen SJ, et al. Relationship of Circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:3213–21. 10.1200/jco.2007.15.8923.
</cite> [<a href="https://doi.org/10.1200/JCO.2007.15.8923" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18591556/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cohen%20SJ,%20et%20al.%20Relationship%20of%20Circulating%20tumor%20cells%20to%20tumor%20response,%20progression-free%20survival,%20and%20overall%20survival%20in%20patients%20with%20metastatic%20colorectal%20cancer.%20J%20Clin%20Oncol.%202008;26:3213%E2%80%9321.%2010.1200/jco.2007.15.8923." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR175">
<span class="label">175.</span><cite>de Bono JS, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14:6302–9. 10.1158/1078-0432.Ccr-08-0872.
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-08-0872" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18829513/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?de%20Bono%20JS,%20et%20al.%20Circulating%20tumor%20cells%20predict%20survival%20benefit%20from%20treatment%20in%20metastatic%20castration-resistant%20prostate%20cancer.%20Clin%20Cancer%20Res.%202008;14:6302%E2%80%939.%2010.1158/1078-0432.Ccr-08-0872." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR176">
<span class="label">176.</span><cite>Cristofanilli M, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781–91. 10.1056/NEJMoa040766.
</cite> [<a href="https://doi.org/10.1056/NEJMoa040766" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15317891/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cristofanilli%20M,%20et%20al.%20Circulating%20tumor%20cells,%20disease%20progression,%20and%20survival%20in%20metastatic%20breast%20cancer.%20N%20Engl%20J%20Med.%202004;351:781%E2%80%9391.%2010.1056/NEJMoa040766." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR177">
<span class="label">177.</span><cite>Cristofanilli M, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol. 2005;23:1420–30. 10.1200/jco.2005.08.140.
</cite> [<a href="https://doi.org/10.1200/JCO.2005.08.140" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15735118/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cristofanilli%20M,%20et%20al.%20Circulating%20tumor%20cells:%20a%20novel%20prognostic%20factor%20for%20newly%20diagnosed%20metastatic%20breast%20cancer.%20J%20Clin%20Oncol.%202005;23:1420%E2%80%9330.%2010.1200/jco.2005.08.140." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR178">
<span class="label">178.</span><cite>Hayes DF, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006;12:4218–24. 10.1158/1078-0432.Ccr-05-2821.
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-05-2821" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16857794/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hayes%20DF,%20et%20al.%20Circulating%20tumor%20cells%20at%20each%20follow-up%20time%20point%20during%20therapy%20of%20metastatic%20breast%20cancer%20patients%20predict%20progression-free%20and%20overall%20survival.%20Clin%20Cancer%20Res.%202006;12:4218%E2%80%9324.%2010.1158/1078-0432.Ccr-05-2821." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR179">
<span class="label">179.</span><cite>Sinoquet L, et al. Programmed cell death ligand 1-Expressing Circulating tumor cells: A new prognostic biomarker in Non-Small cell lung cancer. Clin Chem. 2021;67:1503–12. 10.1093/clinchem/hvab131.
</cite> [<a href="https://doi.org/10.1093/clinchem/hvab131" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34355741/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sinoquet%20L,%20et%20al.%20Programmed%20cell%20death%20ligand%201-Expressing%20Circulating%20tumor%20cells:%20A%20new%20prognostic%20biomarker%20in%20Non-Small%20cell%20lung%20cancer.%20Clin%20Chem.%202021;67:1503%E2%80%9312.%2010.1093/clinchem/hvab131." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR180">
<span class="label">180.</span><cite>Lei Y, et al. Association of preoperative NANOG-Positive Circulating tumor cell levels with recurrence of hepatocellular carcinoma. Front Oncol. 2021;11:601668. 10.3389/fonc.2021.601668.
</cite> [<a href="https://doi.org/10.3389/fonc.2021.601668" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8190394/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34123777/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lei%20Y,%20et%20al.%20Association%20of%20preoperative%20NANOG-Positive%20Circulating%20tumor%20cell%20levels%20with%20recurrence%20of%20hepatocellular%20carcinoma.%20Front%20Oncol.%202021;11:601668.%2010.3389/fonc.2021.601668." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR181">
<span class="label">181.</span><cite>Pan RJ, et al. Detection and clinical value of Circulating tumor cells as an assisted prognostic marker in colorectal cancer patients. Cancer Manag Res. 2021;13:4567–78. 10.2147/cmar.S300554.
</cite> [<a href="https://doi.org/10.2147/CMAR.S300554" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8197664/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34135633/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Pan%20RJ,%20et%20al.%20Detection%20and%20clinical%20value%20of%20Circulating%20tumor%20cells%20as%20an%20assisted%20prognostic%20marker%20in%20colorectal%20cancer%20patients.%20Cancer%20Manag%20Res.%202021;13:4567%E2%80%9378.%2010.2147/cmar.S300554." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR182">
<span class="label">182.</span><cite>Kim ST, et al. Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2 + gastric cancer patients. Ann Oncol. 2018;29:1037–48. 10.1093/annonc/mdy034.
</cite> [<a href="https://doi.org/10.1093/annonc/mdy034" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5913644/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29409051/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kim%20ST,%20et%20al.%20Impact%20of%20genomic%20alterations%20on%20lapatinib%20treatment%20outcome%20and%20cell-free%20genomic%20landscape%20during%20HER2%20therapy%20in%20HER2%20+%20gastric%20cancer%20patients.%20Ann%20Oncol.%202018;29:1037%E2%80%9348.%2010.1093/annonc/mdy034." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR183">
<span class="label">183.</span><cite>Bidard FC, et al. Efficacy of Circulating tumor cell Count-Driven vs Clinician-Driven First-line therapy choice in hormone Receptor-Positive, ERBB2-Negative metastatic breast cancer: the STIC CTC randomized clinical trial. JAMA Oncol. 2021;7:34–41. 10.1001/jamaoncol.2020.5660.
</cite> [<a href="https://doi.org/10.1001/jamaoncol.2020.5660" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7645742/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33151266/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bidard%20FC,%20et%20al.%20Efficacy%20of%20Circulating%20tumor%20cell%20Count-Driven%20vs%20Clinician-Driven%20First-line%20therapy%20choice%20in%20hormone%20Receptor-Positive,%20ERBB2-Negative%20metastatic%20breast%20cancer:%20the%20STIC%20CTC%20randomized%20clinical%20trial.%20JAMA%20Oncol.%202021;7:34%E2%80%9341.%2010.1001/jamaoncol.2020.5660." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR184">
<span class="label">184.</span><cite>Bidard FC, et al. Overall survival with Circulating tumor cell Count-Driven choice of therapy in advanced breast cancer: A randomized trial. J Clin Oncol. 2024;42:383–9. 10.1200/jco.23.00456.
</cite> [<a href="https://doi.org/10.1200/JCO.23.00456" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37931185/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bidard%20FC,%20et%20al.%20Overall%20survival%20with%20Circulating%20tumor%20cell%20Count-Driven%20choice%20of%20therapy%20in%20advanced%20breast%20cancer:%20A%20randomized%20trial.%20J%20Clin%20Oncol.%202024;42:383%E2%80%939.%2010.1200/jco.23.00456." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR185">
<span class="label">185.</span><cite>Cabel L, et al. Clinical utility of Circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial. Br J Cancer. 2021;124:1207–13. 10.1038/s41416-020-01227-3.
</cite> [<a href="https://doi.org/10.1038/s41416-020-01227-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8007590/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33473163/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cabel%20L,%20et%20al.%20Clinical%20utility%20of%20Circulating%20tumour%20cell-based%20monitoring%20of%20late-line%20chemotherapy%20for%20metastatic%20breast%20cancer:%20the%20randomised%20CirCe01%20trial.%20Br%20J%20Cancer.%202021;124:1207%E2%80%9313.%2010.1038/s41416-020-01227-3." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR186">
<span class="label">186.</span><cite>Janni W, et al. Clinical validity of repeated Circulating tumor cell enumeration as an early treatment monitoring tool for metastatic breast cancer in the PREDICT global pooled analysis. Clin Cancer Res. 2025;31:2196–209. 10.1158/1078-0432.Ccr-24-3108.
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-24-3108" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC12130808/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40100138/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Janni%20W,%20et%20al.%20Clinical%20validity%20of%20repeated%20Circulating%20tumor%20cell%20enumeration%20as%20an%20early%20treatment%20monitoring%20tool%20for%20metastatic%20breast%20cancer%20in%20the%20PREDICT%20global%20pooled%20analysis.%20Clin%20Cancer%20Res.%202025;31:2196%E2%80%93209.%2010.1158/1078-0432.Ccr-24-3108." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR187">
<span class="label">187.</span><cite>Yuan S, Wei Z, Hu B, Che S. Visual capturing and profiling of Circulating tumor cells from breast cancer patient’s blood via combining fluorescent IMNPs in a magnet-integrated 3D-printed microfluidic chip. J Clin Oncol. 2025;43:e13038–13038. 10.1200/JCO.2025.43.16_suppl.e13038.</cite> [<a href="https://scholar.google.com/scholar_lookup?Yuan%20S,%20Wei%20Z,%20Hu%20B,%20Che%20S.%20Visual%20capturing%20and%20profiling%20of%20Circulating%20tumor%20cells%20from%20breast%20cancer%20patient%E2%80%99s%20blood%20via%20combining%20fluorescent%20IMNPs%20in%20a%20magnet-integrated%203D-printed%20microfluidic%20chip.%20J%20Clin%20Oncol.%202025;43:e13038%E2%80%9313038.%2010.1200/JCO.2025.43.16_suppl.e13038." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR188">
<span class="label">188.</span><cite>Lindsay CR, et al. A prospective examination of Circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups. Ann Oncol. 2017;28:1523–31. 10.1093/annonc/mdx156.
</cite> [<a href="https://doi.org/10.1093/annonc/mdx156" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28633480/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lindsay%20CR,%20et%20al.%20A%20prospective%20examination%20of%20Circulating%20tumor%20cell%20profiles%20in%20non-small-cell%20lung%20cancer%20molecular%20subgroups.%20Ann%20Oncol.%202017;28:1523%E2%80%9331.%2010.1093/annonc/mdx156." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR189">
<span class="label">189.</span><cite>Alderton GK. Therapy: using CTCs to test drug sensitivity. Nat Rev Cancer. 2014;14:576. 10.1038/nrc3799.
</cite> [<a href="https://doi.org/10.1038/nrc3799" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25079656/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Alderton%20GK.%20Therapy:%20using%20CTCs%20to%20test%20drug%20sensitivity.%20Nat%20Rev%20Cancer.%202014;14:576.%2010.1038/nrc3799." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR190">
<span class="label">190.</span><cite>Cayrefourcq L, et al. Selective treatment pressure in colon cancer drives the molecular profile of resistant Circulating tumor cell clones. Mol Cancer. 2021;20. 10.1186/s12943-021-01326-6.</cite> [<a href="https://doi.org/10.1186/s12943-021-01326-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7869222/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33557844/" class="usa-link">PubMed</a>]</li>
<li id="CR191">
<span class="label">191.</span><cite>Khoo BL, et al. Expansion of patient-derived Circulating tumor cells from liquid biopsies using a CTC microfluidic culture device. Nat Protoc. 2018;13:34–58. 10.1038/nprot.2017.125.
</cite> [<a href="https://doi.org/10.1038/nprot.2017.125" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29215634/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Khoo%20BL,%20et%20al.%20Expansion%20of%20patient-derived%20Circulating%20tumor%20cells%20from%20liquid%20biopsies%20using%20a%20CTC%20microfluidic%20culture%20device.%20Nat%20Protoc.%202018;13:34%E2%80%9358.%2010.1038/nprot.2017.125." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR192">
<span class="label">192.</span><cite>Khoo BL, et al. Liquid biopsy and therapeutic response: Circulating tumor cell cultures for evaluation of anticancer treatment. Sci Adv. 2016;2:e1600274. 10.1126/sciadv.1600274.
</cite> [<a href="https://doi.org/10.1126/sciadv.1600274" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4956185/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27453941/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Khoo%20BL,%20et%20al.%20Liquid%20biopsy%20and%20therapeutic%20response:%20Circulating%20tumor%20cell%20cultures%20for%20evaluation%20of%20anticancer%20treatment.%20Sci%20Adv.%202016;2:e1600274.%2010.1126/sciadv.1600274." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR193">
<span class="label">193.</span><cite>Liu X, et al. Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of Circulating tumor cells from NK cell surveillance. Cancer Cell. 2023;41:272–e287279. 10.1016/j.ccell.2023.01.001.
</cite> [<a href="https://doi.org/10.1016/j.ccell.2023.01.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36706761/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liu%20X,%20et%20al.%20Immune%20checkpoint%20HLA-E:CD94-NKG2A%20mediates%20evasion%20of%20Circulating%20tumor%20cells%20from%20NK%20cell%20surveillance.%20Cancer%20Cell.%202023;41:272%E2%80%93e287279.%2010.1016/j.ccell.2023.01.001." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR194">
<span class="label">194.</span><cite>Zhang YW, Gvozdenovic A, Aceto NA. Molecular voyage: multiomics insights into Circulating tumor cells. Cancer Discov. 2024;14:920–33. 10.1158/2159-8290.Cd-24-0218.
</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-24-0218" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38581442/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20YW,%20Gvozdenovic%20A,%20Aceto%20NA.%20Molecular%20voyage:%20multiomics%20insights%20into%20Circulating%20tumor%20cells.%20Cancer%20Discov.%202024;14:920%E2%80%9333.%2010.1158/2159-8290.Cd-24-0218." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR195">
<span class="label">195.</span><cite>Ebright RY, et al. Deregulation of ribosomal protein expression and translation promotes breast cancer metastasis. Science. 2020;367:1468–73. 10.1126/science.aay0939.
</cite> [<a href="https://doi.org/10.1126/science.aay0939" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7307008/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32029688/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ebright%20RY,%20et%20al.%20Deregulation%20of%20ribosomal%20protein%20expression%20and%20translation%20promotes%20breast%20cancer%20metastasis.%20Science.%202020;367:1468%E2%80%9373.%2010.1126/science.aay0939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR196">
<span class="label">196.</span><cite>Gkountela S, et al. Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding. Cell. 2019;176:98–e112114. 10.1016/j.cell.2018.11.046.
</cite> [<a href="https://doi.org/10.1016/j.cell.2018.11.046" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6363966/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30633912/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gkountela%20S,%20et%20al.%20Circulating%20tumor%20cell%20clustering%20shapes%20DNA%20methylation%20to%20enable%20metastasis%20seeding.%20Cell.%202019;176:98%E2%80%93e112114.%2010.1016/j.cell.2018.11.046." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR197">
<span class="label">197.</span><cite>Guo H, et al. DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and CTCs. Cell. 2023;186:2765–e27822728. 10.1016/j.cell.2023.05.028.
</cite> [<a href="https://doi.org/10.1016/j.cell.2023.05.028" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10436379/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37327786/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Guo%20H,%20et%20al.%20DNA%20hypomethylation%20silences%20anti-tumor%20immune%20genes%20in%20early%20prostate%20cancer%20and%20CTCs.%20Cell.%202023;186:2765%E2%80%93e27822728.%2010.1016/j.cell.2023.05.028." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR198">
<span class="label">198.</span><cite>Kolostova K, Spicka J, Matkowski R, Bobek V. Isolation, primary culture, morphological and molecular characterization of Circulating tumor cells in gynecological cancers. Am J Transl Res. 2015;7:1203–13.
</cite> [<a href="/articles/PMC4548313/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26328005/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kolostova%20K,%20Spicka%20J,%20Matkowski%20R,%20Bobek%20V.%20Isolation,%20primary%20culture,%20morphological%20and%20molecular%20characterization%20of%20Circulating%20tumor%20cells%20in%20gynecological%20cancers.%20Am%20J%20Transl%20Res.%202015;7:1203%E2%80%9313." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR199">
<span class="label">199.</span><cite>Ben-David U, et al. Patient-derived xenografts undergo mouse-specific tumor evolution. Nat Genet. 2017;49:1567–75. 10.1038/ng.3967.
</cite> [<a href="https://doi.org/10.1038/ng.3967" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5659952/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28991255/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ben-David%20U,%20et%20al.%20Patient-derived%20xenografts%20undergo%20mouse-specific%20tumor%20evolution.%20Nat%20Genet.%202017;49:1567%E2%80%9375.%2010.1038/ng.3967." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR200">
<span class="label">200.</span><cite>Cortés-Hernández LE, et al. Proteomic profiling and functional analysis of extracellular vesicles from metastasis-competent Circulating tumor cells in colon cancer. J Exp Clin Cancer Res. 2025;44:102. 10.1186/s13046-025-03360-4.
</cite> [<a href="https://doi.org/10.1186/s13046-025-03360-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11929255/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40119417/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cort%C3%A9s-Hern%C3%A1ndez%20LE,%20et%20al.%20Proteomic%20profiling%20and%20functional%20analysis%20of%20extracellular%20vesicles%20from%20metastasis-competent%20Circulating%20tumor%20cells%20in%20colon%20cancer.%20J%20Exp%20Clin%20Cancer%20Res.%202025;44:102.%2010.1186/s13046-025-03360-4." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR201">
<span class="label">201.</span><cite>Drapkin BJ, et al. Genomic and functional fidelity of small cell lung cancer Patient-Derived xenografts. Cancer Discov. 2018;8:600–15. 10.1158/2159-8290.Cd-17-0935.
</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-17-0935" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6369413/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29483136/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Drapkin%20BJ,%20et%20al.%20Genomic%20and%20functional%20fidelity%20of%20small%20cell%20lung%20cancer%20Patient-Derived%20xenografts.%20Cancer%20Discov.%202018;8:600%E2%80%9315.%2010.1158/2159-8290.Cd-17-0935." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR202">
<span class="label">202.</span><cite>Stewart CA, et al. Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. Nat Cancer. 2020;1:423–36. 10.1038/s43018-019-0020-z.
</cite> [<a href="https://doi.org/10.1038/s43018-019-0020-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7842382/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33521652/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Stewart%20CA,%20et%20al.%20Single-cell%20analyses%20reveal%20increased%20intratumoral%20heterogeneity%20after%20the%20onset%20of%20therapy%20resistance%20in%20small-cell%20lung%20cancer.%20Nat%20Cancer.%202020;1:423%E2%80%9336.%2010.1038/s43018-019-0020-z." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR203">
<span class="label">203.</span><cite>Scheidmann MC, et al. An in vivo CRISPR screen identifies Stepwise genetic dependencies of metastatic progression. Cancer Res. 2022;82:681–94. 10.1158/0008-5472.Can-21-3908.
</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-21-3908" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7612409/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34916221/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Scheidmann%20MC,%20et%20al.%20An%20in%20vivo%20CRISPR%20screen%20identifies%20Stepwise%20genetic%20dependencies%20of%20metastatic%20progression.%20Cancer%20Res.%202022;82:681%E2%80%9394.%2010.1158/0008-5472.Can-21-3908." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR204">
<span class="label">204.</span><cite>Merino D, et al. Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer. Nat Commun. 2019;10:766. 10.1038/s41467-019-08595-2.
</cite> [<a href="https://doi.org/10.1038/s41467-019-08595-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6377663/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30770823/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Merino%20D,%20et%20al.%20Barcoding%20reveals%20complex%20clonal%20behavior%20in%20patient-derived%20xenografts%20of%20metastatic%20triple%20negative%20breast%20cancer.%20Nat%20Commun.%202019;10:766.%2010.1038/s41467-019-08595-2." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR205">
<span class="label">205.</span><cite>Headley MB, et al. Visualization of immediate immune responses to pioneer metastatic cells in the lung. Nature. 2016;531:513–7. 10.1038/nature16985.
</cite> [<a href="https://doi.org/10.1038/nature16985" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4892380/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26982733/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Headley%20MB,%20et%20al.%20Visualization%20of%20immediate%20immune%20responses%20to%20pioneer%20metastatic%20cells%20in%20the%20lung.%20Nature.%202016;531:513%E2%80%937.%2010.1038/nature16985." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR206">
<span class="label">206.</span><cite>Zhan Q, et al. New insights into the correlations between Circulating tumor cells and target organ metastasis. Signal Transduct Target Ther. 2023;8:465. 10.1038/s41392-023-01725-9.
</cite> [<a href="https://doi.org/10.1038/s41392-023-01725-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10739776/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38129401/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhan%20Q,%20et%20al.%20New%20insights%20into%20the%20correlations%20between%20Circulating%20tumor%20cells%20and%20target%20organ%20metastasis.%20Signal%20Transduct%20Target%20Ther.%202023;8:465.%2010.1038/s41392-023-01725-9." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR207">
<span class="label">207.</span><cite>Sun Y, Hepatology et al. 10.1097/hep.0000000000000934 (2024).</cite>
</li>
<li id="CR208">
<span class="label">208.</span><cite>Mohme M, Riethdorf S, Pantel K. Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape. Nat Rev Clin Oncol. 2017;14:155–67. 10.1038/nrclinonc.2016.144.
</cite> [<a href="https://doi.org/10.1038/nrclinonc.2016.144" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27644321/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mohme%20M,%20Riethdorf%20S,%20Pantel%20K.%20Circulating%20and%20disseminated%20tumour%20cells%20-%20mechanisms%20of%20immune%20surveillance%20and%20escape.%20Nat%20Rev%20Clin%20Oncol.%202017;14:155%E2%80%9367.%2010.1038/nrclinonc.2016.144." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR209">
<span class="label">209.</span><cite>Yi Y, et al. Mesenchymal stromal cells increase the natural killer resistance of Circulating tumor cells via intercellular signaling of cGAS-STING-IFNβ-HLA. Adv Sci (Weinh). 2024;11:e2400888. 10.1002/advs.202400888.
</cite> [<a href="https://doi.org/10.1002/advs.202400888" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11151078/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38638003/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yi%20Y,%20et%20al.%20Mesenchymal%20stromal%20cells%20increase%20the%20natural%20killer%20resistance%20of%20Circulating%20tumor%20cells%20via%20intercellular%20signaling%20of%20cGAS-STING-IFN%CE%B2-HLA.%20Adv%20Sci%20(Weinh).%202024;11:e2400888.%2010.1002/advs.202400888." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR210">
<span class="label">210.</span><cite>Moreau JM, Velegraki M, Bolyard C, Rosenblum MD, Li Z. Transforming growth factor-β1 in regulatory T cell biology. Sci Immunol. 2022;7:eabi4613. 10.1126/sciimmunol.abi4613.
</cite> [<a href="https://doi.org/10.1126/sciimmunol.abi4613" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10552796/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35302863/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Moreau%20JM,%20Velegraki%20M,%20Bolyard%20C,%20Rosenblum%20MD,%20Li%20Z.%20Transforming%20growth%20factor-%CE%B21%20in%20regulatory%20T%20cell%20biology.%20Sci%20Immunol.%202022;7:eabi4613.%2010.1126/sciimmunol.abi4613." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR211">
<span class="label">211.</span><cite>Ohara M, et al. Possible involvement of regulatory T cells in tumor onset and progression in primary breast cancer. Cancer Immunol Immunother. 2009;58:441–7. 10.1007/s00262-008-0570-x.
</cite> [<a href="https://doi.org/10.1007/s00262-008-0570-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11030850/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18685848/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ohara%20M,%20et%20al.%20Possible%20involvement%20of%20regulatory%20T%20cells%20in%20tumor%20onset%20and%20progression%20in%20primary%20breast%20cancer.%20Cancer%20Immunol%20Immunother.%202009;58:441%E2%80%937.%2010.1007/s00262-008-0570-x." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR212">
<span class="label">212.</span><cite>Manzotti CN, et al. Inhibition of human T cell proliferation by CTLA-4 utilizes CD80 and requires CD25 + regulatory T cells. Eur J Immunol. 2002;32:2888–96. 
</cite> [<a href="https://doi.org/10.1002/1521-4141(2002010)32:10&amp;#x0003c;2888::Aid-immu2888&amp;#x0003e;.3.0.Co;2-f" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12355442/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Manzotti%20CN,%20et%20al.%20Inhibition%20of%20human%20T%20cell%20proliferation%20by%20CTLA-4%20utilizes%20CD80%20and%20requires%20CD25%20+%20regulatory%20T%20cells.%20Eur%20J%20Immunol.%202002;32:2888%E2%80%9396." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR213">
<span class="label">213.</span><cite>Zhang B, et al. Proximity-enabled covalent binding of IL-2 to IL-2Rα selectively activates regulatory T cells and suppresses autoimmunity. Signal Transduct Target Ther. 2023;8:28. 10.1038/s41392-022-01208-3.
</cite> [<a href="https://doi.org/10.1038/s41392-022-01208-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9871032/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36690610/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20B,%20et%20al.%20Proximity-enabled%20covalent%20binding%20of%20IL-2%20to%20IL-2R%CE%B1%20selectively%20activates%20regulatory%20T%20cells%20and%20suppresses%20autoimmunity.%20Signal%20Transduct%20Target%20Ther.%202023;8:28.%2010.1038/s41392-022-01208-3." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR214">
<span class="label">214.</span><cite>Grover P, Goel PN, Greene MI, Regulatory T, Cells. Regulation of identity and function. Front Immunol. 2021;12:750542. 10.3389/fimmu.2021.750542.
</cite> [<a href="https://doi.org/10.3389/fimmu.2021.750542" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8524049/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34675933/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Grover%20P,%20Goel%20PN,%20Greene%20MI,%20Regulatory%20T,%20Cells.%20Regulation%20of%20identity%20and%20function.%20Front%20Immunol.%202021;12:750542.%2010.3389/fimmu.2021.750542." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR215">
<span class="label">215.</span><cite>Hallermalm K, De Geer A, Kiessling R, Levitsky V, Levitskaya J. Autocrine secretion of Fas ligand shields tumor cells from Fas-mediated killing by cytotoxic lymphocytes. Cancer Res. 2004;64:6775–82. 10.1158/0008-5472.Can-04-0508.
</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-04-0508" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15374996/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hallermalm%20K,%20De%20Geer%20A,%20Kiessling%20R,%20Levitsky%20V,%20Levitskaya%20J.%20Autocrine%20secretion%20of%20Fas%20ligand%20shields%20tumor%20cells%20from%20Fas-mediated%20killing%20by%20cytotoxic%20lymphocytes.%20Cancer%20Res.%202004;64:6775%E2%80%9382.%2010.1158/0008-5472.Can-04-0508." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR216">
<span class="label">216.</span><cite>Placke T, et al. Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res. 2012;72:440–8. 10.1158/0008-5472.Can-11-1872.
</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-11-1872" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22127925/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Placke%20T,%20et%20al.%20Platelet-derived%20MHC%20class%20I%20confers%20a%20pseudonormal%20phenotype%20to%20cancer%20cells%20that%20subverts%20the%20antitumor%20reactivity%20of%20natural%20killer%20immune%20cells.%20Cancer%20Res.%202012;72:440%E2%80%938.%2010.1158/0008-5472.Can-11-1872." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR217">
<span class="label">217.</span><cite>Wu MS, Li CH, Ruppert JG, Chang CC. Cytokeratin 8-MHC class I interactions: a potential novel immune escape phenotype by a lymph node metastatic carcinoma cell line. Biochem Biophys Res Commun. 2013;441:618–23. 10.1016/j.bbrc.2013.10.105.
</cite> [<a href="https://doi.org/10.1016/j.bbrc.2013.10.105" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24183726/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wu%20MS,%20Li%20CH,%20Ruppert%20JG,%20Chang%20CC.%20Cytokeratin%208-MHC%20class%20I%20interactions:%20a%20potential%20novel%20immune%20escape%20phenotype%20by%20a%20lymph%20node%20metastatic%20carcinoma%20cell%20line.%20Biochem%20Biophys%20Res%20Commun.%202013;441:618%E2%80%9323.%2010.1016/j.bbrc.2013.10.105." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR218">
<span class="label">218.</span><cite>Gast CE, et al. Cell fusion potentiates tumor heterogeneity and reveals Circulating hybrid cells that correlate with stage and survival. Sci Adv. 2018;4:eaat7828. 10.1126/sciadv.aat7828.
</cite> [<a href="https://doi.org/10.1126/sciadv.aat7828" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6135550/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30214939/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gast%20CE,%20et%20al.%20Cell%20fusion%20potentiates%20tumor%20heterogeneity%20and%20reveals%20Circulating%20hybrid%20cells%20that%20correlate%20with%20stage%20and%20survival.%20Sci%20Adv.%202018;4:eaat7828.%2010.1126/sciadv.aat7828." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR219">
<span class="label">219.</span><cite>Manjunath Y, et al. Circulating giant Tumor-Macrophage fusion cells are independent prognosticators in patients with NSCLC. J Thorac Oncol. 2020;15:1460–71. 10.1016/j.jtho.2020.04.034.
</cite> [<a href="https://doi.org/10.1016/j.jtho.2020.04.034" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32416323/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Manjunath%20Y,%20et%20al.%20Circulating%20giant%20Tumor-Macrophage%20fusion%20cells%20are%20independent%20prognosticators%20in%20patients%20with%20NSCLC.%20J%20Thorac%20Oncol.%202020;15:1460%E2%80%9371.%2010.1016/j.jtho.2020.04.034." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR220">
<span class="label">220.</span><cite>Anderson AN, et al. Detection of neoplastic-immune hybrid cells with metastatic properties in uveal melanoma. Biomark Res. 2024;12:67. 10.1186/s40364-024-00609-6.
</cite> [<a href="https://doi.org/10.1186/s40364-024-00609-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11264923/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39030653/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Anderson%20AN,%20et%20al.%20Detection%20of%20neoplastic-immune%20hybrid%20cells%20with%20metastatic%20properties%20in%20uveal%20melanoma.%20Biomark%20Res.%202024;12:67.%2010.1186/s40364-024-00609-6." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR221">
<span class="label">221.</span><cite>Morris K, Schnoor B, Papa AL. Platelet cancer cell interplay as a new therapeutic target. Biochim Biophys Acta Rev Cancer. 2022;1877:188770. 10.1016/j.bbcan.2022.188770.
</cite> [<a href="https://doi.org/10.1016/j.bbcan.2022.188770" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35926688/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Morris%20K,%20Schnoor%20B,%20Papa%20AL.%20Platelet%20cancer%20cell%20interplay%20as%20a%20new%20therapeutic%20target.%20Biochim%20Biophys%20Acta%20Rev%20Cancer.%202022;1877:188770.%2010.1016/j.bbcan.2022.188770." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR222">
<span class="label">222.</span><cite>Ward MP, et al. Platelets, immune cells and the coagulation cascade; friend or foe of the Circulating tumour cell? Mol Cancer. 2021;20:59. 10.1186/s12943-021-01347-1.
</cite> [<a href="https://doi.org/10.1186/s12943-021-01347-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8011144/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33789677/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ward%20MP,%20et%20al.%20Platelets,%20immune%20cells%20and%20the%20coagulation%20cascade;%20friend%20or%20foe%20of%20the%20Circulating%20tumour%20cell?%20Mol%20Cancer.%202021;20:59.%2010.1186/s12943-021-01347-1." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR223">
<span class="label">223.</span><cite>Nieswandt B, Hafner M, Echtenacher B, Männel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 1999;59:1295–300.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/10096562/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Nieswandt%20B,%20Hafner%20M,%20Echtenacher%20B,%20M%C3%A4nnel%20DN.%20Lysis%20of%20tumor%20cells%20by%20natural%20killer%20cells%20in%20mice%20is%20impeded%20by%20platelets.%20Cancer%20Res.%201999;59:1295%E2%80%93300." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR224">
<span class="label">224.</span><cite>Rossi T, et al. Transcriptomic profiling of Circulating tumor cells from metastatic breast cancer patients reveals new hints in their biological features and phenotypic heterogeneity. Exp Hematol Oncol. 2025;14:67. 10.1186/s40164-025-00659-y.
</cite> [<a href="https://doi.org/10.1186/s40164-025-00659-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC12054220/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40329429/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rossi%20T,%20et%20al.%20Transcriptomic%20profiling%20of%20Circulating%20tumor%20cells%20from%20metastatic%20breast%20cancer%20patients%20reveals%20new%20hints%20in%20their%20biological%20features%20and%20phenotypic%20heterogeneity.%20Exp%20Hematol%20Oncol.%202025;14:67.%2010.1186/s40164-025-00659-y." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR225">
<span class="label">225.</span><cite>Bates M, et al. Circulating tumour cells: the good, the bad and the ugly. Biochim Biophys Acta Rev Cancer. 2023;1878:188863. 10.1016/j.bbcan.2023.188863.
</cite> [<a href="https://doi.org/10.1016/j.bbcan.2023.188863" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36796527/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bates%20M,%20et%20al.%20Circulating%20tumour%20cells:%20the%20good,%20the%20bad%20and%20the%20ugly.%20Biochim%20Biophys%20Acta%20Rev%20Cancer.%202023;1878:188863.%2010.1016/j.bbcan.2023.188863." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR226">
<span class="label">226.</span><cite>Reduzzi C, et al. The curious phenomenon of dual-positive Circulating cells: longtime overlooked tumor cells. Semin Cancer Biol. 2020;60:344–50. 10.1016/j.semcancer.2019.10.008.
</cite> [<a href="https://doi.org/10.1016/j.semcancer.2019.10.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31626958/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Reduzzi%20C,%20et%20al.%20The%20curious%20phenomenon%20of%20dual-positive%20Circulating%20cells:%20longtime%20overlooked%20tumor%20cells.%20Semin%20Cancer%20Biol.%202020;60:344%E2%80%9350.%2010.1016/j.semcancer.2019.10.008." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR227">
<span class="label">227.</span><cite>Yang C, et al. Circulating tumor cells shielded with extracellular vesicle-derived CD45 evade T cell attack to enable metastasis. Signal Transduct Target Ther. 2024;9:84. 10.1038/s41392-024-01789-1.
</cite> [<a href="https://doi.org/10.1038/s41392-024-01789-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10995208/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38575583/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yang%20C,%20et%20al.%20Circulating%20tumor%20cells%20shielded%20with%20extracellular%20vesicle-derived%20CD45%20evade%20T%20cell%20attack%20to%20enable%20metastasis.%20Signal%20Transduct%20Target%20Ther.%202024;9:84.%2010.1038/s41392-024-01789-1." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR228">
<span class="label">228.</span><cite>Jordan NV, et al. HER2 expression identifies dynamic functional States within Circulating breast cancer cells. Nature. 2016;537:102–6. 10.1038/nature19328.
</cite> [<a href="https://doi.org/10.1038/nature19328" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5161614/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27556950/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jordan%20NV,%20et%20al.%20HER2%20expression%20identifies%20dynamic%20functional%20States%20within%20Circulating%20breast%20cancer%20cells.%20Nature.%202016;537:102%E2%80%936.%2010.1038/nature19328." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR229">
<span class="label">229.</span><cite>Westphalen CB, et al. Long-lived intestinal tuft cells serve as colon cancer-initiating cells. J Clin Invest. 2014;124:1283–95. 10.1172/jci73434.
</cite> [<a href="https://doi.org/10.1172/JCI73434" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3934168/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24487592/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Westphalen%20CB,%20et%20al.%20Long-lived%20intestinal%20tuft%20cells%20serve%20as%20colon%20cancer-initiating%20cells.%20J%20Clin%20Invest.%202014;124:1283%E2%80%9395.%2010.1172/jci73434." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR230">
<span class="label">230.</span><cite>Diamantopoulou Z, et al. The metastatic spread of breast cancer accelerates during sleep. Nature. 2022;607:156–62. 10.1038/s41586-022-04875-y.
</cite> [<a href="https://doi.org/10.1038/s41586-022-04875-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35732738/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Diamantopoulou%20Z,%20et%20al.%20The%20metastatic%20spread%20of%20breast%20cancer%20accelerates%20during%20sleep.%20Nature.%202022;607:156%E2%80%9362.%2010.1038/s41586-022-04875-y." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR231">
<span class="label">231.</span><cite>Fu A, et al. Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer. Cell. 2022;185:1356–e13721326. 10.1016/j.cell.2022.02.027.
</cite> [<a href="https://doi.org/10.1016/j.cell.2022.02.027" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35395179/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Fu%20A,%20et%20al.%20Tumor-resident%20intracellular%20microbiota%20promotes%20metastatic%20colonization%20in%20breast%20cancer.%20Cell.%202022;185:1356%E2%80%93e13721326.%2010.1016/j.cell.2022.02.027." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR232">
<span class="label">232.</span><cite>Cortés-Hernández LE, Eslami SZ, Alix-Panabières C. Circulating tumor cell as the functional aspect of liquid biopsy to understand the metastatic cascade in solid cancer. Mol Aspects Med. 2020;72:100816. 10.1016/j.mam.2019.07.008.
</cite> [<a href="https://doi.org/10.1016/j.mam.2019.07.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31377345/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cort%C3%A9s-Hern%C3%A1ndez%20LE,%20Eslami%20SZ,%20Alix-Panabi%C3%A8res%20C.%20Circulating%20tumor%20cell%20as%20the%20functional%20aspect%20of%20liquid%20biopsy%20to%20understand%20the%20metastatic%20cascade%20in%20solid%20cancer.%20Mol%20Aspects%20Med.%202020;72:100816.%2010.1016/j.mam.2019.07.008." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR233">
<span class="label">233.</span><cite>Cai Y, et al. Collection on reports of molecules linked to epithelial-mesenchymal transition in the process of treating metastasizing cancer: a narrative review. Ann Transl Med. 2021;9:946. 10.21037/atm-20-7002.
</cite> [<a href="https://doi.org/10.21037/atm-20-7002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8263858/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34350261/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cai%20Y,%20et%20al.%20Collection%20on%20reports%20of%20molecules%20linked%20to%20epithelial-mesenchymal%20transition%20in%20the%20process%20of%20treating%20metastasizing%20cancer:%20a%20narrative%20review.%20Ann%20Transl%20Med.%202021;9:946.%2010.21037/atm-20-7002." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR234">
<span class="label">234.</span><cite>Yan Q, et al. Immune checkpoint FGL1 expression of Circulating tumor cells is associated with poor survival in curatively resected hepatocellular carcinoma. Front Oncol. 2022;12:810269. 10.3389/fonc.2022.810269.
</cite> [<a href="https://doi.org/10.3389/fonc.2022.810269" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8901582/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35273912/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yan%20Q,%20et%20al.%20Immune%20checkpoint%20FGL1%20expression%20of%20Circulating%20tumor%20cells%20is%20associated%20with%20poor%20survival%20in%20curatively%20resected%20hepatocellular%20carcinoma.%20Front%20Oncol.%202022;12:810269.%2010.3389/fonc.2022.810269." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR235">
<span class="label">235.</span><cite>Clézardin P, et al. Bone metastasis: mechanisms, therapies, and biomarkers. Physiol Rev. 2021;101:797–855. 10.1152/physrev.00012.2019.
</cite> [<a href="https://doi.org/10.1152/physrev.00012.2019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33356915/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cl%C3%A9zardin%20P,%20et%20al.%20Bone%20metastasis:%20mechanisms,%20therapies,%20and%20biomarkers.%20Physiol%20Rev.%202021;101:797%E2%80%93855.%2010.1152/physrev.00012.2019." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR236">
<span class="label">236.</span><cite>Hamilton G, Rath B. Role of Circulating tumor cell spheroids in drug resistance. Cancer Drug Resist. 2019;2:762–72. 10.20517/cdr.2019.47.
</cite> [<a href="https://doi.org/10.20517/cdr.2019.47" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8992524/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35582592/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hamilton%20G,%20Rath%20B.%20Role%20of%20Circulating%20tumor%20cell%20spheroids%20in%20drug%20resistance.%20Cancer%20Drug%20Resist.%202019;2:762%E2%80%9372.%2010.20517/cdr.2019.47." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR237">
<span class="label">237.</span><cite>Aceto N, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014;158:1110–22. 10.1016/j.cell.2014.07.013.
</cite> [<a href="https://doi.org/10.1016/j.cell.2014.07.013" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4149753/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25171411/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Aceto%20N,%20et%20al.%20Circulating%20tumor%20cell%20clusters%20are%20oligoclonal%20precursors%20of%20breast%20cancer%20metastasis.%20Cell.%202014;158:1110%E2%80%9322.%2010.1016/j.cell.2014.07.013." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR238">
<span class="label">238.</span><cite>Yu M. Metastasis stemming from Circulating tumor cell clusters. Trends Cell Biol. 2019;29:275–6. 10.1016/j.tcb.2019.02.001.
</cite> [<a href="https://doi.org/10.1016/j.tcb.2019.02.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7771971/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30799250/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yu%20M.%20Metastasis%20stemming%20from%20Circulating%20tumor%20cell%20clusters.%20Trends%20Cell%20Biol.%202019;29:275%E2%80%936.%2010.1016/j.tcb.2019.02.001." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR239">
<span class="label">239.</span><cite>Dashzeveg NK, et al. Dynamic glycoprotein hyposialylation promotes chemotherapy evasion and metastatic seeding of quiescent Circulating tumor cell clusters in breast cancer. Cancer Discov. 2023;13:2050–71. 10.1158/2159-8290.Cd-22-0644.
</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-22-0644" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10481132/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37272843/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Dashzeveg%20NK,%20et%20al.%20Dynamic%20glycoprotein%20hyposialylation%20promotes%20chemotherapy%20evasion%20and%20metastatic%20seeding%20of%20quiescent%20Circulating%20tumor%20cell%20clusters%20in%20breast%20cancer.%20Cancer%20Discov.%202023;13:2050%E2%80%9371.%2010.1158/2159-8290.Cd-22-0644." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR240">
<span class="label">240.</span><cite>Han HJ, et al. Fibronectin regulates Anoikis resistance via cell aggregate formation. Cancer Lett. 2021;508:59–72. 10.1016/j.canlet.2021.03.011.
</cite> [<a href="https://doi.org/10.1016/j.canlet.2021.03.011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33771684/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Han%20HJ,%20et%20al.%20Fibronectin%20regulates%20Anoikis%20resistance%20via%20cell%20aggregate%20formation.%20Cancer%20Lett.%202021;508:59%E2%80%9372.%2010.1016/j.canlet.2021.03.011." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR241">
<span class="label">241.</span><cite>Haemmerle M, et al. Platelets reduce Anoikis and promote metastasis by activating YAP1 signaling. Nat Commun. 2017;8:310. 10.1038/s41467-017-00411-z.
</cite> [<a href="https://doi.org/10.1038/s41467-017-00411-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5566477/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28827520/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Haemmerle%20M,%20et%20al.%20Platelets%20reduce%20Anoikis%20and%20promote%20metastasis%20by%20activating%20YAP1%20signaling.%20Nat%20Commun.%202017;8:310.%2010.1038/s41467-017-00411-z." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR242">
<span class="label">242.</span><cite>Hosseini H, et al. Early dissemination seeds metastasis in breast cancer. Nature. 2016;540:552–8. 10.1038/nature20785.
</cite> [<a href="https://doi.org/10.1038/nature20785" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5390864/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27974799/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hosseini%20H,%20et%20al.%20Early%20dissemination%20seeds%20metastasis%20in%20breast%20cancer.%20Nature.%202016;540:552%E2%80%938.%2010.1038/nature20785." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR243">
<span class="label">243.</span><cite>Zhou Q, et al. Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trial. Cancer Cell. 2024;42:1258–e12671252. 10.1016/j.ccell.2024.05.024.
</cite> [<a href="https://doi.org/10.1016/j.ccell.2024.05.024" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38906157/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhou%20Q,%20et%20al.%20Neoadjuvant%20SHR-1701%20with%20or%20without%20chemotherapy%20in%20unresectable%20stage%20III%20non-small-cell%20lung%20cancer:%20A%20proof-of-concept,%20phase%202%20trial.%20Cancer%20Cell.%202024;42:1258%E2%80%93e12671252.%2010.1016/j.ccell.2024.05.024." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR244">
<span class="label">244.</span><cite>Feng J, et al. SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGFβ, for recurrent or metastatic cervical cancer: A clinical expansion cohort of a phase I study. Clin Cancer Res. 2022;28:5297–305. 10.1158/1078-0432.Ccr-22-0346.
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-22-0346" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35653122/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Feng%20J,%20et%20al.%20SHR-1701,%20a%20bifunctional%20fusion%20protein%20targeting%20PD-L1%20and%20TGF%CE%B2,%20for%20recurrent%20or%20metastatic%20cervical%20cancer:%20A%20clinical%20expansion%20cohort%20of%20a%20phase%20I%20study.%20Clin%20Cancer%20Res.%202022;28:5297%E2%80%93305.%2010.1158/1078-0432.Ccr-22-0346." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR245">
<span class="label">245.</span><cite>Peng D, Fu M, Wang M, Wei Y, Wei X. Targeting TGF-β signal transduction for fibrosis and cancer therapy. Mol Cancer. 2022;21:104. 10.1186/s12943-022-01569-x.
</cite> [<a href="https://doi.org/10.1186/s12943-022-01569-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9033932/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35461253/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Peng%20D,%20Fu%20M,%20Wang%20M,%20Wei%20Y,%20Wei%20X.%20Targeting%20TGF-%CE%B2%20signal%20transduction%20for%20fibrosis%20and%20cancer%20therapy.%20Mol%20Cancer.%202022;21:104.%2010.1186/s12943-022-01569-x." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR246">
<span class="label">246.</span><cite>Lengrand J, et al. Pharmacological targeting of netrin-1 inhibits EMT in cancer. Nature. 2023;620:402–8. 10.1038/s41586-023-06372-2.
</cite> [<a href="https://doi.org/10.1038/s41586-023-06372-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7615210/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37532929/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lengrand%20J,%20et%20al.%20Pharmacological%20targeting%20of%20netrin-1%20inhibits%20EMT%20in%20cancer.%20Nature.%202023;620:402%E2%80%938.%2010.1038/s41586-023-06372-2." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR247">
<span class="label">247.</span><cite>Recasens A, Munoz L. Targeting cancer cell dormancy. Trends Pharmacol Sci. 2019;40:128–41. 10.1016/j.tips.2018.12.004.
</cite> [<a href="https://doi.org/10.1016/j.tips.2018.12.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30612715/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Recasens%20A,%20Munoz%20L.%20Targeting%20cancer%20cell%20dormancy.%20Trends%20Pharmacol%20Sci.%202019;40:128%E2%80%9341.%2010.1016/j.tips.2018.12.004." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR248">
<span class="label">248.</span><cite>O’Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol. 2016;13:417–30. 10.1038/nrclinonc.2016.26.
</cite> [<a href="https://doi.org/10.1038/nrclinonc.2016.26" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27030077/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?O%E2%80%99Leary%20B,%20Finn%20RS,%20Turner%20NC.%20Treating%20cancer%20with%20selective%20CDK4/6%20inhibitors.%20Nat%20Rev%20Clin%20Oncol.%202016;13:417%E2%80%9330.%2010.1038/nrclinonc.2016.26." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR249">
<span class="label">249.</span><cite>Clements ME, et al. HDAC inhibitors induce LIFR expression and promote a dormancy phenotype in breast cancer. Oncogene. 2021;40:5314–26. 10.1038/s41388-021-01931-1.
</cite> [<a href="https://doi.org/10.1038/s41388-021-01931-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8403155/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34247191/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Clements%20ME,%20et%20al.%20HDAC%20inhibitors%20induce%20LIFR%20expression%20and%20promote%20a%20dormancy%20phenotype%20in%20breast%20cancer.%20Oncogene.%202021;40:5314%E2%80%9326.%2010.1038/s41388-021-01931-1." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR250">
<span class="label">250.</span><cite>El Touny LH, et al. Combined SFK/MEK Inhibition prevents metastatic outgrowth of dormant tumor cells. J Clin Invest. 2014;124:156–68. 10.1172/jci70259.
</cite> [<a href="https://doi.org/10.1172/JCI70259" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3871237/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24316974/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?El%20Touny%20LH,%20et%20al.%20Combined%20SFK/MEK%20Inhibition%20prevents%20metastatic%20outgrowth%20of%20dormant%20tumor%20cells.%20J%20Clin%20Invest.%202014;124:156%E2%80%9368.%2010.1172/jci70259." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR251">
<span class="label">251.</span><cite>Kurzeder C, et al. Digoxin for reduction of Circulating tumor cell cluster size in metastatic breast cancer: a proof-of-concept trial. Nat Med. 2025;31:1120–4. 10.1038/s41591-024-03486-6.
</cite> [<a href="https://doi.org/10.1038/s41591-024-03486-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC12003195/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39856336/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kurzeder%20C,%20et%20al.%20Digoxin%20for%20reduction%20of%20Circulating%20tumor%20cell%20cluster%20size%20in%20metastatic%20breast%20cancer:%20a%20proof-of-concept%20trial.%20Nat%20Med.%202025;31:1120%E2%80%934.%2010.1038/s41591-024-03486-6." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR252">
<span class="label">252.</span><cite>Szczerba BM, et al. Neutrophils escort Circulating tumour cells to enable cell cycle progression. Nature. 2019;566:553–7. 10.1038/s41586-019-0915-y.
</cite> [<a href="https://doi.org/10.1038/s41586-019-0915-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30728496/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Szczerba%20BM,%20et%20al.%20Neutrophils%20escort%20Circulating%20tumour%20cells%20to%20enable%20cell%20cycle%20progression.%20Nature.%202019;566:553%E2%80%937.%2010.1038/s41586-019-0915-y." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR253">
<span class="label">253.</span><cite>Yang L, et al. The effect of aspirin on Circulating tumor cells in metastatic colorectal and breast cancer patients: a phase II trial study. Clin Transl Oncol. 2018;20:912–21. 10.1007/s12094-017-1806-z.
</cite> [<a href="https://doi.org/10.1007/s12094-017-1806-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29243075/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yang%20L,%20et%20al.%20The%20effect%20of%20aspirin%20on%20Circulating%20tumor%20cells%20in%20metastatic%20colorectal%20and%20breast%20cancer%20patients:%20a%20phase%20II%20trial%20study.%20Clin%20Transl%20Oncol.%202018;20:912%E2%80%9321.%2010.1007/s12094-017-1806-z." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR254">
<span class="label">254.</span><cite>Wei RR, et al. CTC clusters induced by heparanase enhance breast cancer metastasis. Acta Pharmacol Sin. 2018;39:1326–37. 10.1038/aps.2017.189.
</cite> [<a href="https://doi.org/10.1038/aps.2017.189" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6289387/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29417941/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wei%20RR,%20et%20al.%20CTC%20clusters%20induced%20by%20heparanase%20enhance%20breast%20cancer%20metastasis.%20Acta%20Pharmacol%20Sin.%202018;39:1326%E2%80%9337.%2010.1038/aps.2017.189." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR255">
<span class="label">255.</span><cite>Choi JW, et al. Urokinase exerts antimetastatic effects by dissociating clusters of Circulating tumor cells. Cancer Res. 2015;75:4474–82. 10.1158/0008-5472.Can-15-0684.
</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-15-0684" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26527605/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Choi%20JW,%20et%20al.%20Urokinase%20exerts%20antimetastatic%20effects%20by%20dissociating%20clusters%20of%20Circulating%20tumor%20cells.%20Cancer%20Res.%202015;75:4474%E2%80%9382.%2010.1158/0008-5472.Can-15-0684." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR256">
<span class="label">256.</span><cite>Ma Y, Wei J, He W, Ren J. Neutrophil extracellular traps in cancer. MedComm. 2020;5:e647. 10.1002/mco2.647. (2024).</cite> [<a href="https://doi.org/10.1002/mco2.647" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11247337/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39015554/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ma%20Y,%20Wei%20J,%20He%20W,%20Ren%20J.%20Neutrophil%20extracellular%20traps%20in%20cancer.%20MedComm.%202020;5:e647.%2010.1002/mco2.647.%20(2024)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR257">
<span class="label">257.</span><cite>Coupland LA, Chong BH, Parish CR. Platelets and P-selectin control tumor cell metastasis in an organ-specific manner and independently of NK cells. Cancer Res. 2012;72:4662–71. 10.1158/0008-5472.Can-11-4010.
</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-11-4010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22836751/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Coupland%20LA,%20Chong%20BH,%20Parish%20CR.%20Platelets%20and%20P-selectin%20control%20tumor%20cell%20metastasis%20in%20an%20organ-specific%20manner%20and%20independently%20of%20NK%20cells.%20Cancer%20Res.%202012;72:4662%E2%80%9371.%2010.1158/0008-5472.Can-11-4010." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR258">
<span class="label">258.</span><cite>Huang C, et al. Tumour-derived Interleukin 35 promotes pancreatic ductal adenocarcinoma cell extravasation and metastasis by inducing ICAM1 expression. Nat Commun. 2017;8:14035. 10.1038/ncomms14035.
</cite> [<a href="https://doi.org/10.1038/ncomms14035" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5253665/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28102193/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Huang%20C,%20et%20al.%20Tumour-derived%20Interleukin%2035%20promotes%20pancreatic%20ductal%20adenocarcinoma%20cell%20extravasation%20and%20metastasis%20by%20inducing%20ICAM1%20expression.%20Nat%20Commun.%202017;8:14035.%2010.1038/ncomms14035." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR259">
<span class="label">259.</span><cite>Xu XR, Yousef GM, Ni H. Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents. Blood. 2018;131:1777–89. 10.1182/blood-2017-05-743187.
</cite> [<a href="https://doi.org/10.1182/blood-2017-05-743187" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29519806/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Xu%20XR,%20Yousef%20GM,%20Ni%20H.%20Cancer%20and%20platelet%20crosstalk:%20opportunities%20and%20challenges%20for%20aspirin%20and%20other%20antiplatelet%20agents.%20Blood.%202018;131:1777%E2%80%9389.%2010.1182/blood-2017-05-743187." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR260">
<span class="label">260.</span><cite>Leong HS, et al. Invadopodia are required for cancer cell extravasation and are a therapeutic target for metastasis. Cell Rep. 2014;8:1558–70. 10.1016/j.celrep.2014.07.050.
</cite> [<a href="https://doi.org/10.1016/j.celrep.2014.07.050" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25176655/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Leong%20HS,%20et%20al.%20Invadopodia%20are%20required%20for%20cancer%20cell%20extravasation%20and%20are%20a%20therapeutic%20target%20for%20metastasis.%20Cell%20Rep.%202014;8:1558%E2%80%9370.%2010.1016/j.celrep.2014.07.050." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR261">
<span class="label">261.</span><cite>Kyrysyuk O, Wucherpfennig KW. Designing cancer immunotherapies that engage T cells and NK cells. Annu Rev Immunol. 2023;41:17–38. 10.1146/annurev-immunol-101921-044122.
</cite> [<a href="https://doi.org/10.1146/annurev-immunol-101921-044122" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10159905/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36446137/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kyrysyuk%20O,%20Wucherpfennig%20KW.%20Designing%20cancer%20immunotherapies%20that%20engage%20T%20cells%20and%20NK%20cells.%20Annu%20Rev%20Immunol.%202023;41:17%E2%80%9338.%2010.1146/annurev-immunol-101921-044122." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR262">
<span class="label">262.</span><cite>Cassier PA, et al. Netrin-1 Blockade inhibits tumour growth and EMT features in endometrial cancer. Nature. 2023;620:409–16. 10.1038/s41586-023-06367-z.
</cite> [<a href="https://doi.org/10.1038/s41586-023-06367-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10412451/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37532934/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cassier%20PA,%20et%20al.%20Netrin-1%20Blockade%20inhibits%20tumour%20growth%20and%20EMT%20features%20in%20endometrial%20cancer.%20Nature.%202023;620:409%E2%80%9316.%2010.1038/s41586-023-06367-z." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR263">
<span class="label">263.</span><cite>Zhang N, et al. Novel therapeutic strategies: targeting epithelial-mesenchymal transition in colorectal cancer. Lancet Oncol. 2021;22:e358–68. 10.1016/s1470-2045(21)00343-0.
</cite> [<a href="https://doi.org/10.1016/S1470-2045(21)00343-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34339656/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20N,%20et%20al.%20Novel%20therapeutic%20strategies:%20targeting%20epithelial-mesenchymal%20transition%20in%20colorectal%20cancer.%20Lancet%20Oncol.%202021;22:e358%E2%80%9368.%2010.1016/s1470-2045(21)00343-0." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>No datasets were generated or analysed during the current study.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Journal of Hematology &amp; Oncology are provided here courtesy of <strong>BMC</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1186/s13045-025-01733-y"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/13045_2025_Article_1733.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (10.1 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12374358/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12374358/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12374358%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374358/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12374358/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12374358/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40846962/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12374358/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40846962/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12374358/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12374358/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="HnTxbwB666ysuvFNFdoJBoNWB35B6DOu1g5uvZKMGBj9VU1zkdFoa4B55z3g194q">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
